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Red blood cells, their antigens, and alloimmunization
Red blood cell transfusions are a cornerstone for the management of patients with 
compromised hematopoiesis and for those losing large amounts of blood. Over 343,000 
registered donors supplied over 427,000 red cell units in the Netherlands in 2015,1 of which 
around 20% were transfused to patients with oncologic disease entities.2 
 Encountering allogeneic red blood cells e.g. by transfusion, pregnancy or organ transplant 
exposes one to polysaccharide and protein structures that may be different from the 
recipient’s own structures and may therefore be recognized by the immune system. 
Different types of membrane-bound structures, such as lipids and (glyco)proteins anchored 
to the outer red cell membrane and participating in diverse cellular functions may be 
involved. Due to genetically determined interindividual variations, some of these surface 
markers are capable to induce antibody formation and hence, have been defined as red 
cell antigens.3 
 More than 300 of these inherited red cell antigens so far have been identified in 
humans,4 and have been organized into 36 blood group systems.5 Each blood group 
system represents the variation occurring in a single gene or in a cluster of two or more 
closely linked homologous genes.3 
 One of the most well-known (and probably the most complex) red cell antigens is 
Rhesus (Rh) D. A complete deletion of the RHD gene, present in 15% of the Caucasian 
population,6 results in a complete absence of the approximately 30 kd D protein from the 
red cell surface.7 In addition to a complete deletion, the RHD allele (and to a lesser degree 
the RHCE allele) can be subject to mutations that result into variances of the D polypeptide 
e.g. partial D and weak D expression.8 Here, the D antigen is not completely absent, 
but lacks some common epitopes (partial D) or covers the red cell surface at a lower site 
density as compared to normal D (weak D). D variants are more common in people from 
African origin as compared to the Caucasian population.9 
 Contrasting D, blood group antigens within most other blood group systems result 
from single nucleotide polymorphisms (SNPs) in the allele, thereby not interfering with 
the antigen’s expression, but resulting into aminoacid substitutions and consequently 
conformational changes of the protein. For example, the two major co-dominant alleles 
FYa and FYb differ from one another by one single nucleotide at position 125 (G vs A), 
resulting in a glycine or an aspartic acid amino acid at position 42 of the extracellular 
amino-terminal domain of the protein.10 
 As a result of the polymorphic nature of red cell antigens, encountering donor red 
cells expressing non-self antigens might provoke the recipient’s immune system and 
induce an immune response towards these alloantigens. The final outcome of this 
immune response is the formation of alloantibodies. This process is called ‘red cell allo-
immunization’ and forms the focus of this thesis. 
10
CHAPTER 1
Red blood cell alloimmunization: basic immunological 
principles
Although a full immunology review is beyond the scope of this thesis, some general 
concepts of a humoral immune response, and in particular the process of red cell allo-
immunization, might help understand the here presented studies. 
Antibody formation: a delicate interplay of innate and  
adaptive immunity
The immune system is typically divided into an innate and an adaptive immune system. 
Innate immunity refers to non-specific defense mechanisms that come into play immediately 
or within hours of a foreign antigen’s appearance. As such, the innate immune system 
provides a first line of defense against common structures associated with microorganisms. 
In contrast, an adaptive immune response involves a more complex, antigen-specific 
response that is initiated only days following foreign antigen exposure. An adaptive 
immune response enables an immunological memory. As such, upon repeated contact 
with the antigen, the immune system can generate a faster and more magnified response. 
 The innate and adaptive immune system form no separate systems, but strongly 
cooperate with antigen presenting cells (APCs) such as dendritic cells (DCs) and 
macrophages. These APCs provide a crucial link between the two systems and serve as 
the sentinels of the immune system. Surveying the tissues and instructing the adaptive 
immune system in response to peripheral cues,11-14 APCs with their pattern recognition 
receptors (PRPs) here recognize foreign chemical motifs (PAMPs) commonly present in 
non-mammalian organisms, as well as products released from damaged self-tissues 
(DAMPs). Both serve as ‘danger signals’, inducing APCs to mature and migrate to the 
peripheral lymphoid tissues (i.e. lymph nodes, the spleen and the liver). Here, they can 
prime antigen-naive cells of the adaptive immune system by presenting them processed 
discrete peptide fragments within the context of specific human leucocyte antigen (HLA) 
class I and II.15,16 Interactions between costimulatory molecules expressed by the 
maturated APCs and their ligands on adaptive immune system cells are vital in this 
process.17
 The adaptive immune system consists of T lymphocytes and B lymphocytes. Naive T 
cells fall into two large classes. CD8 cytotoxic T cells are critical for the defense against 
viruses and other intracellular pathogens. Via their T cell receptor (TCR), they recognize 
fragments of viral peptides in the context of HLA class I on the external surface of infected 
cells and are directly responsible for killing of these cells.17 In contrast, CD4+ T cells tightly 
orchestrate the behavior and activity of other immune cells by providing essential signals 
to these cells, but they do not have the intrinsic ability of pathogen clearance. Naive CD4+ 
T cells are activated after interaction with antigenic peptides in HLA class II and subsequently 
differentiate into specific subtypes, the latter depending mainly on the cytokine milieu of 
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the microenvironment.18,19 In contrast to cells of the innate immune system which can 
each recognize a wide diversity of pathogens, each cell of the adaptive immune system 
is restricted to respond to one specific antigen. As such, via a complex and elegant 
mechanism of gene rearrangements, a wide diversity in the antigen-receptor repertoire is 
generated, allowing accurate immune surveillance of the tissues.17 
 B lymphocytes are essential for the development of a humoral immune response. 
These cells are generated in the bone marrow after which they continue their development 
in the spleen further maturing into either follicular or marginal zone B lymphocytes.20,21 
Their primary function is to produce antibodies directed against foreign extracellular 
structures. B cells recognize foreign antigen via their unique B cell receptor (BCR), which, 
similarly to T cells, is generated via gene rearrangement processes hereby resulting into 
a wide range of antigen specificities to be represented in its repertoire. The BCR is a 
cell-surface immunoglobulin that has the same specificity as the secreted antibodies 
these cells eventually produce upon activation. When circulating matured follicular B cells 
access the follicular areas of peripheral lymphoid organs, they may recognize foreign 
antigen on APCs via their BCR, internalize, and subsequently present antigenic peptides in 
the context of HLA class II. 
 Upon antigen recognition, B cells proliferate and may rapidly differentiate into anti-
body-secreting plasmablast.21 These cells are short lived. Hence, antibodies produced by 
these cells, often being from IgM class, are usually only shortly present after immunization.16 
A few of the antigen-engaged B cells will undergo further modifications in the germinal 
center of the secondary lymphoid organs (i.e. proliferation, somatic hypermutation, and 
immunoglobulin class switching), inducing the formation of highly effective plasmablasts 
that secrete high affinity antibodies of IgG class.22-24 As this process of antibody formation 
requires accessory signals coming from primed CD4+ T follicular lymphocytes (TFH),
24 this 
route is called thymus-dependent B cell activation. 
 Contrasting thymus-dependent pathways, some antigens are capable to induce B 
cell proliferation in the absence of T cell help. These T-independent antigens for example 
comprise bacterial or viral structures such as lipopolysacharrides and specific DNA or RNA 
repeats.25,26 In humans, splenic marginal zone B cells are important for this process.20,27 
Here, antigenic cross-linking of BCRs on B cells directly induces these B cells to become 
activated, maturate to plasmablasts, and secrete antigen-specific antibodies. T cell 
independent B cell responses usually do not induce immunoglobulin class switching and 
the process is thus characterized by IgM production. In the context of red cell alloimmu-
nization, this route of antibody production applies to carbohydrate red cell antigenic 
structures e.g. antigens within the ABO and Lewis blood group systems.28,29 In addition, 
alloantibodies against these antigens may occur “naturally” (i.e. lacking antigen exposure 
in the context of red cells) due to antigenic crosslinking with common bacterial poly-
saccharides. In this regard, isoagglutinins to the A and B antigens develop early during 
childhood, depending on the person’s own bloodgroup, due to common exposure to 
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bacterial epitopes resembling these red cell antigens. As these anti-A and anti-B IgM 
antibodies are complement-binding, life-threatening intravascular hemolysis can occur 
upon an ABO mismatched red cell transfusion. 
Antibody formation to red cell antigens
In contrast to most immunogens from microbial organisms being consumed and 
processed in lymph nodes, murine models have shown that senescent and damaged red 
cells are anatomically sequestered in the red pulp of the spleen and (to a lesser degree) in 
the liver.30,31 Here, red pulp macrophages predominantly clear the majority of these red 
cells via phagocytosis.30,32,33 Although less capable than DCs, macrophages are also 
involved in antigen presentation, hereby being able to activate antigen-specific B and T 
cells in case of red cell alloantigen exposure. 
 Contrasting the leading role of macrophages under steady state, in the presence of 
a pro-inflammatory stimuli such as the synthetic dsDNA poly(I:C),34 CD11c+ DCs were 
identified as the primary contributors to splenic red cell consumption in mice.31 
Remarkably, plasmacytoid but not conventional DCs seemed responsible. DCs are potent 
antigen presenters and although conventional DCs are more equipped to this function 
than plasmacytoid DCs, both unconditionally require TLR-mediated activation for their 
functioning.35 Consequently, it could be hypothesized that splenic DCs are critically 
responsible for the consistently reported enhanced red cell alloimmunization responses 
observed with poly(I:C) or CpG oligonucleotide induced inflammation.30,36-38 
 In consistence, substantially decreased antibody formation was observed in 
splenectomized mice as compared to non-splenectomized mice. This was shown to at 
least be the result of an impairment of CD4+ T cell priming and expansion,38 a process for 
which DCs again are pivotal. Consequently, antigen-engaged B cells will have been 
prevented from further differentiation into antibody-secreting cells, as they did not receive 
additional required signals. A possible restraint to B cell antigen-priming, as well as red 
cells potentially shunting away from an immunogenic organ towards a more tolerance 
inducing compartment (i.e. the liver)39 are two other valid, though currently not evaluated, 
hypotheses. 
 Taken together, the spleen seems to play a pivotal role in red cell alloimmunization, 
at least in mice. 
Red blood cell alloimmunization: the issue
The process of alloantibody formation in itself may not be harmful. Indeed, antibodies of 
several specificities are known to be seldomly of clinical relevance.6 However, other 
alloantibodies potentially bind donor red cells expressing the allogeneic antigen and 
mediate accelerated destruction of these cells. The efficiency of this red cell clearance is 
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determined by the antibody’s (sub)class, its affinity for the antigen, its complement 
activating capacity, the red cells’ antigen density, and even the unique characteristics of 
the individual’s Fcγ receptors on mononuclear cells.16,40,41 Antibodies that have the 
potential to bind and activate complement may cause intravascular, often severe, red cell 
lysis by induction of membrane-attack complexes. In contrast, red cells opsonized with 
antibodies that lack complement binding are mainly removed in the spleen by cells of the 
mononuclear phagocyte system, while complement binding to red cells makes their 
clearance in the liver more likely.16
 Acute, intravascular IgM and/or complement mediated hemolysis occurs within 
24 hours of blood transfusion. ABO incompatible red cell transfusions in the presence of 
IgM antibodies directed against the A or B antigens are often the responsible cause.3 
Acute reactions may present with sudden onset of fever, flushing, hypotension, pain, 
dyspnea, hemoglobinuria, renal failure, and disseminated intravascular coagulation. As a 
result of current ABO/RhD matching and stringent antibody screening policies, these 
complement-mediated reactions have become relatively uncommon with an estimated 
frequency of 1 per 100,000 red cell units administered.42 Despite, international hemovigilance 
reports have been documenting them for more than two decades as one of the main 
leading causes of transfusion-associated fatalities, with the major part of these events 
resulting from clerical errors.43-46
 Delayed hemolytic transfusion reactions (DHTR) occur at a higher frequency as compared 
to acute reactions.42 As antibody evanescence limits the ability to detect previous 
immunization by pretransfusion antibody screen, re-exposure to a given red cell antigen 
may evoke a secondary immune response in a patient previously sensitized to the antigen. 
Typically, antibodies directed against Rh, Kidd, and Duffy-system antigens are implicated 
in these reactions.47,48 Symptoms may vary from only an asymptomatic positive direct 
antiglobin test (DAT) reaction to fulminant hemolysis resulting in severe anemia (i.e. 
delayed serological vs delayed hemolytic transfusion reaction). Difficulties in obtaining 
compatible blood or fear of further alloimmunization may in these cases even prevent 
receiving needed blood transfusions. Several cases of deceased alloimmunized sickle cell 
disease patients due to a DHTR have been reported.49 In addition to inducing hemolysis 
of donor blood, anti-D among others is known for its capability to induce hemolytic 
disease of the fetus or newborn (HDFN) due to maternal immunization against the 
paternal antigens of the unborn child.50,51 
 Finally, and in addition to the above mentioned clinical complications, the substantial 
financial costs and logistical challenges brought about by red cell alloimmunization 
deserve emphasis. Determination of the specificity of the detected alloantibodies, often 
by complex and additional serologic work-up, and the difficulties in supplying sufficient 




Red blood cell alloimmunization: detection
Type and screen
Prior to their first transfusions, all patients are routinely typed twice for ABO and RhD and 
subsequently transfused with blood compatible for these antigens.52 Typing of minor 
antigens is not performed on routine basis and depends on the policy described in (national) 
guidelines, which may be different for certain specific indications. Such indications involve 
specific diagnoses or clinical situations known to induce a chronic transfusion support 
or a higher chance of alloimmunization, e.g. previously immunized patients and patients 
with hemoglobinopathy.52 In this regard, knowledge on which antigens are not expressed 
on the patient’s red cells enables to select donor units that similarly lack expression of 
these antigens and thus will not elicit alloimmunization. 
 In addition to blood group typing, patients in the Netherlands are routinely screened 
for the presence of red cell alloantibodies within 72 hours prior to each red cell transfusion. 
Screening involves testing the patient’s serum against a commercially available 3-red cell 
test panel, which combines expression of all clinically relevant antigens. Aiming to avoid 
false-negative test results, this 3-cell screening panel is required to homozygously express 
the antigens D, C, c, E, e, k, Fya, Fyb, Jka, Jkb, M, S and s, while K needs to be present minimally 
heterozygously.52 The presence of Cw, Lua, Wra, and Kpa is not mandatory52 and hence, 
antibodies against these antigens might therefore not become detected by screening. 
The technique involves an indirect antiglobulin test (IAT) performed at 37°C. Here, the patient’s 
serum is incubated with donor red cells. If present, alloantibodies from the patient’s serum 
will bind to their cognate antigens expressed by the test red cells. As monomeric IgG anti- 
bodies cannot cross-link adjacent cells, IgG opsonized donor red cells will only agglutinate after 
adding a polyclonal mixture of anti-human IgG antibodies. This agglutination is visualized 
by a clump of red cells. When this screening test is positive, the antibody specificity is 
subsequently determined using the same technique with one or more extended panels 
of donor red cells of known phenotypes.3,52 
 For all patients with clinically relevant alloantibodies, neonates up till three months of 
age, patients who received a solid organ transplant as well as those who received an ABO 
incompatible allogeneic stem cell transplant, an additional cross match safeguard procedure 
is required to ascertain donor compatibility. This cross matching involves testing the 
patient’s serum against the donor erythrocytes unit via the same IAT technique described 
above. 
Genotyping
Although standard serological typing currently remains the gold standard, in the last few 
decades other techniques adding to the sensitivity of typing have been intensively sought for. 
 Compared to conventional serology, DNA-based methods are better suited to detect 
the presence of variant antigens.53 For example, with serological typing, prophylactic D, C, 
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E, and K matching did not prevent sickle cell disease patients to develop a high rate of 
antibodies with Rh specificities even despite receiving blood from predominantly African- 
American donors (i.e. ethnically matched).54,55 As of 1 May, 2016, an actively maintained 
database contains 45 red blood cell genes with together 1,744 alleles4,56 and only the 
allelic sequence of some common nonpolymorphic antigens has yet to be unraveled.9 
 In addition, blood group genotyping provides a means to identify the (absence of) 
antigen expression when test antisera from immunized donors are rare or notoriously 
unreliable, the latter for example being the case for the Dob antigen in the Dombrock 
blood group system.57 As such, genotyping of identified SNPs can function as an additive 
to conventional serological typing,53,57 especially since a wide variety of low- and high 
throughput platforms are now available.53 As an example, the European Bloodgen 
consortium has developed a Luminex beads array capable to genotype over 116 blood 
group-specific SNPs (BLOODchip). The last CE-marked version of this array types 29 SNPs 
that together determine 37 antigens among 10 blood group systems (RhCE, Kell, Kidd, 
Duffy, MNS, Diego, Dumbrock, Colton, Cartwright, and Lutheran) within only four hours 
on the basis of a sample.58 Specifically paid attention for during the developmental 
process, it has gained a high sensitivity to predict unusual Rh variants, although ABO and 
RhD typing is currently not reliably accurate for diagnostic clinical practice.59 
 Yet, simply replacing conventional serological typing by DNA-based methods is 
currently precluded. First, for antigens that are not the direct product of an allele, the 
phenotype may not be easily predicted by the genotype. In this regard, DNA-based 
methods can have problems in discriminating the O allele from an A1 allele, because 
inactivating mutations in the glycosyltransferase gene may occur at many different places 
in the coding region of the gene.9 Second, exchange of DNA sequences between closely 
linked genes may induce all kinds of rare variant gene products.53 Third, the high costs of 
these genotyping techniques currently do not justify a general introduction.9 Finally, false 
prediction of a positive antigen status can occur if an inactivating mutation affecting 
antigen expression (i.e. null phenotype) is not included in the assay.53 
 Despite the above, molecular typing has deserved its credits over the past decades 
and will become more and more important. As such, current useful applications of 
DNA-based typing in transfusion medicine involve fetal Rh DNA typing, red cell antigen 
typing  for the already alloimmunized recipient, determining antigenic phenotypes in 
patients for whom this is serologically impossible (i.e. recently transfused, autoimmune 
antibodies), and donor screening aiming to detect rare blood group phenotypes.9,60
 In future, serological typing especially for post-transcriptional determined blood 
groups like ABO will remain indispensable, however, genotyping likely will become more 
widely available for red cell recipients expected to easily develop alloantibodies. In 
addition, mass-scale genotyping of blood donors will support the expansion of the 
antigen- negative red cell units inventories. Consequently, a more universal application of 
molecular technologies for both donors and recipients of red cells will undoubtedly 
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become integrated into the clinical practice. As such, these new technologies add to the 
prevention of alloimmunization. 
Red blood cell alloimmunization: prevention
Red cell antigen matching: current practices
Currently, all recipients of donor red cell units in developed countries receive ABO and 
RhD compatible blood, hereby avoiding direct ABO incompatibility-mediated hemolysis 
and exposure to the highly potent antigen D.61,62 Despite the effectiveness of antigen 
matching at reducing alloimmunization rates,63-66 alloantibodies against other antigens 
are not prevented by these general measures and attribute to morbidity and even several 
deaths yearly.44,45 
 Although a complete antigenic donor-recipient phenotype match would theoretically 
eliminate all elective transfusion-induced alloimmunizations, this practice is extremely 
expensive and labor consuming. The next best alternative would be to select donor units 
matched at least on the most immunogenic antigens for at least the patients with a higher 
than average alloimmunization risk. In line with this, patients with myelodysplastic 
syndrome, and auto- and/or alloimmunized patients in the Netherlands receive C, c, E, e, 
and K matched blood.52 Similarly, women under 45 years of age receive c, E, and K 
compatible units as alloimmunization might severely complicate future pregnancies if the 
fetus expresses these antigens by paternal inheritance. Patients with hemoglobinopathy 
in addition receive Fya, and preferentially Jkb and Ss matched blood.52 Although several 
studies have clearly demonstrated patients with sickle cell disease to benefit from 
extended matching,63,66,67 for other patient populations, such as women of childbearing 
age and patients with myelodysplastic syndrome, current practices have been merely 
based on expert opinions. 
Determinants of red cell alloimmunization
Earlier reports, including one of our own, illustrated that only a minority of the intensively 
transfused patient population eventually develops alloantibodies despite repeated 
exposure to hundreds of different non-self red cell antigens.68,69 Whether or not a red cell 
recipient ultimately mounts an alloimmune response thus is not a default occurrence, but 
instead seems to depend on various, currently ill defined, factors related to exposure 
loads, the antigen, and the recipient’s immune system’s condition.
Exposure
A first and absolute prerequisite for transfusion-induced alloimmunization is exposure to 
a non-self red cell antigen. In this regard, allogeneic red cell exposure 68-70 and, more 
specifically, exposure to high immunogenic alloantigens, are important determinants of 
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alloimmunization that increase the chance of alloimmunization. Additionally and as 
specified in chapter 2, this chance further depends on the likelihood to encounter a 
non-self antigen and thus on the antigen distribution among both the recipient and the 
donor population. Consequently, ethnicity determined blood group variations between 
e.g. patients with thalassemia or sickle cell disease and their donors, the latter in the 
Netherlands in general being from Caucasian background, at least partly explains why 
these patients have a larger alloimmunization risk.6,54,70,71
Antigen immunogenicity
Second, the potency of an alloantigen to trigger an adaptive immune response is of 
importance and is defined as the antigen’s immunogenicity. Here, the probability that 
non-self peptide fragments fit into the pocket of a human leucocyte antigen (HLA) class II 
and are subsequently presented to CD4+ T cells, logically increases with the number of 
non-self epitopes on the polypeptic structure of the antigen. Similarly, the likelihood that 
multiple antigen-specific naive B cells are present will increase with the degree of 
foreignness of the antigen. Even though a substantial homology between the RhD and 
RhCE genes exists,6 the complete absence of the D protein in RhD-negative individuals 
guarantees exposure to several non-self epitopes when RhD positive red cells are 
transfused. 72,73 The D antigen in this regard represents the most immunogenic red cell 
antigen74 with anti-D formation observed in around 30% of the transfused patient 
population and in up to 80% of healthy volunteers after one single transfusion.61,62,75 
Consequently, as polymorphic red cell antigens within minor blood group systems differ 
to a far lesser extent from one another, this might be one reason why they are far less 
immunogenic than D. 
 Another concept of red cell antigen immunogenicity involves the non-exofacial 
polymorphic structures (NEP) hypothesis, proposed by Zimring et al.76 B cells, via their 
BCR, only recognize molecular structures presented on the outer membrane of red cells. 
However, by internalizing (parts of) the red cell and subsequently presenting both 
extracellular (B cell epitope) and NEP structures, T cells specific for epitopes other than the 
(extracellular) B cell epitope might be able to stimulate these B cells. Thus, next to the 
number of B cell epitopes, the number of NEPs will also determine the immunogenicity of 
the antigen.76 Similarly, the NEP mechanism may induce activation of autoreactive B cells 
even when autoantigen specific T cells are absent.
Patient specific characteristics
Third, the patient’s genetic constitution (nature) as well as nurture-related characteristics 
e.g. environmental factors and the disease related factors, will likely govern the immune 
system’s ability to evoke a red cell alloimmune response.  Available evidence supports 
the view of a ‘responder population’, i.e. patients responding to red cell alloantigens at 
much higher rates than the general transfused population.68 
18
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Several studies implicated polymorphisms in the human leucocyte antigen (HLA) genes 
to affect alloimmunization. Even when a recipient is exposed to antigenic incompatible 
donor red cells, an alloimmune response will only be initiated when these incompatible 
antigens subsequently are presented to cells of the adaptive immune system. In this 
regard, the likelihood of a naive CD4+ T cell to encounter a foreign red cell peptide in the 
context of HLA class II both depends on the foreignness of the antigen as well as on the 
HLA type itself. Thus, the patient-specific HLA type could be responsible for shaping the 
T cell repertoire and thereby determining the likelihood of antigen-specific B cell 
activation.72 Indeed, the high immunogenicity of K might mirror the low HLA restriction 
of this antigen,77,78 while for Kidd and Duffy antigens only particular HLA types seem to 
predispose to antibody induction.78-81 Next to HLA, mutations in genes of importance to 
the functioning of both the innate and adaptive immune system might influence allo-
immunization as well (e.g. cytokine, chemokine, surface receptors, and intracellular signaling 
pathway genes). These have not been broadly investigated so far. One small study in sickle 
cell disease patients reported on a potential role for the TRIM21 gene, which is important 
for intracellular antibody neutralization of coated virions and stimulation of several pro- 
inflammatory transcription pathways.82,83 However, these results might have been due to 
chance as two other studies were not able to confirm this.84,85 In a subsequent case-control 
genome-wide association study, a suggestive association between SNPs in the inhibitory 
Toll-like receptor-10 gene and red cell alloimmunization was reported, albeit again the 
small sample size of the study and the lack of significance prevent firm conclusions.84 
In conclusion, except from some suggestions made for an existing association between 
alloimmunization and HLA type, current available knowledge on genetic variations is 
insufficient to identify the high-risk patient population.
 With regard to clinical conditions, some more evidence is available. Many studies 
have highlighted the high alloimmunization prevalences among patients with sickle cell 
disease and thalassemia. In addition to the large antigenic disparity between these 
patients and their mainly Caucasian red cell donors as well as their often continuous 
dependency on red cell transfusions,54,71,86,87 a potential influence of disease-related 
chronic inflammation has been suggested to contribute to high alloimmunization risks. 
88-90 In line, several murine studies have consistently marked experimentally induced 
inflammation to be a major determinant of alloimmunization.30,36,37,91
 Finally, an enhanced alloimmunization susceptibility has been reported for patients 
with myelodysplastic syndrome (MDS).92-94 Yet, these prevalence-deduced results should 
at least be ascribed to the patients’ high transfusion burden.94 A possible attributable 
influence of other disease related features, e.g. intrinsic biological disease characteristics 
and treatment modalities, has so far been unclear, as various conclusions have been 
proposed.92,93,95,96 Evidence for risks in patients with other oncological disease entities has 
been lacking, except for one study reporting comparable risks for oncologic and non- 
oncologic patients. However, this study based its conclusions on a patient population 
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with a heterogeneity of oncological diagnoses.97 Since the degree of treatment-induced 
immunosuppression will be closely related to the specific oncologic diagnosis, alloimmu-
nization rates observed in a mixed oncologic patient population might not correlate well 
to disease-specific risks. 
The R-FACT study: Risk Factors for Alloimmunization 
after red blood Cell Transfusions
Taken together, there is an urgent need to advance our understanding of the process of 
alloimmunization. A thorough identification of conditions critical for red cell alloimmuni-
zation would help to better discriminate patients likely to induce alloantibody formation 
from those not responding.  As such, this knowledge could support tailoring matching 
strategies, hereby aiming to eradicate transfusion-induced alloimmunization and its 
clinical consequences. 
 The establishment and implementation of a so-called ‘alloimmunization prediction 
score’ in this respect might serve as an important tool for this goal. Such a validated score 
might enable the physician to allocate extended matched blood principally to the 
high-risk patient who will benefit most from extended matched blood. Consequently, this 
could initiate the alignment and optimization of donor management, with sizes and 
variations of blood inventories being adjusted to specific patient needs. 
 With this perspective in mind, the R-FACT study was initiated in 2008. Its case-control 
study design enables to efficiently investigate the associations of several determinants 
with a rather low-prevalent outcome (i.e. alloimmunization). By using an incident new-user 
cohort as source population and subsequently matching non-alloimmunized controls to 
alloimmunized cases based on the number of (lifetime) transfusions, selection of existing 
cases as well as of prevalent transfused recipients was avoided. This ‘incidence-density 
sampling strategy’ guarantees matched controls to form a representative sample of the 
non-alloimmunized transfused source population and to have been exposed to at least 
the same number of transfusions as their matched cases.98,99 Yet, as controls did not 
develop alloantibodies despite their cumulative exposure being at least equivalent to that 
of cases, identification of other risk-modifying factors is permitted.
 By using this R-FACT study design first in a two-center source population of 5,812 
patients, including 156 cases and 312 randomly selected controls, our group previously 
concluded and reported that the storage time of red cell units, evaluated for a clinically 
relevant range between 7 and 28 days, is not associated with the post-transfusion risk of 
alloimmunization.100 In addition, it was illustrated that only the total number of red cell 
units received rather than the time frame over which these units are received (i.e. massive 
versus dispersed) determines red cell alloantibody formation.69,101 
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CHAPTER 1
Outline of this thesis
Since the initiation of the R-FACT study and its first published reports, the two-center 
R-FACT patient cohort has been expanded to a cohort of 24,063 newly-transfused patients 
who were consecutively transfused in six different hospitals in The Netherlands. Participating 
hospitals include three academic hospitals (Leiden University Medical Center, Leiden; 
University Medical Center Utrecht, Utrecht; and VU Medical Center, Amsterdam) and 
three non-academic hospitals (Catharina Hospital, Eindhoven; Jeroen Bosch Hospital, 
‘s Hertogenbosch; and HagaHospital, The Hague). Enlarging our case-control cohort as such 
allows identification of additional conditions that impact the red cell alloimmunization 
process, either related to common disorders or to more specific, rare disease entities. 
The above mentioned studies by Zalpuri et al primarily focused on the association 
between donor-related factors and red cell alloimmunization.69,100 Continuing this research 
line, but now focusing on recipient-related factors, the studies presented in this thesis 
specifically set out to identify clinical conditions determining the process of red cell allo-
immunization. 
 As one of the most important elements of red cell matching strategies, chapter 2 
provides qualitative and quantitative data on the intrinsic potency of several red cell 
antigens to induce red cell alloimmunization. If one fulfills the criteria to receive extended 
matched blood, the likelihood of allogeneic antigen exposure as well as the antigens’ 
immunogenicities will need to be weighed against one another in order to decide on the 
optimal antigen subset this patient deserves to be matched for. In chapters 3-6, we 
subsequently examine which of several potential risk-modifying clinical conditions need 
to be taken into account. We here consecutively study the influence of various types of 
infections with their associated degrees of inflammation (chapter 3), the critical role of 
the spleen in red cell alloimmunization (chapter 4), the effect of general immunosuppressive 
therapeutic agents (chapter 5), and the association of various hematological malignancies 
and solid cancers with red cell alloimmunization (chapter 6). Regarding the latter, disease 
associated treatment regimens as potential strong immunomodulating factors were 
specifically assessed and found to be of major influence. Chapter 7 highlights and 
discusses several of the topics of this thesis and postulates perspectives for future research 
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RED CELL ALLOIMMUNIZATON  
IN RELATION TO ANTIGENS’ EXPOSURE  







Matching donor red cells on recipient antigens prevents alloimmunization. Knowledge 
about the immunogenicity of red cell antigens can help optimize risk-adapted matching 
strategies. We set out to assess the immunogenicity of red cell antigens.  
Methods
In an incident new-user cohort of 21,512 previously non-transfused, non-alloimmunized 
Caucasian patients receiving non-extended matched red cell transfusions in six Dutch 
hospitals between 2006 and 2013, we determined the cumulative number of mismatched 
red cell units per patient. Missing antigen data were addressed using multiple imputation. 
Using Kaplan-Meier analysis, we estimated cumulative alloimmunization incidences per 
mismatched antigen dose as a measure of immunogenicity.  
Findings
Alloantibodies occurred in 2.2% (474/21,512) of all transfused patients with cumulative 
allo immunization incidences increasing up to 7.7% (95% confidence (CI) interval 4.9-11.2) 
after 40 units received. The antigens C, c, E, K, and Jka were responsible for 78% of allo-
immunizations in our cohort. K, E, and Cw were the most immunogenic antigens (cumulative 
immunization incidences 2.3% (CI 1.0-4.8), 1.5% (CI 0.6-3.0), and 1.2% (CI 0.0-10.8) after 
2 mismatched units). These antigens were 8.7, 5.4, and 4.6 times as immunogenic as Fya. 
This immunogenicity order was followed by e, Jka, and c (1.9, 1.9, and 1.6 as strong as Fya). 
Interpretation
Red cell antigens vary in their potency to evoke a humoral immune response. Our findings 
highlight that donor-recipient red cell matching strategies will be most efficient when 
primarily focusing on prevention of C, c, E, K, and Jka alloimmunization. Matching for Fya is 
of lower clinical relevance. Ethnicity determined variations of antigen frequencies prevent 
extrapolating these conclusions to non-Caucasian populations. 
Funding
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THE INTRINSIC IMMUNOGENICITY OF RED CELL ANTIGENS
Introduction
Exposure to foreign red cell antigens may induce alloimmunization. Notwithstanding 
current ABO/RhD matching and stringent antibody screening policies, life-threatening 
hemolytic reactions resulting from boosting of previously induced alloantibodies still 
complicate red cell transfusions.5,6 Moreover, previous alloimmunizations demand extensive 
laboratory efforts and can result in delays in finding compatible donor blood.
 A complete antigenic donor-recipient phenotype match would theoretically eliminate all 
transfusion induced alloimmunizations, however, meets countless logistical and financial 
challenges. The next best alternative is to select donor units matched at least on the most 
immunogenic antigens for patients at high risk. In line with this, patients with myelodysplastic 
syndrome, and auto- and/or alloimmunized patients in the Netherlands are advised to 
receive CcEe and K matched blood, while patients with hemoglobinopathy additionally 
receive Fya and preferentially Jkb and Ss matched blood as well.7 As alloimmunization can 
severely complicate subsequent pregnancies, women under 45 years of age receive cE 
and K matched blood.7 These matching strategies are based on broad expert consensus 
on the antigens’ immunogenicity i.e. their intrinsic potency to stimulate humoral immune 
responses. RhD is without doubt the most immunogenic antigen and is followed by K.1 
However, data on the relative immunogenicity of several other antigens is conflicting,1-3 
requiring additional observational evidence.
 We set out to quantify antigen-specific alloimmunization rates in relation to the 
cumulative number of mismatched transfusions per patient as a measure of the intrinsic 
immunogenicity of red cell antigens. This knowledge will enable an evidence-based design 
of optimizing matching strategies, balancing benefits against costs and logistic aspects.  
Methods
Study design and setting
We performed an incident new-user cohort study among patients consecutively transfused 
in three university hospitals and three non-university hospitals in the Netherlands. 
We included all previously non-transfused and non-alloimmunized patients who received 
at least one red cell transfusion during the study period, provided the availability of at 
least one pre- and post-transfusion antibody screen. The study period varied per hospital 
according to the electronic availability of necessary data: January 1, 2005 to December 31, 
2010 at Leiden University Medical Center (Leiden), September 6, 2006 to December 31, 2013 at 
University Medical Center Utrecht (Utrecht), November 19, 2011 to December 31, 2013 at VU 
University Medical Center (Amsterdam), May 1, 2007 to April 30, 2013 at Catharina Hospital 
(Eindhoven), July 1, 2005 to December 31, 2013 at Jeroen Bosch Hospital (‘s Hertogenbosch), 
and October 5, 2008 to December 31, 2013 at Haga Teaching Hospital (The Hague). 
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CHAPTER 2
We used the following safeguards. First, patients alloimmunized within seven days of a 
mismatched transfusion were excluded as they more likely presented boosting rather 
than primary alloimmunization. Second, the records of alloimmunized patients were 
consulted against the nationwide Dutch alloimmunization registry (TRIX)8 for earlier 
alloantibody detection in other hospitals. Third, allo- rather than auto-immunization was 
verified based on the patient’s phenotype. Fourth, as CcEe and K phenotypes for over 
99% of donor blood units were available, we excluded CcEe and/or K alloimmunized 
patients with no identifiable mismatched transfusion. Finally, we set out to exclude all 
patients who received more than only routinely (ABO/RhD) matched units. To that aim, 
we excluded women below 45 years of age who, in line with Dutch guidelines,7 receive c, 
E, and K compatible units. Auto-immunized patients without alloimmunization, and hemo-
globinopathy patients were excluded as they usually receive extended matched units as 
well.7 In addition, ethnicity determined differences in antigen distribution between hemo-
globinopathy patients and the Dutch, generally Caucasian, donor population would have 
led to unrepresentative alloimmunizations, further compromising the validity of antigen 
immunogenicity estimates. We did not exclude patients with myelodysplastic syndrome 
since, despite Dutch guideline advises,7 they do not receive extended matched blood 
(unpublished personal data). Infants under 6 months of age were excluded as poor 
antibody responses during the first months of life are reported.9 
 The study protocol was approved by the Ethical Review Board in Leiden and by the 
local board of each participating center. 
Detection of red cell alloantibodies
At a maximum of 72 hours prior to red cell transfusion, patients in the Netherlands are 
routinely screened for red cell alloantibodies. According to the Dutch transfusion 
guideline, commercially available screening cells are required to be homozygous positive 
for D, C, c, E, e, K, Fya, Fyb, Jka, Jkb, M, S, and s. The K antigen needs to be present minimally 
heterozygously. The presence of Cw, Lua, Wra, and Kpa is not mandatory on commercially 
available screening cells.7 
 Screening was performed using a 3-cell panel including an indirect antiglobulin test 
(LISS Diamed ID system (Bio-Rad, Cressier, Switzerland), or Ortho Biovue ID system (Ortho 
Clinical Diagnostics, Raritan NJ, United States)) and subsequent antibody identification. 
The antigen Cw was present on 93% of all 3-cell panels used during the time frame of this 
study. 
Data acquisition
Routinely stored data on red cell transfusion dates, product unique identification number, 
dates and results of antibody screens, antibody specificity, and patient’s date of birth and 
sex were gathered from the hospitals’ electronic laboratory information systems. 
31
THE INTRINSIC IMMUNOGENICITY OF RED CELL ANTIGENS
Available antigen phenotypes for all transfused products were delivered by Sanquin 
Blood Supply, Amsterdam, The Netherlands.
Statistical analyses
Overall and antigen-specific cumulative incidence of alloimmunization
All included patients were followed up and labelled as ‘alloimmunized’ upon a first-time 
alloantibody identification or as ‘non-alloimmunized’ if the alloantibody screen remained 
negative. 
 Cumulative numbers of transfused red cell units corresponded to the total number 
of units received up to the last available negative screen for non-alloimmunized patients 
and up to the last verified or presumed antigen-mismatched unit that preceded the first 
positive screen for alloimmunized patients (Figure S1). Consequently, transfusions received 
after these screens were not taken into account. Using Kaplan-Meier survival tables, we then 
calculated overall cumulative alloimmunization incidences and subsequently cumulative 
incidences per antigen. 
 Cumulative incidences with 95% confidence intervals (CI) were calculated with Graphpad 
Prism version 6, using the exponential Greenwood formula. The association between sex 
and alloimmunization incidences was assessed with the log-rank test using SPSS version 
20.0. P-values <0.05 were considered to be statistically significant. 
Immunogenicity of red cell antigens
To evaluate the immunogenicity of various red cell antigens, we calculated cumulative 
alloimmunization incidences per antigen according to the total number of mismatched 
(i.e. antigen-positive) units a patient had received (Figure S1). For this purpose, only those 
at risk for alloimmunization against a given antigen should be considered, i.e. patients 
lacking expression of this antigen. As antigen phenotyping of non-alloimmunized patients 
is limited to ABO and RhD in the Netherlands, we established ‘antigen-negative cohorts’ 
comprising all (per definition antigen-negative) patients alloimmunized to a given antigen 
plus a randomly sampled subgroup of non-alloimmunized patients. Although patients in 
these sampled subgroups not necessarily all lacked expression of the corresponding 
antigen, they only functioned as a representative for the true antigen-negative, non-allo-
immunized individuals in the source population. We based the sampling sizes of these 
subgroups on known antigen frequencies in the Caucasian population.10 Thus, as 29% of 
the Caucasian population express the E antigen,10 71% of our source population lack E 
expression. Given an extensive size of the source population, the numbers of E-positive 
units received by the randomly sampled 71% will closely correspond to the numbers 
received by the true E-negative, non-alloimmunized individuals in the source population. 
This sampling method is not likely liable to selection bias as expression of a given antigen 




To address missing donor phenotypes, we used multiple imputation to complete the 
dataset. Details on frequencies of missing data and the used method are presented in 
table S1.  
 We then calculated cumulative alloimmunization incidences for each antigen according 
to the total number of mismatched units, except for antigens with over 50% missing data. 
 Finally, we compared antigen-specific cumulative alloimmunization incidences with 
those of Fya. Previously, comparisons with K were made.1-4 However, the rate of censoring 
between baseline and N transfusions may compromise the validity of estimated 
cumulative incidences (for illustration, see Supplementary Box 1). Consequently following 
the antigen’s low frequency, the reliability of estimated cumulative anti-K incidences 
decreases with the number of K-positive units exposed as only a few patients are 
repeatedly exposed to K. As in former reports Fya immunogenicity was in the middle of 
the extremes1-4 and as (except for S) the probability that a random individual both does 
not express a given antigen and is exposed to this antigen is the highest for Fya,10 we chose 
Fya as the reference. Due to the above mentioned issues regarding censoring, we only 
calculated cumulative alloimmunization incidences per antigen for antigen-negative 
cohorts containing at least 200 non-censored patients. 
Role of the Funding Source
This study was not externally funded. The corresponding author had full access to all of 
the data and the final responsibility to submit for publication.
Results
A total of 54,347 patients received their first red cell transfusion during the study period, 
of which 21,512 patients fulfilled the inclusion criteria. Figure 1 presents numbers of patients 
per exclusion criterion. The majority of the 32,835 patients deemed ineligible were 
excluded while no antibody screen was performed after their single transfusion episode 
(N=25,037). 
 Table 1 presents patient demographics. Patients received a median of 4 (interquartile 
range (IQR) 2-8) units of red cells during a median follow-up period of 86 (IQR 14-395) days. 
In 474/21,512 patients (2.2%), 536 first formed alloantibodies were detected, the majority 
being against C, c, E and K antigens (table 2). In 51 patients, the alloantibody was detected 
within the second week after the first documented antigen-mismatched transfusion.
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Figure 1  Study flow diagram.
Table 1  Patient demographics of the study population.
N=21,528
Men (N, %) 12,511 (58.1)
Age in years at 1st transfusion, median (range / IQR) 67.7 (0.5-107.2 / 57.5-76.9)
Cumulative units 153,429
Units per patient, median (range / IQR) 4 (1-462 / 2-8)
Follow-up in days, median (range / IQR) 86 (1-3155 / 14-395)
Alloimmunized patients 474
Alloimmunization frequency (%) 2.2
Follow-up period = period in days from 1st red cell transfusion up to the last negative antibody screen for non- 
alloimmunized patients, and up to the first positive alloantibody screen for alloimmunized patients.
IQR = interquartile range.
54,347 newly transfused
21,512 women ≥ 45 years + men of all ages
Excluded (n = 32,835):
No follow-up after single transfusion episode: 25,037
Infants < 6 months of age: 4,322
Women < 45 years: 2,551
Pre-transfusion positive screen: 543
Immunization to non-clinically relevant alloantigens
 or to auto-antigens: 230
RhD immunization: 60
Hemoglobinopathy: 38
Unidentified antigen mismatch: 43
Immunization within 7 days of antigen mismatch: 11
34
CHAPTER 2
Overall cumulative incidence of alloimmunization
The overall cumulative alloimmunization incidence increased to 7.7% (CI 4.9-11.2) after 
40 red cell units transfused (figure 2 upper panel). Antibodies to E and K were formed at 
the highest rates (figure 2 bottom panel). Table 3 presents cumulative alloimmunization 
incidences against various sets of antigens referenced to the overall cumulative alloimmu-
nization incidence after 40 units transfused. Hence, in this ABO/RhD matched patient 
cohort, 78.6% of alloimmunizations were due to immunizations against C, c, E, K, or Jka. 
 Frequencies of anti-c and anti-E mirrored RHD and RHCE gene linkage. In this respect, 
anti-c was only formed by RhD-positive patients and absence of RhD expression led to 
significantly less E alloimmunizations with cumulative allo-E incidences of 1.7% (CI 0.0-32.0) 
and 3.7% (CI 1.4-7.9) after 40 red cell units received for RhD-negative and RhD-positive 
patients, respectively (log-rank p<0.0001). RhD phenotype did not modulate the risk of 
immunization against other, non gene-linked, red cell antigens (figure S2). 
Table 2   Specificity and frequency of first-time formed clinically significant  







anti-C 22 (0.10) 18 (0.10) 4 (0.12)
anti-c 37 (0.17) 37 (0.20) 0 (0)
anti-E 177 (0.82) 173 (0.95) 4 (0.12)
anti-e 4 (0.02) 4 (0.02) 0 (0)
anti-K 122 (0.57) 95 (0.52) 27 (0.81)
anti-Cw 19 (0.09) 18 (0.09) 1 (0.03)
anti-Fya 24 (0.11) 21 (0.12) 3 (0.09) 
anti-Fyb 5 (0.02) 4 (0.02) 1 (0.03)
anti-Jka 50 (0.23) 41 (0.23) 9 (0.27)
anti-Jkb 7 (0.03) 7 (0.04) 0 (0)
anti-Lua 31 (0.14) 29 (0.16) 2 (0.06)
anti-Lub 0 (0.0) 0 (0) 0 (0)
anti-Lea 8 (0.04) 6 (0.03) 2 (0.06)
anti-Leb 3 (0.01) 3 (0.02) 0 (0)
anti-M 18 (0.08) 14 (0.08) 4 (0.12)
anti-N 1 (0.01) 1 (0.01) 0 (0)
anti-S 8 (0.04) 7 (0.04) 1 (0.03)
anti-s 0 (0) 0 (0) 0 (0)
All antibodies 536 478 58
Number of cases 474 (2.20) 419 (2.30) 55 (1.66)
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Figure 2   Cumulative alloimmunization incidences in the general population  
(upper panel) and according to antigen (lower panel).
Cumulative alloimmunization incidences as a function of cumulative red cell units exposed. Antibodies to E and 
secondary to K were formed at the highest incidence rates.
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Among patients over 45 years of age, women showed higher Rh (i.e. CcEe and Cw) and K 
alloimmunization incidences compared to men (7.9% (CI 3.2-15.3) versus 5.2% (CI 2.0-10.9) 
after 40 units received, log-rank p<0.0001, figure S3). Alloimmunization to non-Rh/non-K 
antigens did not differ between male patients under and above 45 years of age (log-rank 
p=0.705). 
Immunogenicity of red cell antigens
The antigen’s specific immunogenicity was derived from cumulative alloimmunization 
incidences according to cumulative antigen mismatched units received. Substantial missing 
antigen data for Leb, Lua, and Lub prevented immunogenicity calculations for these antigens 
(table S1).
 Cumulative alloimmunization incidences after exposure to only two antigen-positive 
units were 2.3% (CI 1.0-4.8), 1.5% (CI 0.6-3.0), and 1.2% (CI 0.0-10.8) for K, E, and Cw respectively. 
Less extensive responses were observed for e, Jka, and c (figure 3 upper panel, table 4). 
Following a similar amount of E exposure, anti-E formation did not differ between 
RhD-negative and RhD-positive patients (log-rank p 0.44).
 The calculated relative immunogenicity of K, E, and Cw was 8.7, 5.4, and 4.6 times 
higher than Fya after only two antigen-positive units. For e, Jka, and c these rates were 1.9, 
1.9, and 1.6, respectively. Relative immunogenicity rates were lower for the other antigens 
(figure 3 bottom panel). 
Table 3   Cumulative alloimmunization incidences (%) against various sets of antigens 





of all antibodies (%)
All antibodies 7.66 (4.89-11.24) 100
E 3.32 (1.20-7.25) 43.3
cE 3.59 (1.40-7.47) 46.9
cEK 5.20 (2.71-8.87) 67.9
cEeK 5.39 (2.84-9.12) 70.4
CcEK 5.74 (3.15-9.42) 74.9
cEK+Jka 5.67 (3.15-9.23) 74.0
CcEK+Jka 6.02 (3.46-9.55) 78.6
CcEK+Jka+Fya 6.24 (3.66-9.76) 81.5
CcEK+Jka+Fya+Cw 6.39 (3.81-9.88) 83.4
* Cumulative alloimmunization incidences as calculated for 40 red cell units transfused.
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When only Cw alloimmunized patients with a verified Cw mismatched transfusion were included 
in the above analysis (N=10, those with assumed Cw mismatched transfusions excluded), 
Cw alloimmunization incidences did not change substantially (1.2% (CI 0.0-10.8 versus 1.0% 
(CI 0.0-12.8) after 2 Cw positive units transfused, log-rank p=0.10).
 As an additional sensitivity analysis, results of antigen immunogenicity calculations 
repeated in only men were identical (figure S4).
Figure 3   The relative immunogenicity of specific antigens presented by cumulative 
alloimmunization incidences as a function of antigen exposure.
(A) Antigen-specific cumulative alloimmunization incidences according to number of antigen-positive red cell 
units received by the antigen-negative patient cohorts, and (B) as referenced to Fya. K, E, Cw, and to a lesser 
degree e, Jka, and c, are the most immunogenic antigens. 
Numbers at risk correspond to total number of patients within the corresponding antigen-negative cohort 
exposed to at least N antigen-positive red cell units. Only data from non-censored cohorts of at least 200 subjects 
are presented. 








































K 19,274    324      35       7      2
E 15,122 1,759    506   195     95
Cw 20,648      20        3       1       0
e      433    172      91     52     36
Jka   4,890 1,665    718   378   227
c   4,247 1,516    683   372   229
C   6,758 1,923    774   403   259
Fya   7,181 2,193    897   445   255
Fyb   3,583 1,278    560   290   172
Jkb   5,482 1,766    725   363   209
Lea 16,427 1,001    222     70     24
M   4,648 1,610    890   372   225
N   5,895 1,798    753   407   234
S   9,479 2,096    746   350   184
s   2,317    893    410   209   141
A
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Discussion
In this study covering 21,512 newly transfused patients, we established estimates of dose- 
specific red cell alloimmunization risks. In agreement with previous reports, K is most potent in 
stimulating humoral alloimmune responses. E demonstrates the second highest immuno-
genicity, and the order of antigen immunogenicity is then followed by Cw, e, Jka, and c. 
 The here established alloimmunization rate of 0.9% after one K-positive unit is five 
times lower than historically assumed.1 Moreover, as previous studies did not take into 
account the cumulative mismatched transfusion burden, contradictory conclusions 
regarding the immunogenic potency of other red cell antigens, including c and E, have 
been reported.1-4 Indeed, the seemingly flattening of the antigens’ alloimmunization risk 
curves illustrates that the chance to alloimmunization diminishes with subsequent antigen 
exposure. We therefore specifically set out to properly estimate the cumulative number 
of antigen-mismatched units each patient had received. Sampling specific-sized ‘antigen- 
negative cohorts’ for each antigen enabled us to estimate the cumulative antigen exposure 
within the true antigen-negative individuals. Selection bias did not interfere with this 
sampling method as the prevalence of a given antigen is not associated with the likelihood 
of exposure in non-alloimmunized patients. 
 The validity of our assessment is confirmed by the constant immunogenicity, though 
diverse alloimmunization rates against c and E, between RhD-negative and RhD-positive 
patients, as was expected based on the known RHD and RHCE gene linkage. Transfusing 
RhD compatible blood has long since been routine practice as this high immunogenic 



















































antigen induces allo-D in around 30% of D-negative transfused patients and in up to 80% 
of healthy volunteers.11,12 Due to this gene linkage, RhD matching not only prevents anti-D 
formation, but in addition effectively protects against E alloimmunization. That is, as only 
6% of the Caucasian RhD-negative population express the E antigen,10 RhD-negative 
patients are rarely exposed to E. Conversely, as 67% of RhD-positive individuals lack E,10 
23% of RhD-positive patients risk E alloimmunization with routine RhD matching. Moreover, 
the comparable anti-E formation after non-self E exposure between RhD-negative and 
RhD-positive patients mirrors the fact that RhD phenotype does not influence E-immuno-
genicity, rather that alloimmunization rates reflect (linkage dependent) exposure. Similarly, 
anti-c was only identified in the RhD-positive patient cohort as a RhD-negative phenotype 
is approximately always accompanied by expression of c. However, the chance of a 
RhD-positive patient to be exposed to c being a non-self antigen is 17%.10 
 Current Dutch matching regimens might seem strict compared to those of other 
Western countries. Despite, for prior auto- and/or alloimmunized patients, as well as for 
multi-transfused patients, better targeted matching will likely further reduce the risk of 
(additional) alloimmunization. As our data seem broadly applicable to populations of 
Caucasian origin, they enable further optimization as well as unification of current 
nationwide evidence-based guidelines. In this regard, matching seems most profitable for 
those antigens with relatively strong immunogenicity, moderate frequency, and potential 
clinical consequences. Hence, red cell transfusions limited to donor units compatible with 
the high to moderate immunogenic antigens C, c, E, K, and Jka would have reduced allo-
immunization incidences by 78%. In line with this, and as anti-Jka is notorious for causing 
delayed hemolytic transfusion reactions,6,13 additional Jka matching for the mentioned 
risk groups seems advisable. Due to its frequency in the Caucasian population and 
intermediate immunogenicity, matching for Fya should be considered optional. The need 
to additionally match for Cw seems debatable as, although this antigen is highly immunogenic, 
severe hemolysis by anti-Cw is rare14 and the chance of subsequent exposure after primary 
immunization small (2%).10
 In agreement with recent data from a 15% overlapping patient cohort,15 we found 
higher cumulative alloimmunization incidences in women compared to men over 45 
years of age, attributed to higher Rh and K alloimmunization rates. This finding is not easily 
accounted for by boosting of pregnancy-induced alloantibodies as we used several 
safeguards to exclude previously alloimmunized women. Moreover, despite (pregnan-
cy-induced) alloantibodies commonly disappearing,16,17 boosting seems an insufficient 
explanation as non-RhD alloantibodies form in only 0.33% of first trimester pregnancies18 
amounting for 30 of our 238 (12.6%) alloimmunized post-fertile women. Indeed, others 
have suggested estrogen or even persisting feto-maternal chimerism to modulate 
alloimmune responses in women.15,19
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Several factors and possible limitations of our results require discussion. 
 First, the time needed for an antibody to develop to serologically detectable levels 
potentially differs per antigen, but these ‘lag periods’ are currently unknown. Additionally, 
titers of previously formed alloantibodies can decrease over time to a degree that prior 
alloimmunizations are no longer detectable by serological tests. Subsequent exposure to 
the antigen might boost these ‘evanescent’ alloantibodies. Indeed, 25 to 40 percent of 
formed alloantibodies will become undetectable over time, with the highest rates 
reported for anti-Jka and anti-Cw.16,17 However, as evanescence rates largely depend on 
the time since exposure (for illustration, see Supplementary Box 2), we were not able to 
estimate the underestimating effect of antibody evanescence on our immunogenicity 
calculations.
 Second, anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M can also occur ‘naturally’, 
i.e. secondary to environmental antigen exposure.10 One might thus wonder whether the 
high immunogenicity of Cw should not be explained by high numbers of naturally formed 
anti-Cw. A sensitivity analysis, including only Cw alloimmunizations which were verified 
(rather than assumed) to be preceded by Cw mismatched transfusions, confirmed our 
conclusions. In fact, Cw immunogenicity may well have been underestimated as 7% of 
used screening cell panels did not present Cw and therefore could not detect anti-Cw. 
Next, some identified anti-M alloantibodies might have been only of IgM class. Although 
according to Dutch guidelines a reference laboratory should determine whether identified 
anti-M antibodies are due to warm-reacting IgG antibodies,7 this procedure has not been 
routinely followed in the Netherlands so far. 
 Third, we set out to exclude all previously transfused and alloimmunized patients. 
Eleven patients presented with a positive screen within seven days after the first anti-
gen-mismatched transfusion and were excluded as these might have reflected boosting. 
Nevertheless, while boosting periods can extend seven days and might even differ per 
antigen, we might not have excluded all previously alloimmunized patients. In this regard, 
51 of 474 patients (10.8%) tested positive for alloantibodies within the second week after a 
first mismatched transfusion, while only a subset of those (N=31) were also tested 
(negative) during the first week after transfusion. Next, due to some unavailable non-Rh/K 
donor phenotypes, it remains possible that we assumed a few of those phenotypes to be 
antigen-positive while in fact the alloimmunized individual was never exposed by 
transfusion. Finally, we cannot exclude that included patients received some transfusions 
in other hospitals prior or during the study period. Consequently, some overestimation of 
the antigens’ immunogenicity has to be reckoned.
 Fourth, we used multiple imputation addressing missing donor antigen phenotypes 
while, contrasting nearly complete CcEe and K phenotyping, expression of other minor 
red cell antigens is less extensively determined among Dutch donors. Several reports have 
emphasized the superiority of multiple imputation over the traditional missing data 
techniques.20-22 Considering data missing at random (MAR), limiting analyses to antigens 
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with less than 50% missing values, and the substantial sample size we performed this 
method in, our followed approach will likely have produced unbiased and rather accurate 
estimates of missing values.22 Our conservative approach, however, consequently 
disabled us from presenting any estimations on the immunogenicity of Leb, Lua, and Lub. 
While anti-Lua antibodies represented 5.7% (31/537) of all detected antibodies, we cannot 
exclude Lua to be of importance in alloimmunization. 
 Fifth, hemoglobinopathy patients, often frequently transfused but from non-Caucasian 
background, were not included in the study. While nearly all donors are of Caucasian 
origin,23 around 12% of the Dutch population is of origin other than Caucasian.24 This 
discordance may have led to a minor deviation of our estimated mismatched transfusions 
in the non-alloimmunized patients. Reported antigen immunogenicities may thus be slightly 
overestimated. In general, due to antigenic, immunological, and genetic differences between 
ethnicities,25,26 our results should not be extrapolated to populations of other ethnic 
backgrounds. 
 Sixth, although anti-D was detected in 60 of our newly-transfused patient population, 
we were unable to analyse and confirm the previously reported high immunogenicity of 
the D antigen11,12 for several reasons. Due to routine RhD matching, only a very small 
minority of our RhD-negative patients received D-mismatched units. Next, while the 
cause of anti-D was often not documented, these antibodies could have been due to 
either unmatched transfusions or recent anti-D administration. 
 Seventh, alloantibody responses may differ between various patient cohorts e.g. 
immuno suppressed versus immune activated patients.25,27,28 This, however, does not 
affect any of our conclusions as we only compared the immunogenicity of red cell 
antigens with one another within the same population. Nevertheless, alloimmunization 
risks will differ between patient cohorts and the here presented incidences should 
therefore not be generalized to populations other than general transfused patients. 
Studies in humans aimed at identifying factors of influence on immunization risks are in 
progress.28,29
 Finally, we did not adjust for homo- versus heterozygous donor genotypes as a 
variable of antigen dose. For most antigens, patients will have received mainly heterozygous 
donor units. As an example, the observed high immunogenicity of E and K is not distorted 
by minor cumulative dose differences as the homozygous prevalence rates are only 2.4% 
and 0.21%, respectively.30 Moreover, we previously did not find an association between 
massive versus dispersed transfusions on the risk of alloimmunization.31 
 Though beyond the scope of the present study, a few related and relevant subjects 
should be mentioned. As an optimal preventive matching strategy demands a compre-
hensively typed donor cohort, high-throughput genotyping might better facilitate rapid 
and complete typing in the near future.32,33 Next, antibody formations needs both 
sensitization of a B cell as well as priming of a naive CD4+ T cell. Thus, in some of our 
non-alloimmunized patients, alloreactive B cells to a given blood group antigen might 
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have been present, yet they lacked specific T cells recognizing a peptide as part of this 
blood group antigen in the context of human leucocyte antigen (HLA). Finally, knowledge 
on factors modulating subsequent alloimmunization (such as the type of first-time formed 
alloantibody possibly determining the rate and type of subsequent alloimmunization) 
might benefit the already alloimmunized patient. 
 In conclusion, the risk of red cell alloimmunization is related to both antigen exposure 
and the antigen’s immunogenicity. In this to our knowledge largest Caucasian cohort 
to date with a defined follow-up reaching an eight year period, we determined the 
immunogenic order of red cell antigens and quantified dose-based immunization risks 
with K and E being the most immunogenic antigens, followed by Cw, e, Jka, and c. Based 
on the likelihood of alloantigen exposure, the antigens’ immunogenicity, and the potential 
detrimental consequences of anti-Jka boosting, we recommend adding Jka matching to 
current CcEe and K based matching strategies, whenever possible and especially in 
high-risk patients. Matching for Fya can be considered, but, as compared to Jka, seems of 
lesser clinical significance. Due to antigenic frequency differences, these conclusions are 
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Supplementary Box 1  The effect of censoring on estimated cumulative incidences.
We calculated cumulative alloimmunization incidence rates only for antigen-negative 
cohorts containing at least 200 non-censored patients. This cut-off was chosen as the 
rate of censoring between baseline and N transfusions can compromise the validity of 
estimated cumulative incidences. In case of a low-frequent antigen (i.e. K), only a few 
patients will repeatedly be exposed to this antigen and the contribution of random 
error to the estimated cumulative incidence thus could become unacceptably large. 
With 200 patients under analysis, one random additional alloimmunization event will 
increase the cumulative alloimmunization rate by maximally 0.5%, which, in our 
opinion, justifies comparison of one risk curve to another. 
 For this same reason, we compared cumulative antigen-specific alloimmunization 
incidences with alloimmunization incidences of Fya. Previously, comparisons with K 
have been made.1-4 However, the reliability of estimated anti-K cumulative incidences 
significantly decreases with the number of K-exposed red cell units as only a minority 
of patients receive multiple K-positive units due to its low antigen frequency (being 
9% in the Dutch donor population).5 As in former reports Fya immunogenicity was in 
the middle of the extreme1-4 and as the probability of exposure to a non-self red cell 
antigen for a random individual is highest (except for S) for Fya,5 we chose Fya as the 
reference. 
 Finally, we present our data as ‘adjusted cumulative risk curves’. As alloimmunized 
patients are censored at the time of immunization, the size of the population at risk is 
reduced as a result of alloimmunization. Alloimmunization can thereby lead to an 
overestimation of the cumulative risk, mainly when a large number of immunization 
events take place. We therefore calculated ‘adjusted’ numbers of alloimmunized 
patients, equalling the number of alloimmunized patients that would have received N 
transfusions had they not been censored at the time of alloimmunization. We used 
these numbers for Kaplan-Meier analysis. 
 The examples A-C illustrate that the distribution of events and the rate of censoring 
can have dramatic effects on final cumulative incidences.
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A  The effect of event distribution on the cumulative risk.













1 10,000 50 0.50 0 0
2 9,000 50 1.05 0 0
3 8,100 50 1.66 0 0
4 7,290 50 2.33 0 0
5 6,560 50 3.08 0 0
6 5,910 0 3.08 50 0.85
7 5,310 0 3.08 50 1.78
8 4,780 0 3.08 50 2.81
9 4,300 0 3.08 50 3.94
10 3,870 0 3.08 50 5.18
Fictitious baseline cohort of 10,000 patients, censoring rate 10% per transfused red cell unit. The same 
number of events induces a higher cumulative risk when these events occur in a smaller cohort.
B  The effect of censoring rates on the cumulative alloimmunization risk.













1 10 10,000 0.10 10,000 0.10
2 10 9,000 0.21 5,000 0.30
3 10 8,100 0.33 2,500 0.70
4 10 7,290 0.47 1,250 1.49
5 10 6,560 0.62 625 3.07
6 10 5,910 0.79 313 6.17
7 10 5,310 0.97 156 12.18
8 10 4,780 1.18 78 23.44
9 10 4,300 1.41 39 43.07
10 10 3,870 1.67 20 71.54
Fictitious baseline cohort of 10,000 patients with a fixed number of 10 alloimmunization events per 
transfused red cell unit. Censoring rates of 10% versus 50% per transfused red cell unit. A high censoring rate 
induces a disproportionally increase of the cumulative risk.
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1 100 10,000 1.00 10,000 1.00
2 100 9,000 2.10 9,090 2.09
3 100 8,100 3.31 8,274 3.27
4 100 7,290 4.63 7,538 4.56
5 100 6,560 6.09 6,879 5.94
6 100 5,910 7.68 6,293 7.44
7 100 5,310 9.42 5,752 9.05
8 100 4,780 11.31 5,277 10.77
9 100 4,300 13.37 4,848 12.61
10 100 3,870 15.61 4,467 14.57
Fictitious baseline cohort of 10,000 patients, censoring rate 10% per red cell transfusion. Not adjusting for 
censored alloimmunized patients overestimates the cumulative risk after 10 red cell transfusions by 7.1% 
((15.61-14.57) / 14.57) * 100.
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Supplementary Box 2   Estimated evanescence rates are dependent on the time 
following antibody induction. 
Reported rates of evanesced antibodies6,7so far have been based on prevalences 
(i.e. the frequency of evanesced alloantibodies at a certain time point) rather than on 
incidences (i.e. the frequency of evanesced alloantibodies according to the time 
following exposure). These studies reported evanescence rates as high as 25 to 40% 
for anti-Jka and anti-Cw.  
 When considering these numbers, one should realize that the frequency of 
evanesced antibodies increases significantly with increasing time since antibody 
induction. Alloantibodies against antigens of moderate frequency will in general form 
rather early during the transfusion history as with every transfusion the likelihood to be 
exposed to this alloantigen is rather high. In contrast, induction of alloantibodies 
against low or high frequent antigens will be more evenly distributed along the 
transfusion history. Thus, even though two types of antibodies evanescence at the 
same rate, the observed frequency of evanesced antibodies will diverge with the 
number of red cell units exposed as illustrated in a fictitious example for anti-A and 
anti-B here below. In conclusion, reported rates of evanesced antibodies are highly 
dependent on the chance of alloantigen exposure and thus on antigen population 
frequencies. Addressing evanescence into incidence-based alloimmunization calculations 
is only possible with data on serological follow-up at multiple fixed times after antigen 
exposure being available. 







1 20 0 20 100
2 10 10 20 66.7
3 3 10 13 39.4
4 2 6.5 8.5 24.3
5 0 4.25 4.25 12.1







1 7 0 7 100
2 7 3.5 10.5 75.0
3 7 5.25 12.25 58.3
4 7 6.13 13.13 46.9
5 7 6.53 13.56 38.7
Fictitious example of a transfused cohort in which 35 patients formed alloantibodies against a moderately 




Due to a relatively high likelihood of (non-self) A exposure per time event, most of 
these anti-A’s will be formed early. Thus, in this example, 88% of the 35 formed anti-A’s 
will not be detected after a follow-up of 5 time events. In contrast, as anti-B forms at 
lower rates due to a lower chance of encountering this (non-self) antigen per time 
event, only 61% of the 35 formed anti-B’s will not be detected after a follow-up of 
5 time events. 
Table S1  Overview of missing donor antigen data and the use of multiple imputation.




















Percentages of missing antigen values in 152,412 red cell units transfused to 21,512 patients. 
To address missing donor phenotypes, multiple imputation was used thereby creating five imputed datasets. 
Here, we assumed randomness of missing data (i.e missing values depended on observed data, but not on the 
value of the missing variable itself).8,9 Imputation was only performed for antigen-negative cohorts with less 
than 50% missing antigen data. Consequently, Leb, Lua, and Lub were excluded from antigen immunogenicity 
calculations. 
Predictor variables for the imputation model included transfusion center, age under or above 45 years, sex, allo-
immunization status, and known red cell antigen phenotypes of the blood product (i.e. other, non-missing 
antigens).
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Figure S1   Illustration of calculations for cumulative numbers of transfused  
(antigen-mismatched) red cell units.
Non-alloimmunized patients were followed-up until their last available negative screen and alloimmunized patients 
were followed-up until the first positive screen. Alloimmunizations detected within seven days of a mismatched 
transfusion were excluded from analyses as they most likely represented boosting from previous induced alloim-
munization rather than primary alloimmunization. 
In this example, one non-immunized K-negative patient and one K-immunized patient both received four red cells 












Figure S2   RhD-negative individuals do not form anti-c and rarely anti-E.
Due to linkage of the RHD and RHCE gene, approximately all RhD-negative patients express the c antigen and 
cannot form allo-anti-c. As only 2.9% of RhD-negative Dutch donors are E-positive, RhD matching strongly 
reduces the risk of allo-anti-E formation in RhD-negative patients. RhD phenotype is not associated to the risk of 
alloimmunization against other red cell antigens as here demonstrated for anti-K.
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Figure S3   Cumulative alloimmunization incidences according to sex in patients aged 
45 years and above.






women > 45 years
men > 45 years
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Cumulative alloimmunization incidences, % (CI):
against all antigens against the antigens CcEe, Cw, and K










5 1.41 (0.56-3.01) 2.91 (1.59-4.88) 0.88 (0.24-2.48) 2.24 (1.11-4.19)
10 2.73 (1.35-4.94) 4.62 (2.70-7.30) 1.85 (0.66-4.17) 3.46 (1.80-6.07)
20 4.60 (2.45-7.77) 6.69 (3.96-10.37) 3.52 (1.51-6.90) 5.00 (2.57-8.62)
40 7.08 (3.44-12.49) 9.51 (4.80-16.23) 5.23 (1.97-10.90) 7.91 (3.24-15.31)
Women as compared to men over 45 years of age showed statistically significant higher alloimmunization 
incidences (figure) due to higher Rh and K immunization rates (table).
CI = 95% confidence interval.
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Figure S4   Cumulative alloimmunization incidences as a function of antigen exposure 
in the male  population.









































K 11,215    242      21       5      2
E   8,787 1,171    363   150     85
Cw 12,025      18        4       1       0
e      246    106      54     29     16
Jka   2,847 1,074    461   249   145
c   2,469    988    480   273   166
C   3,935 1,227    574   321   181
Fya   4,178 1,386    584   316   188
Fyb   2,090    758    353   206   135
Jkb   3,194 1,094    503   284   176
Lea   9,571    664    156     52     18
M   2,709 1,029    465   245   148
N   3,432 1,124    491   261   159
S   5,520 1,316    512   247   134
s   1,347    542    259   159   105
Male cohort
Cumulative incidence, % (CI)
Mismatched 
units (N)







































The relative antigen immunogenicity and the antigen potency order observed in male did not differ from the 
entire cohort.
CI = 95% confidence interval. Only data from non-censored cohorts of at least 200 subjects are presented.
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RED CELL ALLOIMMUNIZATION  






Red cell alloantigen exposure can cause alloantibody associated morbidity. Murine models 
have suggested inflammation to modulate red cell alloimmunization. This study quantifies 
alloimmunization risks during infectious episodes in humans.
We performed a multicenter case-control study within a source population of patients 
receiving their first and subsequent red cell transfusions during an eight year follow-up 
period. Patients developing a first transfusion-induced red cell alloantibody (N=505) were 
each compared with two similarly exposed, but non-alloimmunized controls (N=1,010) 
during a five week ‘alloimmunization risk period’ using multivariate logistic regression 
analysis. 
Transfusions during ‘severe’ bacterial (tissue-invasive) infections were associated with 
increased risks of alloantibody development (adjusted relative risk (RR) 1.34, 95% confidence 
interval (CI) 0.97-1.85), especially when these infections were accompanied with long- 
standing fever (RR 3.06, CI 1.57-5.96). Disseminated viral disorders demonstrated a trend 
towards increased risks (RR 2.41, CI 0.89-6.53), in apparent contrast to a possible protection 
associated with Gram-negative bacteremia (RR 0.58, CI 0.13-1.14). ‘Simple’ bacterial infections, 
Gram-positive bacteremia, fungal infections, maximum CRP values, and leukocytosis were 
not associated with red cell alloimmunization.
These findings are consistent with murine models. Confirmational research is needed 
before patients likely to develop alloantibodies may be identified based on their infectious 
conditions at time of transfusion. 
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Introduction
Red cell alloimmunization challenges providing compatible donor blood and, most 
importantly, might induce severe hemolytic transfusion reactions.1, 2 Consequently, some 
selected patients receive extended matched blood.2, 3 Despite the effectiveness of these 
risk-based matching practices,4-6 non-selected patients do experience alloimmunization- 
mediated complications1, 2, 7 warranting consideration of additional risk factors.
 Next to the chance to encounter a high immunogenic non-self antigen,8 clinical 
conditions affecting the recipient’s immune response likely modulate alloimmunization. 
Identification of such factors might enable allocating extended matched blood principally 
to high risk patients. 
 Experimentally induced inflammation has consistently been marked as a major 
determinant of red cell alloimmunization in mice.9-12 In line, pro-inflammatory conditions 
related to sickle cell disease as well as febrile reactions to donor platelets were shown to 
enhance alloimmunization in humans.13, 14 Apart from one case report,15 to the best of our 
knowledge, the influence of infection-associated inflammation on red cell alloimmunization 
in humans has not been reported. 
 In this nested case-control study, we quantify relative alloimmunization risks for patients 
receiving red cell units during an infectious episode, according to the type of infection, 
its intensity, and the patient’s inflammatory response to it. 
Methods
Study design and setting
We performed a nested case-control study within a source population of previously 
non-transfused and non-alloimmunized patients in three university and three reference 
hospitals in the Netherlands. Using this design, we compared patients who developed red 
cell alloantibodies following transfusion with non-alloimmunized controls on the basis of 
supposed causal attributes, including various types of infections. Details on the source 
population, including its eligibility criteria, and our case-control study design have been 
previously published.8, 16
 To summarize, patients were eligible if they received their first red cell transfusion 
during the study period in one of the participating hospitals, provided this transfusion 
was preceded by a negative antibody screen and followed by an antibody screen, hereby 
permitting evaluation of alloantibody development. The study period per hospital depended 
on electronic availability of necessary data between January 1, 2005 and December 31, 
2013 (for details, see supplementary box 1). All red cell units were prepared by buffy-coat 
depletion of whole blood donations, subsequently filtered through a leukocyte depletion 
filter, and stored in SAGM for a maximum of 35 days.3 
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Patients were defined as case upon developing a first, transfusion-induced red cell 
alloantibody directed against one of the following antigens: c, C, e, E, K, Cw, Fya, Fyb, Jka, 
Jkb, Lea, Leb, Lua, Lub, M, N, S, or s. Anti-D immunized patients were not taken into 
consideration since we were unable to discriminate whether anti-D was caused by 
unmatched transfusions, or (mainly regarding fertile women) was due to recent anti-D 
administration in the context of a D-positive pregnancy or transfusion. Patients who 
formed antibodies, yet either lacked exposure to a (documented or assumed) antigen- 
positive red cell unit or expressed the antigen themselves (i.e. auto-immunized patients) 
were deemed ineligible. In addition, alloimmunized patients were excluded if their 
first-time alloantibody positive screen occurred within seven days of the first mismatched 
transfusion, as these more likely represented boosting to earlier primary immunizations. 
By consulting the nationwide alloimmunization registry,17 we additionally excluded patients 
previously diagnosed with alloimmunization in other hospitals. Considering the above 
mentioned criteria, we specifically aimed to exclude previously alloimmunized patients, 
including pregnancy-induced immunizations in women. Finally, hemoglobinopathy 
patients and infants below six months of age were not included. 
 Each eligible case was matched to two randomly selected non-alloimmunized control 
patients based on the hospital and on the (lifetime) number of red cell transfusions 
received at the time of alloimmunization. This ‘incidence-density sampling strategy’ 
ensured that controls were exposed to at least the same amount of transfusions as their 
matched cases and thus formed a representative sample of the source population.18
 For all cases, we assumed that the last antigen-mismatched transfusion (the ‘Nth’ 
or implicated transfusion) preceding the first positive screen most likely elicited allo-
immunization. If this last mismatched transfusion could not be identified due to incomplete 
typing of donor units, we assumed the last non-tested unit preceding the first positive 
screen by at least seven days to have elicited alloimmunization. An ‘alloimmunization risk 
period’ was then constructed stretching from 30 days before up to seven days after this 
implicated Nth transfusion. A similar risk period around the Nth transfusion was determined 
for the matched controls. The implicated transfusion and its alloimmunization risk period 
are illustrated in Figure 1. 
 For all cases and controls, we recorded various clinical conditions during the allo-
immunization risk period. 
 The study protocol was approved by the Ethical Review Board at the Leiden University 
Medical Center in Leiden and by the local board of each participating center. 
First-formed red cell alloantibodies
At a maximum of 72 hours prior to red cell transfusion, patients in the Netherlands are 
routinely screened for red cell alloantibodies. According to the Dutch transfusion 
guideline, commercially available 3-cell screening panels are required to be homozygous 
positive for D, C, c, E, e, K, Fya, Fyb, Jka, Jkb, M, S and s. The K antigen needs to be present 
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minimally heterozygously. The presence of Cw, Lua, Wra, and Kpa is not mandatory on 
commercially available screening cells.3 Antibody screening involves a three-cell panel 
using an indirect antiglobulin test (column agglutination technology from BioRad, Cressier, 
Switzerland, or from Ortho Clinical Diagnostics, Raritan NJ, United States). If positive, 
screening is followed by subsequent antibody identification by an 11-cell panel using the 
same technique.
Data acquisition
We gathered routinely stored data on red cell transfusion dates, dates and results of 
antibody screens (including antibody specificity), patients’ date of birth, sex, and leukocyte 
counts from the hospitals’ electronic laboratory information systems. In addition, we 
examined the medical charts of all cases and controls for the presence of various potential 
clinical risk variables during the alloimmunization risk period, including dates of infection, 
the causative microorganisms, dates of fever (temperature ≥38.5 °C), leukocyte counts, 
and CRP values. 
Figure 1  The implicated transfusion and alloimmunization risk period.
The last antigen mismatched transfusion preceding the first serological detection of an antibody was defined as 
the ‘implicated (or Nth) transfusion’ since this transfusion most likely influenced alloimmunization. To exclude 
possible boosting events, this implicated transfusion was required to precede the first positive screen by at least 
seven days (i.e. lag period). An alloimmunization risk period was then constructed starting 30 days before and 
finishing 7 days after this implicated transfusion. 
Controls received at least the same number of red cell units as their matched case. A similar alloimmunization risk 











Bacterial infections comprised tissue-invasive infections (i.e. involving an anatomic site 
location) and bacteremia (i.e. involving positive blood cultures). 
 Tissue-invasive bacterial infections were considered present when confirmed by 
either a positive blood or tissue culture, or when a suspected clinical infectious phenotype 
was supported by an overtly disease-specific radiographic anomaly e.g. a clear lobar 
consolidation on a chest x-ray in a patient with fever and cough. We categorized these 
infections into ‘mild’ or ‘severe’ according to their expected degree of systemic inflammation. 
Mild tissue-invasive bacterial infections included: routine (tip) cultures from central catheters, 
catheter induced phlebitis, lower urinary tract infections, bacterial enteritis, skin and 
superficial wound infections, and upper respiratory tract infections. ‘Severe’ tissue-invasive 
bacterial infections included: abscesses, intra-abdominal infections including spontaneously 
or secondarily infected abdominal fluid collections, arthritis, bursitis, myositis, fasciitis, 
infected hematoma, bacterial meningitis, deep wound or skin infections, endocarditis, 
mediastinitis, pericarditis, infected foreign material, lower respiratory tract infections, 
osteomyelitis, spondylodiscitis, and upper urinary tract infections.
 Bacteremia were categorized according to their Gram-positive or Gram-negative 
causative microorganism. 
 For the qualification of a viral infection, a positive PCR test demonstrating the 
replication of viral RNA or DNA was needed or, in case a PCR test was not performed, the 
clinical condition needed to be clearly virally induced e.g. herpes labialis. Viremia and 
disseminated viral zoster infections were defined as ‘disseminated viral infections’, 
contrasting ‘local viral infections’ restricted to one anatomic site location. 
Statistical analyses
The associations of various infections with the development of red cell alloimmunization 
were evaluated using logistic regression analyses. For crude relative risk (RR) calculations, 
we conditioned on the matched variables i.e. hospital and cumulative number of red cell 
units received. 
 For multivariate analyses, we also conditioned on measured confounders taking into 
account that a confounder meets the prerequisites of being associated with the exposure 
(i.e. infections) in the source population, is (a marker for) a causal risk factor of the outcome 
(i.e. alloimmunization), and is not in the causal pathway between the exposure.19, 20 
Consequently, we used the following strategy. First, we identified a subset of covariates to 
be confounders of a given determinant based on their observed association with the 
determinant within the source population (i.e. the non-alloimmunized controls). Such an 
association was defined as a ≥3% difference in covariate presence between controls 
exposed and controls not exposed to the determinant. Covariates in the causal pathway 
between the determinant and the outcome were not considered as confounders.19 
Second, to be able to accurately control for confounders with low prevalences, we 
estimated a probability score for each determinant using logistic regression with the 
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potential confounders as predictors.21  Third, to minimize bias due to missing data on the 
confounders, we used multiple imputation. Details on the used model can be found in 
the Supplementary Box 2. Finally, we evaluated the association between various types of 
infections and red cell alloimmunization by subsequently entering the corresponding 
probability scores into the logistic regression model with alloimmunization as the outcome 
and conditioning on the matched variables.
 We next assessed the association of level of CRP values and leukocytosis as possible 
markers of inflammation with red cell alloimmunization. Leukocytosis was categorized 
as maximum measured leukocyte counts of 10-15, 15-20, 20-30, and >30x109/L, and 
referenced to normal counts (4-10x109/L). Maximum measured CRP values were categorized 
as 30-100, 100-200, 200-300, and >300 mg/L, and referenced to values ≤30 mg/L. Missing 
CRP and leukocyte value were multiply imputed using the same strategy as described 
above. While the likelihood that an increased inflammatory parameter has been recorded at 
least once increases with the number of measurements and thus with the duration of 
hospitalization, we repeated these analyses limited to parameters measured within the 
week following the implicated transfusion. As elevated CRP levels and leukocytosis reflect 
various clinical conditions preventing causal inferences, we present here only unadjusted RRs. 
 As anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M can also form ‘naturally’ (e.g. 
directly in response to microbial epitope exposure),22 we evaluated a possible association 
between the presence of these antibodies and various types of infections using Pearson’s 
chi-square test. P-values <0.05 were considered to be statistically significant.
 As we used an incidence-density sampling procedure to select controls,18 we interpreted 
and present all odds ratios as RR with 95% confidence intervals (CI). 
Sensitivity analyses
For some patients, the presence or absence of a certain type of infection could not be 
determined. These patients were left out of the corresponding analysis. Regarding severe 
bacterial infections, we performed a sensitivity analysis in which these patients were 
alternately assigned to exposure and non-exposure of this infection.
 For patients with a suspected lower respiratory infection without conclusive or 
available cultures, we considered this infection to be due to a bacterial microorganism. 
Although viral or (rarely) fungal pathogens may cause pneumonia, bacterial microorganisms 
are the most common cause in Dutch hospitalized patients, with Streptococcus Pneumoniae 
and Haemophilus Influenzae alone representing 30-75% of causative pathogens.23
 Finally, since contaminated blood cultures positive for coagulase-negative staphylococci 
(CNS) might dilute an existing effect of Gram-positive bacteremia, we compared RRs for all 




Among 54,347 newly-transfused patients, 24,063 were considered eligible (Figure S1) of 
which 505 patients (2.1%) formed red-cell alloantibodies. Thirty-seven of these alloimmunized 
patients (7.3%) only received units of which the cognate antigen was unknown. For these, 
we assumed the last non-tested unit preceding the first positive screen to have elicited 
alloimmunization. 
 General and clinical characteristics of the 505 cases and their 1,010 matched controls 
during the alloimmunization risk period are presented in Table 1. 
Infections during the alloimmunization risk period
Among all cases and controls, 473 patients were diagnosed with at least one infection 
during the alloimmunization risk period. Of these, 417 suffered from bacterial infections, 
53 from viral infections, and 56 from fungal infections (Table 2). 
 For 222 of 269 patients (82.5%) diagnosed with a severe tissue-invasive bacterial 
infection, the causal microorganism was identified by culture. For three of 53 virally-infected 
patients, no PCR test was performed during the alloimmunization risk period. These 
patients were nevertheless included based on their clinical condition: one patient 
receiving an allogeneic stem cell transplantation with an outbreak of varicella zoster, one 
patient receiving chemotherapy for a Burkitt lymphoma with herpes labialis, and one 
patient with liver cirrhosis due to a chronic hepatitis C infection. 
 Identified confounders per alloimmunization determinant are presented in Table S1 
and S2. As illustrated, control subjects with viral infections were younger, had received 
more red cell units, and were more often leukopenic as compared to those without viral 
infections. These differences were likely due to a higher frequency of hematological 
malignancies and associated treatment modalities. 
 Missing data for any identified confounder per determinant was maximally 3.1%. 
For 343 patients (22.6%), CRP values were not measured during the risk period (Table S3).
The association between various types of infections and red cell 
alloimmunization 
Table 3 presents the number of cases and controls diagnosed per type of infection. For 
some patients, the presence or absence of a certain type of infection could not be 
determined. The majority of these cases were due to an unestablished origin of the 
inflammatory condition (i.e. being due to infection or other inflammatory causes). In order 
to avoid misclassification, we omitted these patients from the corresponding analysis.
 Mild bacterial infections were not associated to alloimmunization. Patients with a 
severe tissue-invasive bacterial infection tended towards increased alloimmunization risks 
(adjusted RR 1.34 (CI 0.97-1.85), Table 3). Relative risks increased to significance when these 
infections were accompanied with long-lasting fever (adjusted RR 3.06 (CI 1.57-5.96) with 
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Men 237 (46.9) 568 (56.2)
Age in years (median, IQR) 67.0 (55.0-75.9) 65.3 (51.6-75.1)
Transfused in university hospitals 232 (45.9) 464 (45.9)
Cumulative (lifetime) number of red cell units up till 
implicated transfusion (median, IQR)
4 (2-8) 4 (2-8)
Single transfused (N, %) 





Cumulative number of red cell units during risk 
period (median, IQR)
3 (2-6) 4 (2-8)
Days transfused during risk period (median, IQR) 1 (1-3) 2 (1-3)
ICU admission


















Diabetes mellitus type 1 6 (1.2) 7 (0.7)
Diabetes mellitus type 2 91 (18.0) 176 (17.4) 1
Atherosclerosis * 198 (39.5) 314 (31.5) 17
Chronic obstructive airway disease † 43 (8.5) 89 (9.0) 20
Splenectomy (in past or during risk period) 1 (0.2) 19 (1.9)
Organ transplant 4 (0.8) 23 (2.3)
Liver cirrhosis 13 (2.6) 24 (2.4) 2
Hematological malignancy 60 (11.9) 210 (20.8) 13
Carcinoma 112 (22.3) 183 (18.2) 7
Chemotherapy 66 (13.1) 219 (21.8) 6
Radiotherapy 15 (3.0) 37 (3.6)
Leukopenia ‡ 102 (20.2) 313 (31.0) 41
Hematopoietic stem cell transplantation (auto-
logous or allogeneic, in past or during risk period)
10 (2.0) 63 (6.2)
Graft versus host disease (acute or chronic) 4 (1.5) 15 (0.8) 3
Immunosuppressant medication § 154 (30.9) 423 (42.4) 20
GFR ≤ 30 ml/min || 56 (11.1) 149 (14.8) 2
Dialysis (either chronic or acute) ¶ 31 (6.1) 98 (9.7)
Values are n (%), unless otherwise stated. Numbers of patients for whom data on certain diagnoses and/or 
treatment modalities were not documented are presented as missing. 
IQR = interquartile range. * systemic or coronary atherosclerosis. † chronic asthma bronchiale or chronic obstructive 
pulmonary disease. ‡ at least once measured leukocyte counts below lower limit of normal. § medication under 
subcategory H02 (corticosteroids) or L04 (other immunosuppressants) within the Anatomical Therapeutic 
Chemical (ATC) classification index. || glomerular filtration rate (GFR) below 30 ml/min during at least one week 
of the risk period (with GFR calculated using the Modification of Diet in Renal Diseases (MDRD) equation). 
¶ hemodialysis, peritoneal dialysis, or continuous veno-venous hemofiltration needed for at least one day during 
the risk period. 
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Table 2   Infections diagnosed during the alloimmunization risk period. 
A  Locus of bacterial infections according to severity
Mild bacterial infections N Severe bacterial infections N
Diagnosed in N patients 116 Diagnosed in N patients 269
Bacterial enteritis 12 Abdominal infections (including
abscesses)
87
Catheter related * 37
Lower urinary tract infection 36 Arthritis, bursitis, myositis, fasciitis, 
infected hematoma
11
Skin and superficial wound infections 25 Bacterial meningitis 5
Upper respiratory tract infection 11 Deep wound or skin infection 20
Endocarditis, mediastinitis, pericarditis 21
Infected foreign material 15
Lower respiratory tract infection 85
Non-abdominal abscesses 17
Osteomyelitis, spondylodiscitis 5
Upper urinary tract infection 19
B  Microorganism genus (and species)
Gram-positive bacteremia N Gram-negative bacteremia N
Diagnosed in N patients 117 Diagnosed in N patients 57
Bacillus 1 Bacteroides 4
Clostridium 1 Burkholdera 1
Corynebacterium 2 Capnocytophaga 1
Enterococcus 30 Enterobacter 8
Gemella 2 Escheria (Coli) 23
Listeria 1 Neisseria (Meningitides) 1
Micrococcus 1 Klebsiella 11
Staphylococcus 62 Proteus 2
excluding coagulase negative 22 Pseudomonas 9
Streptococcus 25 Serratia 7
Stenotrophomonas 1
Viral infections Fungal infections
Diagnosed in N patients 53 Diagnosed in N patients 56
Local viral infections Aspergillus (pulmonary) 11
BK (cystitis) 1 Candida 42
HSV (stomatitis) 13 stomatitis 10
Respiratory virus † 11 candidemia 11
Enteral virus ‡ 2 other location 22
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fever present for at least seven days, Table 4). The timing of fever i.e. occurring close to the 
implicated transfusion or at any time point during the risk period did not influence RRs 
(data not shown). RRs from a sensitivity analysis in which patients originally omitted from 
the analysis on severe bacterial infection (N=47) were alternately assigned to exposure 
and non-exposure of this infection did not differ (RR 1.26 (CI 0.93-1.71) versus 1.33 (0.97-1.83), 
respectively). 
 Since alloantibodies against E, Cw, Lea, Leb, Lua, and M can also form ‘naturally’ (e.g. in 
response to microbial epitope exposure rather than to transfusion-related red cell 
exposure),22 we evaluated a possible association between the induction of these 
antibodies and various infections using Pearson’s chi-square test. The distribution of 
alloantibodies known to also occur ‘naturally’ did not differ between patients with and 
without severe bacterial infections (Table 5).
 Interestingly, patients with a Gram-negative bacteremia tended to demonstrate 
reduced alloimmunization rates (adjusted RR 0.58, (CI 0.13-1.14)), while Gram-positive 
bacteremia was not associated with red cell alloimmunization (Table 3). To exclude a 
potential dilution of an existing effect by contaminated blood cultures positive for CNS, 
we in addition evaluated the association of non-CNS Gram-positive bacteremia with allo-
immunization. RRs from this analysis were identical to originally calculated RRs. 
 Any viral disease tended to be associated with increased red cell alloimmunization 
incidences. The adjusted RR associated with disseminated viral infections was 2.41 (CI 
0.89-6.53). The presence of fever did not influence RRs of viral infections (Table 4). 
Table 2   Continued. 
B  Microorganism genus (and species)
Viral infections Fungal infections
Disseminated viral diseases Pneumocystis (jirovecii) 2
Adenoviremia 3 Penicillium (pulmonary) 1
BK viremia 1
Cytomegalovirus viremia 11
Epstein Barr Virus viremia 2
Hepatitis C viremia 6
Human Herpesvirus- 6 viremia 2
Human immunodeficiency virus 3
Varicella Zoster Virus reactivation 3
Cumulative numbers per type of infection do not necessarily equal the number of patients diagnosed with this 
infection, as individual patients can have been infected with multiple microorganisms and types of infections.
* routine (tip) cultures from central catheters and catheter induced phlebitis. † coronavirus (1), H1N1 virus (1), 
herpes simplex virus- 1 with bronchial location (1), influenza-virus (2), para-influenza virus (2), respiratory syncytial 
virus (1), rhinovirus (3). ‡ norovirus (1), rotavirus (1).
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Fungal infections, as well as candidemia and invasive aspergillus infections separately, 
were associated with heterogeneous RRs not reaching significance (Table 3). 
The association between laboratory indicators of inflammation and red 
cell alloimmunization
Neither leukocytosis nor CRP value was associated with red cell alloimmunization (Table S4). 
A sensitivity analysis on parameters determined within the week following the implicated 
transfusion did not change results (Table S4). 
Table 3   Association between (various types of) bacterial and viral infections and  
red cell alloimmunization. 

















39/499 77/989 0.99 (0.66-1.49) 1.08 (0.70-1.66) 27











24/504 61/1009 0.82 (0.40-1.67) 0.96 (0.56-1.65) 2
13/505 44/1010 0.57 (0.30-1.09) 0.58 (0.13-1.14) 0
Viral infections
all 15/503 38/1003 0.72 (0.38-1.38) 1.56 (0.75-3.25) 9
local
disseminated
7/503 20/1003 0.71 (0.29-1.74) 1.80 (0.65-4.98) 9





12/501 44/1001 0.50 (0.25-0.99) 0.60 (0.29-1.25) 13
4/505 7/1010 1.19 (0.31-4.55) 2.93 (0.54-15.89) 0
1/503 10/1004 0.17 (0.02-1.42) 0.33 (0.03-3.28) 8
Patients for whom the presence or absence of a given infection could not be determined were excluded from 
the corresponding analysis. 
* Adjusted for: number of transfused red cell units and hospital. † Additionally adjusted for identified potential 
confounders (for details, see Table S2). RR = relative risk. CI = 95% confidence interval. CNS = coagulase negative 
staphylococcus. 
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Table 4   Infections and red cell alloimmunization according to the presence of  
fever and its duration. 




RR (CI) * Adjusted RR (CI) †
Severe bacterial 
infection
- 390/490 809/978 ref ref
+ - 17/490 48/978 0.72 (0.41-1.29) 0.79 (0.44-1.43)
+ 1-6 days 59/490 101/978 1.20 (0.84-1.71) 1.33 (0.91-1.99)
+ ≥7 days 24/490 20/978 2.67 (1.40-5.07) 3.06 (1.57-5.96)
Gram-positive 
bacteremia
- 468/502 921/1003 ref ref
+ - 3/502 13/1003 0.51 (0.15-1.81) 0.88 (0.24-3.28)
+ 1-6 days 21/502 54/1003 0.72 (0.42-1.22) 0.92 (0.52-1.61)
+ ≥7 days 10/502 15/1003 1.29 (0.55-3.03) 2.14 (0.84-5.41)
Gram-negative 
bacteremia
- 492/505 966/1010 ref ref
+ - 0/505 6/1010 0 (NC) 0 (NC)
+ 1-6 days 12/505 34/1010 0.70 (0.35-1.39) 0.71 (0.35-1.45)
+ ≥7 days 1/505 4/1010 0.52 (0.04-6.30) 0.53 (0.04-6.62)
Disseminated  
viral diseases
- 495/505 990/1010 ref ref
+ - 4/505 7/1010 1.14 (0.33-3.97) 1.89 (0.50-7.15)
+ 1-6 days 4/505 9/1010 0.61 (0.16-2.38) 3.77 (0.64-22.24)
+ ≥7 days 2/505 4/1010 1.12 (0.20-6.39) 2.58 (0.37-17. .82)
Only numbers of patients for whom the presence or absence of a given infection could be determined are 
presented. * Adjusted for: number of transfused red cell units and hospital. † Additionally adjusted for identified 




Table 5   Specificity and frequency of first-formed red cell alloantibodies according  



















anti-C 23 (4.0) 19 (5.2) 1 (0.9) 0 (0) 1 (7.1)
anti-c 41 (7.2) 25 (6.8) 8 (7.1) 0 (0) 1 (7.1)
anti-E 185 (32.3) 113 (30.7) 41 (36.4) 4 (26.7) 5 (35.7)
anti-e 5 (0.9) 5 (1.4) 0 (0) 0 (0) 0 (0)
anti-K 126 (22.0) 88 (23.9) 21 (18.6) 3 (20.0) 6 (42.9)
anti-Cw 19 (3.3) 10 (2.7) 4 (3.5) 3 (20.0) 0 (0)
anti-Fya 31 (5.4) 24 (6.5) 4 (3.5) 1 (6.7) 0 (0)
anti-Fyb 5 (0.9) 4 (1.1) 1 (0.9) 0 (0) 0 (0)
anti-Jka 54 (9..4) 37 (10.1) 8 (7.1) 3 (20.0) 0 (0)
anti-Jkb 7 (1.2) 4 (1.1) 2 (1.8) 0 (0) 0 (0)
anti-Lea 7 (1.2) 2 (0.5) 4 (3.5) 0 (0) 0 (0)
anti-Leb 3 (0.5) 1 (0.3) 1 (0.9) 0 (0) 0 (0)
anti-Lua 32 (5.6) 19 (5.2) 9 (8.0) 0 (0) 0 (0)
anti-Lub 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
anti-M 22 (3.8) 14 (3.8) 5 (4.4) 1 (6.7) 0 (0)
anti-N 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0)
anti-S 12 (2.1) 7 (1.9) 4 (3.5) 0 (0) 1 (7.1)
anti-s 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
(possibly) natural 
occurring *
268 (46.7) 159  (43.2) 64 (56.6) 8 (53.3) 5 (35.7)
All antibodies 573 368 113 15 14
Number of 
patients
505 325 100 10 13
* including: anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M. No difference in distribution of (possibly) 
natural occurring alloantibodies was observed between patients with and without severe bacterial infections 
(p=0.08), disseminated viral infections (p=0.93), and Gram-negative bacteremia (p=0.41).
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Discussion
This first study of its kind in transfused patients suggests a possible association between 
infectious conditions and red cell alloimmunization. Specifically, our observations suggest 
alloimmunization to be influenced by the type and intensity of, and the patient’s 
inflammatory response to infections. In summary, severe (tissue-invasive) bacterial and 
viral infections were associated with increased alloimmunization incidences (RRs 1.34 (CI 
0.97-1.85) and 2.41 (CI 0.89-6.53)). In contrast, Gram-negative bacteremia coincided with a 
2-fold reduction of alloimmunization risk (RR 0.58 (CI 0.13-1.14)). 
 Our findings certainly require additional confirmational research. However, they seem 
biological plausible and are in line with prior animal experiment observations. 
 First, long-lasting fever with severe bacterial infections was associated with a substantially 
increased risk (RR 3.06 (CI 1.57-5.96)). Here, persistence of fever could have reflected the 
most severe bacterial infections inducing a profound inflammatory response. Alternately 
or additionally, fever might have been due to other concomitant inflammatory conditions. 
Yet, both explanations are consistent with the ‘danger model’ which postulates that an 
immune response is facilitated by pathogen associated molecular patterns or structures 
released from cells undergoing stress.24-26 
 Second, although the 95% confidence interval encompassing 1 (i.e. a null effect) 
warrants firm conclusions, we observed substantially increased alloimmunization rates in 
patients with systemic viral infections. Murine experiments showed similar effects for 
poly(I:C),9-12 a synthetic viral RNA analogue which agonizes Toll-like receptor (TLR)-3.27 
These poly(I:C) effects were attributed to an increased dendritic cell consumption of 
transfused cells with upregulation of costimulatory molecules, and activation and proliferation 
of naive CD4+ antigen-specific T cells.9, 10 An existing molecular mimicry between certain 
viral peptides and CD4+ T cell red cell antigen epitopes was also suggested, albeit 
observed effects in polyomavirus infected mice did not reach statistical significance.28
 Although we did not analyze the association between latent viral infections and red 
cell alloimmunization, these might be relevant as well. In addition, assessment of possible 
different effects of RNA and DNA viruses was prevented by low event numbers. 
 Third, we observed a 2-fold alloimmunization incidence reduction during Gram- 
negative bacteremia. Analogous to viral infections, these findings require confirmational 
research. Yet, they again corroborate animal experiments showing significantly attenuated 
 alloimmunization responses upon lipopolysaccharide (LPS) pretreatment in mice.10 LPS, 
an endotoxin in the outer cell membrane of Gram-negative bacteria, strongly stimulates 
innate immunity by agonizing TLR-4 on macrophages and dendritic cells. Conversely, LPS 
is also implicated in a transient, possibly self-protective immune paralysis, known as LPS 
tolerance.29-31 Restimulation with LPS in this respect initiates blockage of CD4+ T cell 
functioning via impaired release of TNFα, IL-12, and IL-18 from monocytes and dendritic 
cells together with a diminished upregulation of MHC class-II and costimulatory 
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molecules.29, 32 While regulatory T cells selectively express TLRs (including TLR-4), their LPS 
induced proliferation might also contribute to the observed effects in both mice and 
human.33 Finally, we cannot exclude an indirect role for Gram-negative bacteremia on red 
cell alloimmunization due to their common association with other modulators. Indeed, 
suppressed mitogenic B and T lymphocyte responses were observed following administration 
of antibiotics, including cephalosporins, an antibiotic class frequently used in the treatment of 
Gram-negative bacterial infections.34, 35
 In intriguing contrast to the effects observed for Gram-negative bacteremia, we did 
not observe any association between Gram-positive bacteremia and red cell alloimmuniza-
tion. A common lower degree of acute inflammation evoked by gram-positive as compared 
to gram-negative bloodstream infections due to differing virulence mechanisms forms 
one hypothetical explanation.29, 36, 37
 Despite RRs for fungal infections not significantly differing from those for Gram- 
negative bacteremia, the heterogeneous RRs for individual fungal microorganisms and 
the lack of other supportive evidence prevent tentative inferences. Indeed, contrasting 
our estimated RR, one report suggested neonatal alloimmunization to be related to a 
disseminated histoplasmosis infection.15
 The ultimate goal of our study would be to establish an accurate alloimmunization 
prediction model, serving as a practical tool for risk-based extended matching. Such a 
model would be most feasible when based on routinely measured patient parameters. 
In this perspective, we did not observe any association of the level of leukocytosis and 
CRP values with alloimmunization, possibly due to the multifactorial nature of these 
parameters. Other biomarkers e.g. cytokine levels and immune cell subsets might be 
better discriminative, yet, could not be evaluated in the current study.  
Our study design, results, and interpretations require additional remarks: 
 First, our incidence-density sampling strategy guarantees that selected controls 
were similarly exposed as their matched cases.18 Hereby, our RRs are not influenced by 
transfusion burden, being a main determinant of red cell alloimmunization.8
 Second, by identifying the implicated transfusion, we could study conditions present 
at that given time. Since the duration of alloimmunization modulation is currently 
unknown and will also likely differ per risk factor, we chose a seemingly large risk period to 
precede the implicated transfusion. Although one could argue this strategy to possibly 
dilute some effects, it on the other hand assures inclusion of most factors of influence at 
the time of exposure. For example, repeated LPS exposure might induce a state of 
tolerance persisting for up to 30 days.38 In addition, a recent study showed that poly(I:C) 
facilitates red cell alloimmunization for at least 14 days with its maximum effect reached 
seven days after administration.39 As a validation of our chosen risk period length, a 
sensitivity analysis on infections diagnosed during the week preceding or following the 
implicated transfusion did not change our conclusions (data not shown). Similarly, only 
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the duration of fever accompanying severe bacterial infections rather than its timing in 
the risk period affected alloimmunization. As we aimed to target the most likely first 
initiation of an alloimmune response, we limited the risk period to the first seven days 
following the implicated transfusion. 
 Third, actual lag periods per antigen-specific antibody are currently unknown. As 
such, our chosen lag period of seven days might not completely have prevented the 
exclusion of patients demonstrating recall responses, including women immunized due 
to prior pregnancies. Direct antiglobulin tests were not performed on a routine base 
shortly following transfusion and as such were of no help in identifying these patients. 
However, as non-RhD alloantibodies form in only 0.33% of first trimester pregnancies,40 
we believe substantial influence of previous pregnancies unlikely. Moreover, erroneously 
considering a substantial amount of boosting reactions as primary alloimmunization 
events would have biased our RRs towards the null-effect. Indeed, a sensitivity analysis in 
which we excluded the 53 patients in whom alloantibodies were discovered during the 
second week following their first antigen-incompatible transfusion did not substantially 
change RRs (data not shown). In conclusion, we believe the eventual bias due to our 
choice of the lag period to be small.
 Fourth, to avoid invalid inferences due to misclassification, we did not define patients 
with a non-established etiology of their inflammatory phenotype as exposed patients. 
For example, for a vascular compromised patient diagnosed with osteomyelitis, wound 
cultures positive for Staphylococcus Aureus might have represented normal skin flora 
colonization of a primary ischemic wound. Consequently, the analysis on severe bacterial 
infections did not include this patient. A sensitivity analysis confirmed our results not to be 
affected by this possible misclassification bias. 
 In conclusion, our data suggest a potential risk modifying influence of infection- 
associated inflammation on red cell alloimmunization in transfused patients. Alloimmuni-
zation seems induced with severe bacterial or viral infections, but might be skewed 
towards protection in the presence of Gram-negative bacteremia. Further confirmational 
research is needed to ultimately identify the high-risk patient and, consequently, better 
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The study period varied per hospital according to the electronic availability of 
necessary data: January 1, 2005 to December 31, 2010 at Leiden University Medical 
Center (Leiden), September 6, 2006 to December 31, 2013 at University Medical Center 
Utrecht (Utrecht), November 19, 2011 to December 31, 2013 at VU University Medical 
Center (Amsterdam), May 1, 2007 to April 30, 2013 at Catharina Hospital (Eindhoven), 
July 1, 2005 to December 31, 2013 at Jeroen Bosch Hospital (‘s Hertogenbosch), and 
October 5, 2008 to December 31, 2013 at Haga Teaching Hospital (The Hague).
Supplementary Box 2
To provide values for some missing predictor values, we performed multiple imputation 
creating five imputed datasets. Predictor variables included: alloimmunization status, 
age, sex, number of transfusions received, (types of) infection, (duration of) fever, 
(duration of) admittance at the intensive care unit, (types of) surgery, (types of) 
malignancies, chemotherapy treatment, radiotherapy treatment, use of immuno-
suppressant medication, (timing of) allogeneic and/or autologous stem cell trans-
plantation, graft versus host disease, diabetes mellitus type 1, diabetes mellitus type 2, 
atherosclerosis, liver cirrhosis, renal insufficiency with a GFR ≤ 30 ml/min, measured 
minimum leukocyte counts, measured maximum leukocyte counts, and measured 
maximum CRP values.
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Figure S1   Flow diagram of source population establishment.
Figure adapted from: Evers, D., Middelburg, R.A., de Haas, M., Zalpuri, S., de Vooght, K. M., Visser, O., Péquériaux, N.C., 
Hudig, F., Schonewille, H., Zwaginga, J.J. Red cell alloimmunization in relation to antigens’ exposure and their 
immunogenicity: a cohort study. Lancet Haematol. 2016;3(6):e284-92.
54,347 newly transfused
final source population: 24,063
Excluded (n = 30,284):
No follow-up after single transfusion episode: 25,037
Infants < 6 months of age: 4,322
Pre-transfusion positive screen: 543
Immunization to other than assessed antigen: 290
Hemoglobinopathy: 38
Unidentified mismatch: 43














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S2   Subset of variables defined as confounders per determinant for 
alloimmunization. 
Determinant Confounders
all below determinants age, gender, (duration of ) ICU admittance, (type of ) hematologic 
malignancy, chemotherapy, (degree of ) leukopenia, 
immunosuppressant medication, GFR ≤ 30 ml/min.
mild or severe (tissue invasive) 
bacterial infection
thoracic surgery, abdominal surgery, diabetes mellitus type 
2, COPD, carcinoma, (timing of ) HSCT, dialysis, Gram-positive 
bacteremia, Gram-negative bacteremia, fungal infection.
mild bacterial infection thoracic surgery, diabetes mellitus type 2, organ transplant, 
carcinoma, dialysis, Gram-positive bacteremia, Gram-negative 
bacteremia, mild bacterial infection, disseminated viral infection, 
fungal infection.
severe bacterial infection thoracic surgery, abdominal surgery, atherosclerosis, COPD, 
splenectomy in past or during risk period, (timing of ) HSCT, 
dialysis, Gram-positive bacteremia, Gram-negative bacteremia, 
mild bacterial infection, fungal infection.
bacteremia (all types) thoracic surgery, abdominal surgery, diabetes mellitus type 2, 
carcinoma, dialysis, mild bacterial infection, severe bacterial 
infection, local viral infection, disseminated viral infection, fungal 
infection.
Gram-positive bacteremia thoracic surgery, diabetes mellitus type 2, carcinoma, (timing 
of ) HSCT, dialysis, Gram-negative bacteremia, severe bacterial 
infection, mild bacterial infection, local viral infection, 
disseminated viral infection, fungal infection. 
Gram-negative bacteremia abdominal surgery, diabetes mellitus type 2, atherosclerosis, 
(timing of ) HSCT, dialysis, Gram-positive bacteremia, mild 
bacterial infection, severe bacterial infection, fungal infection. 
local viral infection thoracic surgery, abdominal surgery, diabetes mellitus type 
2, atherosclerosis, carcinoma, radiotherapy, (timing of ) HSCT, 
dialysis, Gram-positive bacteremia, severe bacterial infection, 
mild bacterial infection. 
disseminated viral infection thoracic surgery, abdominal surgery, diabetes mellitus type 2, 
atherosclerosis, COPD, splenectomy in past or during risk period, 
carcinoma, (timing of ) HSCT, (acute or chronic) graft versus host 
disease, Gram-positive bacteremia, Gram-negative bacteremia, 
mild bacterial infection, fungal infection. 
fungal infection thoracic surgery, abdominal surgery, diabetes mellitus type 2, 
atherosclerosis,  carcinoma, (timing of ) HSCT, dialysis, Gram-
positive bacteremia, Gram-negative bacteremia, severe bacterial 
infection, disseminated viral infection. 
candidemia abdominal surgery, diabetes mellitus type 2, atherosclerosis,  
COPD, organ transplant, carcinoma, (timing of ) HCT, dialysis, 
Gram-positive bacteremia, Gram-negative bacteremia, severe 
bacterial infection, mild bacterial infection, local viral infection, 
disseminated viral infection. 
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Table S2   Continued. 
Determinant Confounders
Aspergillus infection thoracic surgery, abdominal surgery, atherosclerosis, 
radiotherapy, (timing of ) HSCT, dialysis, Gram-positive 
bacteremia, Gram-negative bacteremia, severe bacterial 
infection, mild bacterial infection, local viral infection. 
All types of infections were associated with the variables listed under ‘all’. In addition, several other potential 
confounders were identified per determinant. Atherosclerosis = systemic or coronary atherosclerosis. Chemotherapy = 
medication under subcategory L01 within the Anatomical Therapeutic Chemical (ATC) classification index. COPD 
= chronic asthma bronchiale or chronic obstructive pulmonary disease. Dialysis = || hemodialysis, peritoneal 
dialysis, or continuous veno-venous hemofiltration needed for at least one day during the risk period. GFR ≤ 30 
ml/min = glomerular filtration rate (GFR) below 30 ml/min during at least one week of the risk period (calculated 
according to the Modification of Diet in Renal Diseases (MDRD) equation). HSCT = hematopoietic stem cell 
transplant. Immunosuppressant medication = medication under subcategory H02 (corticosteroids) or L04 (other 
immunosuppressants) within the ATC classification index.
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Table S3   Overview of imputed data per recorded variable. 










Age C 0 (0) (mature) lymphoma C 3 (0.2)
Gender C 0 (0) Carcinoma C 7 (0.5)
(duration of ) ICU 
admittance
C 4 (0.3) Chemotherapy C 8 (0.5)
Thoracic surgery C 0 (0) Radiotherapy C 0 (0)
Abdominal surgery C 0 (0) HSCT (in past or during risk 
period)
C 0 (0)
Diabetes mellitus type 2 C 1 (0.1) Use of immunosuppressants C 20 (1.3)
Atherosclerosis C 17 (1.1) Leukopenia C 41 (2.7)
COPD C 20 (1.3) Maximum leukocyte counts D 41 (2.7)
GFR ≤ 30 ml/min C 2 (0.1) Maximum CRP values D 343 (22.6)
Dialysis C 0 (0) Gram-positive bacteremia C+D 10 (0.7)
Splenectomy (in past or 
during risk period)
C 0 (0) Gram-negative bacteremia C+D 0 (0)
Organ transplant C 0 (0) Severe bacterial infection C+D 47 (3.1)
Liver failure C 2 (0.1) Mild bacterial infection C+D 27 (1.8)
Acute leukemia C 1 (0.1) Local viral infection C+D 9 (0.6)
Myelodysplastic syndrome C 3 (0.2) Disseminated viral infection C+D 0 (0)




C = confounder of any determinant; D = determinant. 
Atherosclerosis = systemic or coronary atherosclerosis. Chemotherapy  =  medication under subcategory L01 
within the Anatomical Therapeutic Chemical (ATC) classification index. COPD = chronic asthma bronchiale or 
chronic obstructive pulmonary disease. Dialysis = || hemodialysis, peritoneal dialysis, or continuous veno-venous 
hemofiltration needed for at least one day during the risk period. GFR ≤ 30 ml/min = glomerular filtration rate 
(GFR) below 30 ml/min during at least one week of the risk period (calculated according to the Modification of 
Diet in Renal Diseases (MDRD) equation). HSCT = hematopoietic stem cell transplant. Immunosuppressant 
medication = medication under subcategory H02 (corticosteroids) or L04 (other immunosuppressants) within 
the ATC classification index. 
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Table S4   Infections diagnosed during the alloimmunization risk period. 













118 242 0.88 (0.56-1.20)
91 164 0.99 (0.70-1.39)
71 152 0.83 (0.56-1.21)
43 96 0.79 (0.51-1.22)







95 184 1.20 (0.80-1.79)
120 259 1.08 (0.73-1.60)
126 219 1.37 (0.91-2.05)
95 185 1.22 (0.77-1.92)













143 251 1.02 (0.73-1.43)
76 158 0.84 (0.56-1.24)
59 110 0.97 (0.64-1.48)
21 53 0.67 (0.36-1.23)







129 251 1.07 (0.57-2.03)
141 292 1.01 (0.59-1.72)
110 202 1.14 (0.72-1.81)
51 115 0.92 (0.50-1.69)
Leukocytosis and elevated CRP values A. at least once measured during the alloimmunization risk period and B. 
at least once measured during the week following the implicated transfusion. Both did not predict the risk of red 
cell alloimmunization. 
* Adjusted for: number of transfused red cell units and hospital. † as referenced to maximum leucocyte counts 
within the normal range (i.e. 4-10x10^9L). ‡ as referenced to maximum CRP values ≤ 30 mg/L. RR = relative risk. CI 
= 95% confidence interval.
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ABSENCE OF THE SPLEEN 
AND THE OCCURRENCE OF RED CELL 




ABSENCE OF THE SPLEEN PROTECTS AGAINST RED CELL ALLOIMMUNIZATION
With its unique anatomy and location amidst the circulatory system, the spleen allows an 
intimate contact between its resident cells and blood passing the organ. Senescent and 
damaged red cells are primarily sequestered in the splenic red pulp and consumed by its 
macrophages.1 Consequently, this route facilitates presentation of non-self antigens of 
transfused red cells to splenic immune cells as a first and essential step in red cell allo-
immunization. Indeed, the splenic microenvironment has been demonstrated to play a 
prominent role in red cell alloimmunization in mice.2,3 Contrasting these animal studies, 
some observational studies in thalassemic patients suggested splenectomy to be associated 
to increased red cell alloimmunization,4,5 while others did not find any association.6,7
 In the current study, we assessed the association between the anatomic absence of 
the spleen and (transfusion-related) red cell alloantibody induction in our multicenter 
case-control R-FACT study cohort. This cohort includes 505 alloimmunized cases and 
1,010 non-alloimmunized matched controls among an earlier described, primarily 
Caucasian, source population of 24,063 patients receiving their first and subsequent red 
cell transfusions between January 2005 and December 2013 at one of six participating 
hospitals in the Netherlands.8 A detailed description of our case-control cohort and our 
used methodology has been published recently.9
 Summarizing, cases were identified as all patients who developed a first transfusion- 
induced alloantibody during the course of their transfusion history against the antigens: 
c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, N, S, or s. Here, we considered the last 
(documented or assumed) antigen mismatched transfusion preceding the first positive 
screen (i.e. the Nth transfusion) to likely have elicited alloimmunization and defined this as 
the ‘implicated transfusion’. If this last mismatched transfusion could not be identified due 
to incomplete donor typing, the last non-tested unit preceding the first positive screen 
was considered as the implicated transfusion. Based on an ‘incidence-density sampling 
strategy’, for each identified case we randomly sampled two non-alloimmunized control 
subjects out of the source population, on the precondition that these controls had 
received at least an equivalent number of (lifetime) red cell transfusion in the same study 
center as the case. The Nth transfusion in these sampled controls, corresponding to the 
implicated transfusion of their matched cases, was then marked. Subsequently, we constructed 
a so-called ‘alloimmunization risk period’ in both cases and controls, stretching from 30 days 
before to seven days after this Nth (implicated) transfusion. Finally, we compared the 
presence of a history of splenectomy at the time of the alloimmunization risk period in 
cases and controls. 
 The study protocol was approved by the Ethical Review Board in Leiden and by the 
board of each participating center. 
 At the alloimmunization risk period, splenectomy had been performed in 20 patients, 
namely one case (0.2%) versus 19 controls (1.9%) (Table 1). In 12 patients, splenic injury was 
caused by severe trauma or complicated abdominal surgery, while no patient underwent 
a splenectomy in the context of an autoimmune disease. Sixteen of the splenectomized 
88
CHAPTER 4
Table 1   Demographics and splenectomy details of 19 non-alloimmunized and  
1 alloimmunized splenectomized patients. 





A 70/M Yes orthotopic liver transplantation complicated by splenic 
damage.
B 30/M No total pancreatectomy complicated by retroperitoneal 
hematoma and splenic infarction.
C 16/F No spontaneous splenic rupture shortly following post 
allogeneic stem cell transplantation.
D 39/M No severe trauma with intra-abdominal organ damage.
E 34/F No pregnancy complicated by rupture of a splenic artery 
aneurysm.
F 40/M No severe trauma with intra-abdominal organ damage.
G 74/F No resection of a large intra-abdominal liposarcoma, 
including splenectomy.
H 58/F No unilateral nephrectomy for renal cell carcinoma 
complicated by splenic damage.
I 72/F No resection of a large intra-abdominal liposarcoma.
J 55/M No polycythemia vera associated splenomegaly.
K 82/M No distal pancreatectomy with splenectomy.
L 46/M No severe trauma with intra-abdominal organ damage.
M 30/M No severe trauma with intra-abdominal organ damage.
N 63/M No pancreatic necrosis following a history of 
pancreaticojejunostomy.
O 49/M No severe trauma with intra-abdominal organ damage.
P 76/M No coronary artery bypass surgery complicated by an 
incarcerated inguinal hernia with secondary peritonitis 
and intra-abdominal hemorrhage.
Q 77/F No resection of a large intra-abdominal sarcoma.
R 67/F No adrenectomy for metastasized adrenal carcinoma 
complicated by splenic damage.
S 75/M No unilateral nephrectomy for renal cell carcinoma 
complicated by severe intra-abdominal bleeding.
T 73/M No infective endocarditis with septic embolism and splenic 
abscesses.
Anti-M and anti-E were detected in patient A respectively 23, 23, and 21 days after the first allo-M and allo-E 
exposure, the splenectomy, and the implicated transfusion.
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patients received their implicated (Nth) transfusion at or after splenectomy (median 0, 
range 0-3612 days). In three other patients, splenectomy followed the implicated transfusion by 
1-4 days. Consequently, in these patients immunization against the administered blood 
was considered as being modulated by the splenectomy. Subsequent red cell transfusions 
beyond splenectomy were received by all, but two (patient L and N) controls (median 19 units; 
range 0-59, table 2), with one control being further transfused beyond the study period. 
Red cell alloantibodies were not developed (data available up until april 2017).
 Only one splenectomized patient developed alloantibodies (patient A). In this patient, 
anti-E and anti-M were simultaneously detected 23 days after a combined orthotopic liver 
transplantation and splenectomy, during and following which he received 6 E-positive 
and at least 8 M-positive units. Using multivariate logistic regression analysis conditioning 
on the matched variables plus identified potential confounders (Table S1), we estimated 
that splenectomized patients had a 20-fold reduced risk of allo immunization as compared to 
patients lacking a history of splenectomy (adjusted relative risk (RR) 0.05, 95% confidence 
interval (CI) 0.01-0.55). Omitting patients L and N who were not further exposed by red cell 
transfusions following splenectomy did not change the RR (0.05 (95%CI 0.01-0.62)). 
 Since transfusions were administered both before and after splenectomy, estimation 
of an alloimmunization risk from the time of splenectomy onwards should be related to 
both pre- and post-splenectomy red cell exposures. Based on an estimated number of 
245 splenectomized patients within the entire source population, we calculated that 13 
splenectomized patients instead of only patient A were expected to have developed 
alloantibodies had splenectomy not influenced alloimmunization (for calculations, see 
Table 2). We hereby assumed the red cell exposures of the 19 splenectomized controls to 
represent the red cell exposure pattern of all splenectomized patients within the source 
population. 
 To the best of our knowledge, this is the first study in humans reporting red cell allo-
immunization to be highly unlikely following splenectomy. Our observation underlines 
the spleen’s function in protective adaptive immunity against non-self antigens present in 
the circulation and corroborates with earlier studies in splenectomized mice. Even in the 
setting of poly(I:C) induced inflammation (a condition strongly linked with alloimmunization), 
murine red cell alloimmune responses were completely abrogated and suggested to be 
due to a splenectomy induced impairment of CD4+ T cell priming and expansion.2,3 Since 
T cell priming requires efficient antigen-presentation, it seems not surprisingly that splenic 
conventional CD11c+ dendritic cells have been strongly implicated in murine red cell allo-
immunization.10 In agreement with these findings, the splenic T cell subsets were shown 




Table 2   Illustration of expected versus observed numbers of alloimmunized patients 
within the splenectomized source population. 
Step 1:  Estimation of number of splenectomized patients within the source 
population
Among 14,901 patients from the Leiden University Medical Center, University Medical Center 
Utrecht and Jeroen Bosch Hospital ‘s Hertogenbosch, 155 patient with a documented 
history of splenectomy receiving red cell transfusions beyond their splenectomy were 
identified by searching their clinical files via information technology resources. None of 
these patients developed red cell antibodies. As these patients represent 62.0 % of the 
entire source cohort, the total number of splenectomized patients within the source 
cohort will approximate 245. 
Step 2:  Comparison of expected versus observed number of alloimmunized 
patients within the splenectomized source population
Based on the cumulative number of red cell units received pre- and post-splenectomy 
and reported cumulative incidences according to number of red cell units transfused,8 
the expected alloimmunization risk per splenectomized patient encountered from 
splenectomy onwards (Δ p) can be deduced from the absolute risk at the time of 
splenectomy (pT1) and the risk at the time of last serological follow-up (pT2).
 Consequently, would splenectomy not have influenced alloimmunization, one would 
have expected 1.059 alloimmunizations per 20 splenectomized patients. This number 
corresponds to an estimated total of 13 alloimmunizations among the estimated 245 
splenectomized patients (5.3%). As only one splenectomized patient within the source 
population developed alloantibodies, it seems conceivable that approximately 12 patients 
were protected from alloimmunization due to splenectomy, corresponding to a crude 
relative risk of 0.08.
Patient T1: number of  
red cell units received 
before splenectomy
T2: cumulative number of 
red cell units received  
up till last screen
pT1 pT2 Δ p
A 0 19 0.000 0.063 0.063
B 0 2 0.000 0.016 0.016
C 15 30 0.061 0.084 0.023
D 0 11 0.000 0.051 0.051
E 0 16 0.000 0.063 0.063
F 0 8 0.000 0.037 0.037
G 0 31 0.000 0.084 0.084
H 0 19 0.000 0.063 0.063
I 4 31 0.027 0.084 0.057
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Contrary to our results, observational studies in patients with major thalassemia and sickle 
cell disease (a population not included in the current study) so far did not find any 
abrogation of red cell antibody development with splenectomy. Some even concluded 
these patients to be more prone to red cell alloimmunization.4,5 Yet, hemoglobinopathy 
patients in need of splenectomy are often highly transfusion dependent, causing a 
beforehand high exposure related cumulative alloimmunization risk.8 As such, exposure 
related confounding cannot be excluded as most of these studies did not correct for the 
cumulative exposure at the time of primary alloimmunization. Second, none reported 
the timing of alloimmunization to splenectomy nor the transfusion burden at the time 
of splenectomy, leaving the question whether alloimmunization, or even only CD4+ T cell 
sensitization,12 had not already occurred prior to splenectomy. With regard to the latter, 
alloimmunization following splenectomy could as such represent a T cell dependent process 
and may explain why some hemoglobinopathy patients still develop alloantibodies 
despite absence of the spleen. In addition, it is unknown how a functional deficiency of 
the spleen, as is known to be frequent in sickle cell disease patients, modulates red cell 
alloimmunization. As such, we argue it of importance to re-evaluate primary alloimmuni-
zation potentials in hemoglobinopathy patients with either anatomic or functional asplenia 
Table 2  Continued. 
Patient T1: number of  
red cell units received 
before splenectomy
T2: cumulative number of 
red cell units received  
up till last screen
pT1 pT2 Δ p
J 0 34 0.000 0.089 0.089
K 0 19 0.000 0.063 0.063
L 2 2 0.016 0.016 0.000
M 0 10 0.000 0.047 0.047
N 21 21 0.067 0.067 0.000
O 0 59 0.000 0.104 0.104
P 30 53 0.084 0.104 0.019
Q 4 13 0.027 0.058 0.031
R 0 21 0.000 0.067 0.067
S 1 38 0.010 0.089 0.079
T 0 53 0.000 0.104 0.104
SUM 1.059
pT1 = the chance to have developed red cell alloantibodies following the number of red cell exposures at T1. pT2 = the 
chance to have developed red cell alloantibodies following the number of red cell exposures at T2. Δ p = the chance to 
have developed red cell alloantibodies between T1 and T2 (i.e. following splenectomy). P-values were deduced from 
reported cumulative incidences according to number of red cell units transfused.8 
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by carefully taking into account the above mentioned methodological issues, in order to 
elucidate the spleen’s role in immunization against allogeneic blood cells in this specific 
patient population. 
 Concerning the anti-E and anti-M formed by the splenectomized patient A, we should 
first recognize that they might have developed independent of red cell exposure, i.e. as 
so-called “naturally occurring antibodies”. Second, the induction of anti-M (if from the IgM 
class) might implicate a T cell-independent humoral immune response, for which the 
spleen is known to be essential.13 Although an accessory spleen, present in over 10% of 
humans, was not identified via post-splenectomy CT scanning of the abdomen, some 
functional splenic tissue might have remained after splenectomy mediating alloimmuni-
zation. Third, the specific combination of a donor liver transplant with splenectomy could 
have caused red cell alloimmunization via pre-primed lymphocytes derived from the 
donor’s liver transplant (i.e. passenger lymphocyte syndrome). A similar mechanism has 
been reported in a patient developing non-hemolytic anti-M after multiorgan transplant.14 
Unfortunately, we could not retrieve the red cell antigenic phenotype of the liver donor to 
corroborate this hypothesis. Finally, we do not imply an absolute abolishment of red cell 
alloimmunization after splenectomy. Indeed, substantial evidence shows that at least a 
few asplenic patients are still capable to mount a protective immune response following 
non-conjugated polysaccharide vaccination.15 In addition, the absence of a functional 
spleen can, at least partly, be compensated by vaccines targeting a germinal center B cell 
response.16 Yet, the non-intravenous route of vaccines and the common use of conjugates 
differ considerably from the administration of donor red cells, facilitating epitope presentation 
and efficient induction of T cell dependent alloimmune responses in non-splenic lymphoid 
organs. 
 In conclusion, our findings suggest that splenectomy is strongly associated to protection 
from primary red cell alloimmunization in the general transfused patient population. 
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IMMUNOSUPPRESSANTS 
AND ALLOIMMUNIZATION AGAINST 






Patients receiving red blood cell transfusions are at risk of developing alloantibodies against 
donor red cell antigens. The risk of alloimmunization is dependent on the number of units 
administered and the patient’s genetic predispostion, but has also been suggested to 
be modulated by a patient’s clinical profile. Our aim was to examine whether immuno-
suppressants suppress the development of clinically relevant red cell alloantibodies. 
Methods
A two-center case- referent study was performed where case patients and control patients 
were sampled from all consecutive patients (N=17,750) who had received their first and 
subsequent red cell transfusions in a five year period in the study centers. Cases were all 
patients with a first detected red cell alloantibody preceded by negative antibody screens. 
Control patients were two-to-one matched to the case patients based on the number of 
red cell transfusions. Logistic regression analysis was used to examine the association 
between immunosuppressant exposure and the subsequent occurrence of red cell allo-
immunization.
Results
A total of 156 case patients and 312 control patients in the study received a median of 
6 transfusions (interquartile ranges 3-11). Among the total study population, 207 patients 
received immunosuppressive therapy, with 142 patients receiving only corticosteroids, 
4 receiving only other immunosuppressants and 61 receiving both. The incidence of allo-
immunization among patients using immunosuppressants was lower than among other 
patients receiving red blood cells, adjusted relative rate (RR) 0.55 (95% confidence interval 
(CI) 0.34- 0.91). 
Interpretation
Our findings support a considerably lower risk of alloimmunization with the use of immuno-
suppressive medications. 
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Introduction
Patients receiving red blood cell transfusions are at risk of developing alloantibodies 
against donor red blood cell antigens.1 Alloimmunization against clinically relevant red 
cell antigens can cause serious complications like acute and delayed hemolytic transfusion 
reactions. In light of this, it becomes important to study the risk factors associated with 
alloimmunization in detail, in order to predict which patients are most vulnerable to allo-
immunization and may be considered for more extended matched red blood cell 
transfusions. On the other hand, identifying clinical factors protecting patients against 
 alloimmunization would be equally important.
 The risk of alloimmunization is dependent on the number of red cell units administered.1 
The extent of alloimmunization has been studied in various populations with the 
incidence of alloimmunization increasing with the number of units, ranging from 7% to 
13% in a general transfused population.1-2 The risk of alloimmunization is also determined 
by a patient’s genetic predisposition to form an immune response to these non-self 
antigens.3 In addition, it has been suggested that a patient’s clinical condition is associated 
with modulation of the alloimmunization risk.4 Immunosuppressive therapy could be of 
particular importance in this respect, because red blood cell transfusions and immuno-
suppressive therapy often coincide in intensive care, trauma, active autoimmune disorder, 
cancer, and organ transplant patients. 
 The use of immunosuppressants among a general transfused population and its 
effect on the risk of clinically relevant red cell alloimmunization, however, has not been 
reported and was the purpose of this study.
Methods
Design and study population
A matched case-referent study was performed at two Dutch university hospitals (Leiden 
University Medical Center, Leiden and University Medical Center Utrecht, Utrecht, the 
Netherlands). Details of our case-referent study design have been previously published5 
and are presented in chapter 3 of this thesis. In short, the source population comprised of 
all previously non-transfused, non-alloimmunized patients who received their first red cell 
transfusion at one of the study centers. The study period was January 2005 to December 
2010 at Leiden University Medical Center and January 2006 to December 2011 at University 
Medical Center Utrecht, Utrecht. 
 Case patients were patients with first-time detected clinically relevant red cell allo- 
antibodies and control patients were patients who did not have formed any clinically 
relevant red cell alloantibody after the same number of transfusions as the matched case. 
The control sampling was conducted on the principles of a risk-set sampling strategy,6-7 
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i.e. for any given case (with N red cell units received up until alloantibody formation), two 
control patients with at least the same number of units were randomly selected from the 
source population (figure 1). Control patients were then matched to case patients based 
on the N number of units received (figure 1). Case and control patients were also matched 
on the study center.
 The transfusion policy in the study centers was as follows: 1. routinely transfused red 
cell concentrates were in SAGM and pre-storage leukoreduced and 2. all patients were 
routinely screened for alloantibodies before transfusion, which was repeated at least 
every 72 hour, if further transfusions were required. 
Alloimmunization risk period
We first set out to define an ‘alloimmunization risk period’ preceding the antibody detection 
in order to identify the concurrent clinical conditions that in combination with an antigen 
mismatched transfused unit (implicated unit) could have led to alloimmunization.5,8 
We measured all the study variables within this alloimmunization risk period.
 This risk period stretched from 30 days before up to seven days after the implicated 
unit. We chose the risk period not to include the week just before the positive screen to 
permit at least one week to allow appropriate time for the development of alloantibodies 
(lag period). The risk period definition is illustrated in figure 1. A similar clinical risk period 
surrounding the Nth transfusion was defined for the matched control patients with the 
Nth transfusion corresponding to the implicated unit received by the case (figure 1).
 Using the above defined method to establish an alloimmunization risk period, we found 
in the majority (88%) of our case patients at least one transfusion with the mismatched 
antigen in the risk period immediately preceding the antibody identification. For the 
remainder of case patients, we looked further back into their transfusion history to identify 
the transfused unit with a mismatched antigen and re-defined the alloimmunization risk 
period as per the above mentioned definition around that particular mismatched 
transfusion.
Identification of initial (first time formed) clinically relevant red cell alloantibodies
Red cell alloantibodies were defined as warm reacting clinically significant antibodies 
(against: C, E, c, e, Cw, K, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, N, S and s), and were screened 
for using a three cell panel including an indirect antiglobulin test (LISS Diamed ID gel 
system) throughout the study period. Positive screening in the three cell panel led to 
subsequent identification of the antibody or antibodies by a standard 11 cell panel using 
the same technique. 
 Alloantibodies of other specificities than those mentioned, as well as cold reacting 
alloantibodies are not routinely detected by the three cell panel screening method and 
were thus not considered to be included as cases of clinical alloimmunization.
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Medication classification
To classify the immunosuppressive therapy into corticosteroids and other immuno-
suppressants categories (table 1), the World Health Organization’s ATC (Anatomical Therapeutic 
Chemical) classification index was used (source: http://www.whocc.no/atc_ddd_index). 
Medications classified under category H, subcategory H02 were included as corticoste-
roids; medications classified under category L, subcategory L04 were included as (other) 
immunosuppressants (table 1). 
Data collection and definitions
Transfusion dates, results of the antibody investigations, patients’ date of birth, gender, 
and clinical data on the presence of chronic obstructive pulmonary disease (COPD), infections 
(bacterial, viral, or fungal; infections diagnosed by laboratory serological techniques 
Figure 1  Control patient selection and the alloimmunization risk period.
The chronological order from case patient identification to alloimmunization risk period definition is marked 
from step 1 to 5.
1.  A case is detected after three units of red cells received.
2.  All transfusion recipients who received at least three units of red cells and developed no antibodies up until 
three transfusions are considered as the referent population.
3.  From this referent population, two controls are selected at random.
4.  A ‘lag period’ of seven days is introduced between the day of antibody detection to prevent the inclusion of 
patients demonstrating possible recall events. As such, the second but not the third unit transfused here 
might have mounted an alloimmune response and is defined as the implicated transfusion. 
5.  For both the case and the two matched controls, an alloimmunization risk period stretching from 30 days 
before up to 7 days after the second unit transfused is established as the alloimmunization risk period.
1. Case 
one three five
2. Population at risk for being a case
two four
antibody





5. Alloimmunization risk period
(matched on 2 transfused red cell units) 
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including blood and tissue cultures), fever (temperature above 38.5 °C), transplants (organ 
and hematopoietic stem cell), allergies (food, dust, animal and chemical), autoimmune 
diseases, leukemia (acute lymphoblastic, acute myeloid, chronic lymphocytic, juvenile 
myelomonocytic), mature lymphoma, chemotherapy, surgeries (thoracic, abdominal, 
cranial and facial, upper and lower limbs excluding transluminal angiography), traumas 
(high impact traumas including cars, motorbikes and bicycles; falls) and diabetes (type 1 
and type 2) were collected from clinical files within the defined alloimmunization risk 
period of alloimmunization. Use of immunosuppressive medications within this risk 
period was verified by consulting the hospitals’ electronic patient dossiers and information 
management systems.
 At the time of this analysis, we had not yet reached the target number of hospitals 
stated in the R-FACT protocol (500 case patients) due a general delay in initiating the 
R-FACT study protocol in other hospitals. 
Data analyses
The association between the use of immunosuppressive medications and alloimmunization 
was modeled using a logistic regression model. Odds ratios were interpreted as relative rates 
throughout the manuscript. All relative rates (RR) were corrected for the matching factors 
(i.e. total number of transfusions and study center) and presented with a 95% confidence 
interval (CI). 
 We compared patients receiving 1. any immunosuppressive medication, 2. exclusively 
corticosteroids, 3. exclusively other immunosuppressants, and 4. both of these in combination, 
to patients not exposed to any of these medications, within the alloimmunization risk 
period.
 The adjusted relative rates were adjusted for the above mentioned potential clinical 
confounders with age categorized as ≤25, 26-50, 50-75, and >75 years of age. 
Results
Characteristics of the study population
Out of a total of 17,750 transfused patients, 468 patients were studied (156 case patients, 
312 control patients). Fifty-six percent (N=261) of patients were from Utrecht and 44% 
(N=207) were from the Leiden study center. The study population had a median age of 
59 years, (interquartile range (IQR) 38-70) and comprised of 56% males. Case patients 
had received a median of 6 units of red cells (IQR 3-11) before alloantibody formation. 
Antibodies were detected for the first time after a median of 123 days (IQR 25-333) 
following the first transfusion.
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Use of immunosuppressive therapy in the alloimmunization risk period
A total of 207 patients used any immunosuppressant medications during the alloimmuni-
zation risk period including 54 cases (34.6%) and 153 controls (49.0%). Prednisone/ prednisolone 
(50.2%), dexamethasone (46.9%), hydrocortisone (24.1%), mycophenolate mofetil (17.9%) 
and cyclosporine (16.4%) were the most used immunosuppressants (Table 1). Information 
on medications and immunosuppressive therapy could not be traced for 18 patients 
(9 controls and 9 cases) and these patients were omitted from the analysis.
Among the source population, (i.e. represented by the control patients), patients using 
immunosuppressive medications were more often males, and younger as compared to 
patients not using immunosuppressive medications. Patients using immunosuppressive 
medications more often had (any type of) infection, allergies, leukemia, and mature 
lymphoma, more often underwent transplants, and more often used chemotherapy. 
They less frequently underwent surgeries and traumas as compared to patients not using 
immunosuppressive medications (Table 2). The distribution of auto-immune diseases, 
diabetes type 1 and type 2 was similar in both patient populations.
Table 1   Types of Immunosuppressive medication used by 207 out of 468 patients 
(44.2%) of the total study population. 









Mycophenolate mofetil 37 (17.9)
Azathioprine 5 (2.4)
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Immunosuppressives and risk of alloimmunization
Table 3 presents relative rates for patients using any type of immunosuppressants, only 
corticosteroids, only other immunosuppressants or both, as compared to patients using 
none of these. Compared with patients not using any immunosuppressive medications, 
patients using only corticosteroids, only other immunosuppressants, or both all had a 
lower alloimmunization rate with an adjusted RR of 0.70 (CI 0.42-1.16), 0.51 (CI 0.04-7.10), and 
0.19 (CI 0.07-0.53), respectively. 
Discussion
In our case-referent study among previously non-transfused, non-alloimmunized patients, 
exposure to immunosuppressives was associated with a lower incidence of clinically 
relevant red cell alloantibodies against donor red blood cells. 
 The number of patients using only other immunosuppressants was very low and 
hence, RRs presented with wide CIs. These low patient numbers reflect the standard 
clinical practice where immunosuppressive therapy frequently encompasses prednisone 
or other corticosteroids.
 To appreciate our findings, several aspects need to be discussed. Strength of our 
study is the control sampling strategy. By using a risk-set sampling strategy, our control 
patients formed a representative sample of the source population.7 In this study we 
Table 3   Relative rate of alloimmunization in patients using only corticosteroids, only other 
immunosuppressants and both as compared to using none. 








None 96 150 ref ref
Corticosteroids and/or immuno-
suppressants


















RR = relative risk. CI = 95% confidence interval. 
* adjusted for the matching variables (number of matched transfusions and hospital).
† adjusted for matching variables, sex, age, COPD, infection, fever, transplants, allergies, auto-immune diseases, 
leukemia, mature lymphoma, chemotherapy, surgeries, trauma, diabetes type 1, and diabetes type 2.
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examined the combined immune modulating effects of transfusion exposure and that of 
immunosuppressives administered in the defined alloimmunization risk period. For this 
purpose, we carefully defined this risk period aiming to be able to study clinical concurrent 
events with possible immune modulating effects. While the observed protective 
association between immunosuppressive therapy and alloimmunization may in part be 
the result of other risk factors for alloimmunization that are also associated with the use of 
immunosuppressants (confounding factors), we carefully measured  other risk factors and 
adjusted for them in our analyses.
 Although the possibility of unknown transfusions at a different hospital cannot be 
entirely ruled out by our strategy due to absence of such information in the transfusion 
records of the study centers, all selected patients needed to have a negative antibody 
screen preceding the first transfusion and at least followed by one post transfusion 
antibody screen. This strategy is not entirely excluding recall immune responses to earlier 
primary immunizations. We, however, do not expect this to have affected our study 
findings as there is no reason to believe that patients with unknown previous transfusions 
or with unknown previous antibodies are more likely to be exposed (or unexposed) to any 
of the potential confounding variables. 
 To our knowledge, this is the first study in humans that shows the presence and 
extent of the protective effect of immune suppressive medications on alloimmunization 
against clinically relevant red cell antigens. A causal nature of the observed association 
with use of immunosuppressants is biologically plausible. Their role in suppressing transplant 
rejection in patients undergoing solid organ transplants has been well documented.9 
In addition, immunosuppressive therapy has been shown to impair humoral immune 
responses to  vaccines and antigens.10-11 With respect to corticosteroids, hydrocortisone 
has been shown to diminish in vitro responses to streptokinase-streptodornase and tetanus 
toxoid vaccinations as indication of a suppressed immune response.12 This diminished 
immune response in the presence of corticosteroids has been attributed to transient lym-
phocytopenia by the redistribution of circulating T cells to other body compartments.13 
It has been also demonstrated that proliferation of T cells can be inhibited by cortico-
steroids.14-19 For example, glucocorticoids inhibit production of T cell growth factor and 
block the clonal expansion necessary to amplify a primary response.17,20,21 
 Other immunosuppressive drugs also suppress T cell responses.22 Proliferation of B 
and T lymphocytes is inhibited by immunosuppressants like mycophenolate and 
 rituximab,11,23while agents like cyclosporine and tacrolimus inhibit the activation and 
 differentiation of T cells by inhibiting calcineurin. In addition, a lower influenza vaccine 
antibody response and diminished T cell proliferation responses have been shown with 
these drugs in immunosuppressed liver transplant patients.24
 Considering the mechanisms of alloimmunization against red cell antigens, this process 
is both B cell and T helper cell dependent. Although the short lived formation of non- 
naturally occurring IgM antibodies by IgM B cell memory cells is mainly T cell independent, 
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the subsequent memory B cell response and the formation of more high affinity IgG is 
T cell helper dependent. It is therefore likely that in the presence of corticosteroids and 
other immunosuppressive drugs, the T cell mediated responses to donor red cell antigens 
are impaired. Of course, the observed mediated risk reduction of alloimmunization need 
not be entirely caused by immunosuppressive agents, however, a direct attributive effect 
is strongly plausible. 
 As such, when aiming for an eventual alloimmunization risk prediction on the basis of 
clinical factors, immunosuppressives might be added to such a prediction score. This may 
enable to distinguish high risk patients for alloimmunization who might benefit from cost 
effective, extended donor blood phenotype matching strategies.
 In summary, corticosteroids and other immunosuppressant medications appear to 
have a considerable protective effect on alloimmunization in patients transfused with 
donor red blood cells. While immune activating conditions are often the reason to start 
these drugs and coincide with their use, the inhibiting effect that was observed in our 
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TREATMENTS FOR HEMATOLOGICAL 
MALIGNANCIES IN CONTRAST  
TO THOSE FOR SOLID CANCERS  






Red cell alloimmunization may induce severe hemolytic side effects. Identification of risk 
modifying conditions will help tailor preventative strategies. This study aims to quantify 
the associations of hematological malignancies and solid cancers with red cell alloimmu-
nization in patients receiving red cell transfusions. 
We performed a nested multicenter case-control study in a source population of 24,063 
patients receiving their first and subsequent red cell transfusions during an eight year 
follow-up period. Cases (N=505), defined as patients developing a first transfusion-in-
duced red cell alloantibody, were each compared with two non-alloimmunized controls 
(N=1,010) who received a similar number of red cell units. Using multivariate logistic 
regression analyses, we evaluated the association of various malignancies and treatment 
regimens with alloimmunization during a delineated 5-week risk period. 
The incidence of alloimmunization among patients with acute (myeloid or lymphoid) 
leukemia and mature (B or T cell) lymphoma was significantly reduced as compared to 
patients without these malignancies (adjusted relative risks (RR) with 95% confidence 
interval (CI) 0.36 (0.19-0.68) and 0.30 (CI 0.12-0.81)). Associations were primarily explained 
by immunosuppressive treatments (RR for (any type of) chemotherapy combined with 
immunotherapy 0.27, CI 0.09-0.83). Alloimmunization risks were similarly diminished in 
allogeneic or autologous stem cell transplanted patients (RR 0.34, CI 0.16-0.74), at least 
during the six months post-transplantation. Alloimmunization risks of patients with other 
hematological diseases, solid cancers, and their associated treatment regimens were 
similar to risks in the general transfused population.
Our findings suggest that, in contrast to malignancies in general, hemato-oncologic 
patients treated with dose-intensive regimens have strongly diminished red cell alloim-
munization risks. 
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Introduction
Transfusion of red cells causes exposure to non-self antigens and, consequently, may induce 
alloantibody formation. Although prior alloimmunization necessitates the exclusive 
administration of donor blood being negative for the cognate antigen, accidental 
re-exposure may induce severe hemolytic transfusion reactions.1, 2 Prevention of alloim-
munization and its consequences is pursued by transfusing ABO/RhD compatible units 
to all red cell recipients. In addition, matching beyond those antigens is recommended 
for certain patients considered to be at high risk of alloimmunization due to repeated 
exposure, since the number of transfusions is strongly associated with the likelihood of 
alloimmunization.3-5 As such, in several high-income countries, patients with hemoglo-
binopathies and with myelodysplastic syndrome (MDS), who often face regular transfusions 
over long periods of time, receive red cell units matched for the most immunogenic and 
clinical relevant antigens C, c, E, e, and K.3, 4 
 The ability of the recipient’s immune system to evoke a humoral alloimmune response 
upon red cell alloantigen exposure is likely modulated by the recipient’s clinical condition.6-8 
In this regard, while oncologic patients were suggested to have a similar alloimmunization 
risk as compared to the general transfused population,9-11 some studies reported high 
alloimmunization incidences among MDS patients.12, 13 Importantly, apart from the study 
of Sanz et al,13 these reports did not take the cumulative red cell exposure into account, 
which is often considerable in the oncologic patient population and a main determinant 
of alloimmunization.5 Hence, a possible influence of disease-specific features is largely 
unclear. In addition, various cancer types differ from one another in their intrinsic immuno-
biological characteristics as well as in the immunosuppressive nature of their treatments. 
Therefore, alloimmunization rates observed in a heterogeneous oncologic patient population 
likely cannot be extrapolated to specific diseases.
 We here report the results of a nested case-control study quantifying the associations 
of various hematological malignancies and solid cancers with the risk of red cell alloimmu-
nization in a cohort of red cell transfusion recipients. 
Methods
Study design and setting
We performed a nested case-control study within a mainly Caucasian source population 
of patients receiving their first and subsequent red cell transfusion between 2005 and 
2013 at one of six Dutch participating hospitals. All six hospitals treat patients with 
oncological diagnoses, including standard remission-induction chemotherapy for acute 
leukemia patients. Allogeneic hematopoietic stem cell transplantations (HSCTs) are performed 
in three, and autologous HSCTs in four of these sites.
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Details on the source population including eligibility criteria, the study period per hospital, 
and our methods were previously published5, 14 and are described in detail in chapter 3 of 
this thesis. 
 In short, cases were all patients who developed a first transfusion-induced alloantibody 
against: c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, N, S, or s. For all cases, we 
assumed the last antigen mismatched transfusion preceding the first positive screen (the 
´Nth´ transfusion) to likely have elicited alloimmunization and defined this as the implicated 
transfusion. If this last mismatched transfusion could not be identified due to incomplete 
donor typing, the last non-tested unit preceding the first positive screen was considered 
as the implicated transfusion. For each case, we then randomly sampled two non-allo-
immunized controls on the precondition that these patients received at least N or more 
transfusions in the same hospital, hereby following an ‘incidence-density sampling 
strategy’.15 After marking the Nth transfusion in the two matched controls, we subsequently 
constructed a so-called ‘alloimmunization risk period’ in both the case and the two 
controls, which stretches from 30 days before to seven days after this Nth (implicated) 
transfusion (for further illustration, see chapter 3, Figure 1 of this thesis). Next, by consulting 
the hospitals’ electronic laboratory information systems and the medical charts of all 
patients, we recorded the presence of various clinical conditions during this period. 
 The study protocol was approved by the Ethical Review Board in Leiden and by the 
board of each participating center. 
Data acquisition and statistical analyses
We gathered routinely stored data on red cell transfusion dates, dates and results of 
antibody screens (including antibody specificity), patients’ date of birth, sex, and leukocyte 
counts from the hospitals’ electronic laboratory information systems. In addition, we 
examined the medical charts of all cases and controls for the presence of various potential 
clinical risk variables during the alloimmunization risk period, including (hemato-)
oncological diagnoses and treatment modalities. 
 The associations of hematological malignancies and solid cancers with the development 
of red cell alloimmunization were evaluated using conditional logistic regression models. 
For crude relative risk (RR) calculations, we conditioned on the matched variables i.e. 
hospital and cumulative number of red cell units received. To control for additional 
confounders, we first identified covariates as possible confounders of a given determinant, 
based on their observed association with this determinant among the source population 
(i.e. the non-alloimmunized controls).16 Such an association was defined as a ≥3% difference 
in covariate presence between controls exposed and controls not exposed to a given 
determinant. Covariates in the causal pathway between the determinant and the outcome 
were not considered as confounders.16 Second, to address missing data on these 
confounders, we performed multiple imputation creating five imputed datasets. Predictor 
variables included: alloimmunization status, age, gender, number of transfusions received, 
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(types of) malignancies, chemo- and/or immunotherapy, radiotherapy, use of immuno-
suppressant medication, (timing of) allogeneic and/or autologous stem cell transplant, 
graft versus host disease, (types of) infection, (duration of) fever, (duration of) ICU admittance, 
(types of) surgery, diabetes mellitus type 1, diabetes mellitus type 2,  atherosclerosis, liver 
cirrhosis, renal insufficiency with a GFR ≤ 30 ml/min, dialysis, minimum leukocyte counts, 
maximum leukocyte counts, and maximum CRP values. 
 Third, to also accurately control for confounders with rare prevalences, we estimated 
a probability score for each determinant using logistic regression with the potential 
confounders as predictors.17 Finally, we evaluated the association of various types of 
malignancies and treatment modalities with red cell alloimmunization by entering the 
corresponding probability scores next to the matching variables into the logistic 
regression model with alloimmunization as the outcome.
 We next assessed the association between (the degree of) leukopenia and red cell 
alloimmunization. Missing leukocyte counts were similarly multiply imputed (see below). 
Minimum leukocyte counts were subcategorized into 2-4, 1-2 and <1x 109/L and referenced 
to normal counts (4-10x109/L). Since the likelihood that a low leukocyte count has been 
recorded at least once increases with the number of measurements and thus with the 
duration of hospitalization, we repeated this analysis limited to leukocyte counts measured 
within the week following the implicated transfusion. 
 A possible association between leukopenia (i.e. leukocyte counts <4x109/L) and type 
of malignancy was evaluated using Pearson’s chi-square test.
 As we used an incidence-density sampling procedure for selecting controls,15 we 
interpreted and present all odds ratios as RR with 95% confidence intervals (CI).
Malignancies and their treatments
We used internationally accepted response criteria to define the remission state of various 
hematologic malignancies.18-22 Malignancies in complete remission during the alloimmu-
nization risk period were considered as absent. The presence of minimal residual disease 
was not taken into account. All medication under subcategory L01 in the World Health 
Organization’s ATC (Anatomic Therapeutic Chemical) classification index23 was defined 
as chemotherapy, with the exception of agents in the pharmacological subgroup L01XC 
as these involve monoclonal antibodies. Within subgroup L01XC and L04AA, we defined 
rituximab, alemtuzumab, and anti-thymocyte globulin (ATG, rabbit or horse derived) 




Among 54,347 newly-transfused patients, 24,063 met all study criteria. The majority of 
excluded patients were ineligible due to the absence of an antibody screen following a 
single transfusion episode (N=25,037). 
 First-formed red cell alloantibodies were identified in 505 patients (2.1%, table S1). 
Thirty-seven of those patients (7.3%), including 21/32 (65.6%) who formed anti-Lua, 
only received units for which testing of the cognate antigen had not been performed. 
As explained, we here assumed the last non-tested unit preceding the first positive screen 
to have elicited alloimmunization. 
 General and clinical characteristics of the 505 alloimmunized patients and their 1,010 
matched control subjects are presented in Table 1. 







Men 237 (46.9) 568 (56.2)
Age in years (median, IQR) 67.0 (55.0-75.9) 65.3 (51.6-75.1)
Cumulative number of red cell units received 
(median, IQR)
lifetime* 4 (2-8) 4 (2-8)
during risk period 3 (2-6) 4 (2-8)
Days transfused during risk period (median, IQR) 1 (1-3) 2 (1-3
Men 237 (46.9) 568 (56.2)
Age in years (median, IQR) 67.0 (55.0-75.9) 65.3 (51.6-75.1)
Patient diagnoses
Diabetes mellitus (type 1 or 2) 97 (19.2) 183 (18.1) 1
GFR ≤ 30 ml/min † 56 (11.1) 149 (14.8)
Atherosclerosis ‡ 198 (39.5) 314 (31.5) 17
Chronic obstructive airway disease § 43 (8.5) 89 (9.0) 20
Splenectomy (in past or during risk period) 1 (0.2) 19 (1.9)
Liver cirrhosis 13 (2.6) 24 (2.4) 2
Hematological malignancy 60 (11.9) 210 (20.8) 13
Carcinoma 112 (22.3) 183 (18.2) 7
Treatment interventions
ICU admission 177 (36.5) 369 (35.0)
Surgery 267 (52.9) 457 (45.2) 2
Organ transplant 4 (0.8) 23 (2.3)
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Malignancies present during the alloimmunization risk period
A total of 606 patients (40.0%) had at least one type of malignancy: 270 had a hematological 
malignancy, and 338 a solid tumor (two patients presented with both types of malignancies). 
Table S2 presents types and subtypes of malignancies.
 The presence of a malignancy could not be confirmed for 12 patients: four patients 
with a clinical condition suspected for a malignancy that was not further evaluated, four 
patients with a suspected malignancy in whom a malignancy was later confirmed, and 
four patients receiving treatment for a solid tumor for whom the remission status at the 
time of the risk period was unclear. These 12 patients were omitted from the corresponding 
analyses. 







Dialysis (either chronic or acute) || 31 (6.1) 98 (9.7)
Immunosuppressant medication ¶ 154 (30.9) 423 (42.4) 20
Chemotherapy ** 66 (13.1) 224 (22.2) 6
Radiotherapy 15 (3.0) 37 (3.7)
Stem cell transplant (autologous or allogeneic, in 
past or during risk period)
10 (2.0) 63 (6.2)
Treatment related complications
Leukopenia †† 102 (20.2) 313 31.0)














Values are n (%), unless otherwise stated. Numbers of patients with unavailable data per variable are presented 
as missing. IQR = interquartile range. 
* up until the first positive screen for cases and up until the last available (negative) screen for controls. † glomerular 
filtration rate (GFR) below 30 ml/min during at least one week of the risk period (with GFR calculated using the 
Modification of Diet in Renal Diseases (MDRD) equation). ‡ systemic or coronary atherosclerosis. § chronic asthma 
bronchiale or chronic obstructive pulmonary disease. || hemodialysis, peritoneal dialysis, or continuous veno- 
venous hemofiltration needed for at least one day during the risk period. ¶ medication under subcategory H02 
(corticosteroids) or L04 (other immunosuppressants) within the World Health Organization’s Anatomical 
Therapeutic Chemical (ATC) classification index.  ** medication under subcategory L01 in the ATC classification 
index with the exception of agents in the subgroup L01XC (monoclonal antibodies). †† at least once measured 
leukocyte counts below lower limit of normal. 
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Table S3 and table S4 present identified confounders per type of malignancy. Control 
patients with acute leukemia and lymphoma, as compared to control patients without 
these diseases, were younger and had less comorbidity, including renal insufficiency 
and presence of other malignancies. They received more frequently chemotherapy and 
 immunosuppressant medication and had more frequently decreased leukocyte counts. 
The frequency of missing data per identified confounder was maximally 2.7%. 
The association between types of malignancies and red cell 
alloimmunization 
Table 2 presents number of cases and controls according to various types of malignancies. 
Acute leukemia was present in 14 cases (2.8%) as compared to 74 (7.3%) controls. The 
incidence of red cell alloimmunization in patients with acute (myeloid or lymphoblastic) 













Acute leukemia 14 (2.8) 74 (7.3) 0.31 (0.17-0.58) 0.36 (0.19-0.68) 1
myeloid 14 (2.8) 62 (6.1) 0.38 (0.20-0.71) 0.41 (0.22-0.79) 0
lymphoblastic ‡ 0 (0) 12 (1.2) 0.00 (NC) 0.00 (NC) 1
Myelodysplastic syndrome § 18 (3.6) 46 (4.6) 0.76 (0.43-1.36) 0.75 (0.41-1.36) 2
Multiple myeloma 10 (2.0) 26 (2.6) 0.77 (0.36-1.62) 0.79 (0.36-1.71) 0
Myeloproliferative neoplasm || 9 (1.8) 29 (2.9) 0.62 (0.29-1.33) 0.64 (0.29-1.41) 0
Chronic lymphatic leukemia 5 (1.0) 7 (0.7) 1.45 (0.45-4.67) 1.20 (0.36-3.93) 0
Lymphoma ¶
all 5 (1.0) 35 (3.5) 0.27 (0.10-0.69) 0.30 (0.12-0.81) 2
(mature) B cell lymphoma 4 (0.8) 28 (2.8) 0.27 (0.09-0.77) 0.30 (0.10-0.89) 2
T cell lymphoma 1 (0.2) 6 (0.6) 0.33 (0.04-2.75) 0.37 (0.04-3.15) 2
Non-hematologic 
malignancies
Carcinoma 112 (22.3) 183 (18.2) 1.30 (0.99-1.70) 1.01 (0.75-1.37) 7
Other 12 (2.4) 31 (3.1) 0.77 (0.39-1.53) 0.83 (0.41-1.68) 1
Values are n (%). * Adjusted for the matched variables: number of transfused red cell units and hospital. † Additionally 
adjusted for other potential confounders (for details, see Table S3 en S4). ‡ acute lymphoblastic leukemia and 
acute lymphoblastic lymphoma. § six patients were diagnosed with a myelodysplastic syndrome in combination 
with another hemato-oncological disorder. || including polycythemia vera, essential thrombocytosis, primary 
myelofibrosis, juvenile and chronic myelomonocytic leukemia. ¶ One patient was diagnosed with an undifferen-
tiated mature lymphoma. NC = not computable.
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leukemia and in patients with mature (B or T cell) lymphoma was reduced (adjusted RR 
0.36 (CI 0.19-0.68) and 0.30 (CI 0.12-0.81), respectively). Conversely, patients with chronic 
lymphatic leukemia (CLL) showed a modest, albeit statistically non-significant, increased 
risk (adjusted RR 1.20, CI 0.36-3.93). No association between the other types of malignancies 
and red cell alloimmunization was observed, including MDS and solid malignancies. 
Similarly, subtypes of solid tumors were not associated to red cell alloimmunization, 
although some RRs presented with wide CIs (Table S5). As extensive matching recommen-
dations have only been introduced since 2011 in the Netherlands,3 only 1 of 64 patients 
(1.6%) with MDS received CcEe and K matched units. 
Effects were similar in all six hospitals (data not shown). 
















none 437 (86.9) 782 (77.7) ref ref
(only) chemotherapy ‡ 61 (12.1) 180 (17.9) 0.57 (0.41-0.79) 0.86 (0.54-1.36)
(only) immunotherapy § 1 (0.2) 4 (0.4) 0.57 (0.06-5.67) 0.62  (0.07-5.18)
chemo- and 
immunotherapy
4 (0.8) 40 (4.0) 0.17 (0.06-0.48) 0.27 (0.09-0.83)
HSCT 0
type
autologous or allogeneic || 10 (2.0) 64 (6.3) 0.29 (0.14-0.58) 0.34 (0.16-0.74)
timing (months before 
implicated transfusion)
none 495 (98.0) 946 (93.7) ref ref
0-1 4 (0.8) 27 (2.7) 0.28 (0.09-0.81) 0.34 (0.11-1.07)
>1-6 3 (0.6) 24 (2.4) 0.22 (0.06-0.75) 0.24 (0.07-0.86)
>6 3 (0.6) 13 (1.3) 0.46 (0.13-1.70) 0.55 (0.14-2.09)
Radiotherapy 15 (3.0) 39 (3.9) 0.78 (0.42-1.44) 0.75 (0.39-1.44) 0
Values are n (%). * Adjusted for the matched variables: number of transfused red cell units and hospital. † Additionally 
adjusted for other potential confounders (for details, see Table S4). ‡ all medication under subcategory L01 within 
the Anatomical Therapeutic Chemical (ATC) classification index with the exception of monoclonal antibodies. 
§ monoclonal antibodies directed against B and/or T lymphocyte markers received by 49 patients (rituximab 
N=20, alemtuzumab N=5, and anti-thymocyte globulin N=25). || 10 patients received an allogeneic HSCT after an 
earlier autologous HSCT. HSCT = hematopoietic stem cell transplant (either autologous or allogeneic) received 
before or during the alloimmunization risk period. 
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The association between treatment modalities and red cell 
alloimmunization 
A total of 290 patients received chemo- and/or (anti-lymphocyte) immunotherapy during 
the implicated risk period. Use of any type of chemotherapy without immunotherapy was 
not associated with red cell alloimmunization. However, when regimens included 
 lymphocyte-targeted monoclonal antibodies the adjusted RR was 0.27 (CI 0.09-0.83) 
(table 3). Twenty-five of the 49 patients (51%) treated with monoclonal antibodies received 
ATG (with or without alemtuzumab), aiming in vivo depletion of T cells in the context of 
an allogeneic HSCT (N=21), aplastic anemia (N=3), or combined pancreas-kidney organ 
transplant (N=1). 
 Patients receiving chemotherapeutic agents for acute leukemia or lymphoma during 
the implicated risk period had substantially reduced alloimmunization incidences (RR 0.29 
(0.14-0.60) and 0.08 (0.01-0.57), respectively). This risk reduction seemed not majorly 
further influenced by the time interval between the initial diagnosis and the risk period 
(data not shown). In contrast, non-treated patients with these disorders demonstrated 
risks comparable to the remainder of the patient population (Table 4). Sixty-two of the 
74 treated patients (84%) with acute leukemia received induction therapy during the allo-
immunization risk period. Analogous to acute leukemia and mature lymphoma, the 22 
patients who received treatment for their MDS (including 13 patients receiving induction 
therapy and seven receiving hypomethylating agents), demonstrated a trend towards 
reduced alloimmunization incidences (RR 0.31 (CI 0.09-1.06), Table 4). Chemotherapy did 
not modulate risks in patients with other types of hematological malignancies or carcinoma 
(Table 4). 
 A total of 54 patients received radiotherapy (of any dose and frequency), including 
10 patients who received total body irradiation in the setting of an allogeneic HSCT. 
Radiotherapy was not associated with red cell alloimmunization (Table 3). 
 Respectively 51, 13, and 10 patients underwent an allogeneic HSCT, an autologous 
HSCT, or both in the time course preceding or during the risk period. In 51 patients, 
a reduced-intensity allogeneic HSCT conditioning regimen was followed (including eight 
patients who received a double cord transplant), whilst 10 patients received a myeloablative 
conditioning regimen. Alloimmunization incidences were substantially decreased in 
(allogeneic or autologous) in these stem cell transplant recipients (RR 0.34, CI 0.16-0.74), at 
least during the first six months after transplantation (Table 3). Alloimmunization risks did 
not differ between recipients of an autologous or allogeneic HSCT (data not shown). 
 Lastly, the degree of leukopenia was strongly associated with diminished red cell 
 alloimmunization (Table 5). Here, patients with leukocyte counts of <1.0x109/L demonstrated 
an adjusted RR of 0.33 (CI 0.20-0.55). Similar results were obtained when we restricted 
these analyses to leucocyte counts determined within the week following the implicated 
transfusion (Table 5). The degree of leukopenia was associated with the type of malignancy 
and the receipt of chemotherapy. In this regard, minimum leukocyte counts of <1.0x109/L 
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- 489 931 ref ref
+ - 4 10 0.77 (0.22-2.66) 0.88 (0.25-3.09)
+ + 10 64 0.25 (0.12-0.51) 0.29 (0.14-0.60)
Myelodysplastic syndrome
- 484 959 ref ref
+ - 15 28 1.06 (0.54-2.07) 1.04 (0.52-2.06)
+ + 3 18 0.32 (0.09-1.12) 0.31 (0.09-1.06)
Multiple myeloma
- 493 981 ref ref
+ - 4 7 1.14 (0.32-4.06) 1.19 (0.33-4.34)
+ + 6 18 0.67 (0.26-1.72) 0.70 (0.27-1.82)
Myeloproliferative neoplasm
- 494 977 ref ref
+ - 3 13 0.46 (0.13-1.63) 0.48 (0.13-1.73)
+ + 6 16 0.75 (0.29-1.95) 0.79 (0.30-2.09)
Chronic lymphatic leukemia
- 499 999 ref ref
+ - 1 3 0.49 (0.05-4.85) 0.67 (0.07-6.47)
+ + 3 4 1.27 (0.27-6.01) 1.53 (0.33-7.11)
Lymphoma
- 498 969 ref ref
+ - 4 7 1.08 (0.31-3.76) 1.26 (0.35-4.51)
+ + 1 28 0.07 (0.01-0.49) 0.08 (0.01-0.57)
Carcinoma
- 390 821 ref ref
+ - 85 141 1.28 (0.95-1.73) 0.99 (0.71-1.38)
+ + 26 39 1.40 (0.84-2.35) 1.14 (0.67-1.94)
+ = present; - = absent. Only numbers of patients for whom the presence or absence of a given malignancy and 
the use of chemotherapy during the alloimmunization risk period could be determined are presented. * Adjusted 
for the matched variables: number of transfused red cell units and hospital. † Additionally adjusted for other 
potential confounders (for details, see Table S4).
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were observed in respectively 66.2%, 75.9%, and 13.8% of patients with acute leukemia, 
lymphoma, and carcinoma receiving chemotherapy during the risk period (p<0.0001 for 
carcinoma versus acute leukemia and for carcinoma versus lymphoma). 
Discussion
In this nested case-control study, we evaluated whether patients diagnosed with hematological 
malignancies and solid cancers differed in their risk to form red cell alloantibodies as compared 
to the general transfused patient population. Patients treated for acute leukemia (either of 
myeloid or lymphoblastic origin) and patients with mature (B or T cell) lymphomas 
demonstrated a 3-fold decreased incidence of clinically relevant alloantibodies against 
red cell alloantigens. In contrast, alloimmunization incidences among patients treated for 
other hematological malignancies or solid tumors were similar to those among the 
non-malignant patient population. 
 Although earlier reports only observed similar or even increased red cell alloimmuni-
zation frequencies in the oncologic patient population,9-11 these prevalence-based 
studies did not adjust for the substantial number of transfusions these patients usually 
receive. However, the cumulative transfusion dose is a well-known important determinant 
Table 5   Leukopenia and red cell alloimmunization risks. 
Minimum  








Adjusted RR (CI) †
Alloimmunization risk period ‡
4-10 307 524 ref ref
2-<4 61 128 0.82 (0.58-1.15) 0.87 (0.61-1.24)
1-<2 14 43 0.52 (0.27-0.99) 0.59 (0.31-1.13)
<1 26 142 0.27 (0.17-0.44) 0.33 (0.20-0.55)
≤1 week following implicated transfusion
4-10 273 485 ref ref
2-<4 44 107 0.72 (0.47-1.10) 0.80 (0.52-1.23)
1-<2 15 41 0.60 (0.30-1.23) 0.75 (0.36-1.58)
<1 19 119 0.24 (0.13-0.44) 0.34 (0.17-0.66)
Minimum leukocyte counts as measured during the alloimmunization risk period and as measured during the 
week following the implicated transfusion. Values are n (%). Cumulative numbers of presented cases and controls 
do not necessarily equal the total number of cases and controls, as patients with leukocytosis are not presented. 
* Adjusted for the matched variables: number of transfused red cell units and hospital. † Additionally adjusted for 
other potential confounders (for details, see Table S4). ‡ p = 0.02 for trend analysis.
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of alloimmunization.5 Consequently, the observed positive associations might have been 
completely due to a rather intensive red cell transfusion support that is generally needed 
in the treatment of certain malignancies rather than to disease-specific characteristics 
itself. Finally, no studies so far compared specific oncologic diseases for alloimmunization 
risks with one another. 
 Our findings suggest that especially the dose-intensive immunosuppressive therapy 
influences alloimmunization. This seems biologically plausible. Several classical cytotoxic 
agents frequently used in the treatment of acute leukemia and lymphoma, including 
 cyclophosphamide, purine nucleoside analogs, and anthracyclines, are known to induce 
prolonged (mainly naive) CD4+ T cell and B cell depletion.24-27 Moreover, chemotherapeutic 
regimens often include corticosteroids, a class of immunosuppressants which we earlier 
reported for to protect against red cell alloimmunization.8 Significantly reduced red cell 
alloimmunization incidences were also found in patients receiving anti-lymphocyte 
targeted agents (i.e. ATG, alemtuzumab, and rituximab). ATG is well known for its strong 
and prolonged T cell depleting effects.28, 29 Additionally, ATG preparations contain 
antibodies against several B and even plasma cell-specific markers.29, 30 In agreement, 
eradication of B cells by rituximab has been shown to coincide with impaired primary as well 
as recall vaccine responses.31-34 Finally, we observed profoundly lower alloimmunization 
rates in the setting of an (either autologous or allogeneic) HSCT, which appeared to be 
sustained at least during the first six months after transplantation. Even though we cannot 
fully exclude the eight alloimmunizations following an allogeneic HSCT to have been 
elicited by donor-recipient red cell antigen mismatches (in addition to exposure via 
transfusion), these findings are consistent with previous studies reporting anti-D formation 
to be rare in RhD-negative HSCT recipients exposed to RhD.35-37 Depending on 
age-associated thymic functioning, type of stem cell harvest, and intensity of T cell 
depletion strategies, reconstitution of adaptive immune cells generally takes up to six to 
12 months following HSCT,38-43 whilst humoral immunity may continue to be deficient, 
even after several years.44, 45
 Although treatment-induced immunosuppression seems the principal explanation 
of our observations, other non-measured factors associated with receiving treatment (e.g. 
co-morbidities and disease stage) might have interacted with disease-specific effects on 
the immune response. Hence, we cannot exclude part of the observed effects to be 
directly related to the diseases themselves, i.e. induction of an immunosuppressive but 
tumor tolerant state via host immune evasion mechanisms of malignant cells.46-49 
 Furthermore, as patients received a large diversity of chemotherapeutic regimens at 
varying periods preceding the alloimmunization risk period, we were unable to reliably 
conclude whether and to what extent patients in complete remission of their treated 
malignancy should be considered as significantly immunosuppressed. As such, our 
presented RRs might underestimate true effects and our results do not preclude these 
patients to have a diminished red cell alloimmunization risk. 
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In contrast to some other studies,12, 13 our incidence-based analysis did not demonstrate 
an enhanced alloimmunization susceptibility with a diagnosis of MDS. However, and 
similar to intensively treated patients with acute leukemia and mature lymphoma, patients 
who received treatment for their MDS tended to show reduced alloimmunization 
incidences. Consequently, the decision to transfuse extended donor-matched products 
to this patient population should not be based on the MDS diagnosis itself, but on other 
factors associated to an increased alloimmune response e.g. a high transfusion burden. 
 Finally, the alloimmunization RR in patients with chronic lymphatic leukemia (CLL) 
independent of their treatment seemed increased as compared to lymphoma patients, 
although we acknowledge that the number of CLL patients in the current study is 
insufficient to confirm such a hypothesis. Yet, CLL is characterized by profound immune 
disturbances including non-clonal formation of IgG auto-antibodies directed against 
blood cell antigens.50-52 A disturbance of the normal regulatory potential by the disease 
has been implicated in these observations. Seemingly in contrast with these findings, 
antimicrobial vaccination responses are often compromised in CLL patients.53 
Some final comments regarding our methods seem appropriate. 
 First, the use of an incidence-density sampling strategy guaranteed that controls 
were exposed to at least the same amount of red cell units as their matched cases.15, 54 
Given this adjustment for cumulative number of red cell exposures, our RRs reflect relative 
risks independent of exposures. Our defined alloimmunization risk period specifically 
functioned to comprehensively study the influential effect of conditions present around 
the time of red cell exposure. As the immunosuppressive effects of various treatment 
regimens only slowly extinguish, we preferred a relatively long risk period to precede the 
implicated transfusion.  
 Second, our strategies do not fully guarantee the exclusion of all boosting events. 
Actual ‘lag periods’ i.e. the time needed before antibody levels become detectable after 
primary antigen encounter, are currently unknown and may even differ per antigen. 
Regarding our chosen lag period of seven days, we thus cannot fully exclude to have 
included patients whose antibody titers became undetectable over time and 
demonstrated recall responses rapidly upon re-exposure to the alloantigen. However, 
erroneously considering a substantial amount of boosting reactions as primary alloimmu-
nization events would have biased our RRs towards the null-effect. Indeed, a sensitivity 
analysis in which we excluded the 53 patients in whom alloantibodies were discovered 
during the second week following their first antigen-incompatible transfusion did not 
change RRs (data not shown). We therefore believe the eventual bias due to our choice of 
the lag period to be small.
 Third, no associations of other than the above mentioned hematological malignancies 
and specific types of solid malignancies with red cell alloimmunization was observed, 
although the low numbers of some of these subgroups and the accordingly wide CIs per 
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RR prevent firm conclusions. A substantially larger study or a meta-analysis of similar 
studies is needed to assess whether these malignancies are truly indeed not associated 
to red cell alloimmunization. Also, due to incomplete remission evaluations available during 
the alloimmunization risk period, we were unable to assess whether the disease stage 
itself is associated to cell alloimmunization. 
 Finally, since patients treated with chemotherapy received a diversity of chemo-
therapeutic agents and combinations, as well as varying dose intensities, we were not 
able to quantify risks per single agent.
 In conclusion, red cell alloimmunization risks are significantly reduced in patients 
treated for acute leukemia and mature lymphomas, as well as in recipients of an (autologous 
or allogeneic) HSCT. These diminished immune responses most likely reflect the intensity of 
treatment-associated immunosuppression. In contrast, alloimmunization risks in patients 
with other hematologic diseases and in patients with solid cancers are similar to those in 
the general, non-oncologic transfused patient population. These findings clearly indicate that, 
in addition to cumulative red cell exposure, disease-specific conditions should be taken into 
account when considering the risk of red cell alloimmunization, hereby ultimately aiming 
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Supplementary Material
Table S1   Specificity and distribution of first-formed red cell alloantibodies according to  
the presence and type of malignancy. 
Alloantibody specificity All patients,  
N (%)





anti-C 23 (4.0) 0 (0) 4 (3.1)
anti-c 41 (7.2) 0 (0) 6 (4.7)
anti-E 185 (32.3) 4 (20.0) 43 (33.3)
anti-e 5 (0.9) 0 (0) 1 (0.8)
anti-K 126 (22.0) 3 (15.0) 32 (24.8)
anti-Cw 19 (3.3) 1 (5.0) 4 (3.1)
anti-Fya 31 (5.4) 0 (0) 3 (2.3)
anti-Fyb 5 (0.9) 0 (0) 1 (0.8)
anti-Jka 54 (9.4) 3 (15.0) 17 (13.2)
anti-Jkb 7 (1.2) 2 (10.0) 0 (0)
anti-Lea 7 (1.2) 2 (10.0) 2 (1.5)
anti-Leb 3 (0.5) 0 (0) 1 (0.8)
anti-Lua 32 (5.6) 3 (15.0) 9 (7.0)
anti-Lub 0 (0) 0 (0) 0 (0)
anti-M 22 (3.8) 2 (10.0) 3 (2.3)
anti-N 1 (0.2) 0 (0) 0 (0)
anti-S 12 (2.1) 0 (0) 3 (2.3)
anti-s 0 (0) 0 (0) 0 (0)
All antibodies 573 20 129
(possibly) natural occurring * 268 (46.7) 12 (60.0) 62 (48.1)
generally not inducing hemoysis† 55 (9.6) 5 (25.0) 12 (9.3)
N patients 505 19 112
N patients with ≥ 2 first-time alloantibodies 63 (12.5) 1 (5.3) 15 (13.4)
* including: anti-E, anti-Cw, anti-Lea, anti-Leb, anti-Lua, and anti-M. † Including: anti-Lua, anti-M and anti-N. 
The distribution of (possibly) natural occurring antibodies did not significantly differ between patients with acute 
leukemia or mature lymphoma as compared to the remaining of the study population, including patients with 
carcinoma (p=0.09, chi square test). In contrast, the frequency of non-hemolytic alloantibodies was higher in 
alloimmunized patients with acute leukemia or mature lymphoma as compared to the remaining of the 
immunized population (p=0.03). However, this did not affect conclusions presented in table 2 (data not shown).
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Table S2   Categories and types of malignancies present during the alloimmunization  
risk period. 
Hematologic malignancies N Carcinomas N
Diagnosed in N patients 270 Diagnosed in N patients 295
Acute leukemia 88 Adrenal 2
myeloid (AML) 76 Bile tract 2
lymphoblastic (ALL) * 12 Breast 21
Myelodysplastic syndrome 63 Cervix, endometrial 14
Multiple myeloma 36 Colorectal 71
Myeloproliferative neoplasm 38 Duodenal, stomach 15
Chronic lymphatic leukemia 12 Esophagus 11
Lymphoma 40 Head and neck 17
(mature) B cell lymphoma † 32 Hepatic cell 6
T cell lymphoma ‡ 7 Lung § 41
undifferentiated 1 Ovarian 19
Pancreatic 7
Prostate 21
Other N Renal cell 20
Diagnosed in N patients 43 Squamous cell 3
Germ cell tumors 4 Unknown primary origin || 3
Melanoma 1 Urothelial 20
Neuro-endocrine tumors 3 Vaginal, vulvar 2
Stromal and mesenchymal neoplasms 35 Other 1
Cumulative numbers of types of malignancies per category may exceed the number of patients per category, as 
some patients were diagnosed with two malignant diseases.
* acute lymphoblastic leukemia and acute lymphoblastic lymphoma. † of which: 6 patients with Burkitt lymphoma, 
11 with diffuse large B cell lymphoma, 5 with follicular lymphoma, 1 with hairy cell lymphoma, 4 with Hodgkin 
lymphoma, 3 with mantle cell lymphoma, 1 with low-grade B cell lymphoma not otherwise specified, and 1 with 
lymphoplasmacytic lymphoma. ‡ of which: 3 patients with anaplastic T cell lymphoma, 1 with mycosis fungoides, 
and 3 with peripheral T cell lymphoma not otherwise specified. One patient was diagnosed with an undifferen-
tiated mature lymphoma. § of which 37 patients with non-small cell lung carcinoma and 4 with small cell lung 
carcinoma. || of which: 2 patients with adenocarcinoma with unknown primary and 1 with squamous cell 
carcinoma with unknown primary.
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Table S4   Subset of variables identified as confounders per determinant for 
alloimmunization. 
Determinant Confounders
All Age, gender, (duration of ) ICU admittance, thoracic surgery, 
atherosclerosis, GFR ≤ 30 ml/min, dialysis.
Acute leukemia Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, MPN, 
lymphoma, carcinoma
Myelodysplastic syndrome Idem as under ‘all’, plus: abdominal surgery, DM2.
Multiple myeloma Idem as under ‘all’, plus: abdominal surgery, DM2, acute leukemia, 
lymphoma, carcinoma.




Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, acute 
leukemia, MDS, lymphoma, carcinoma.
Lymphoma Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, acute 
leukemia, MPN, carcinoma.
Carcinoma Idem as under ‘all’, plus: abdominal surgery, acute leukemia, MDS, 
MM, MPN, lymphoma.
Other malignancies Idem as under ‘all’, plus: abdominal surgery, back or spinal surgery, 
splenectomy in past or during risk period, acute leukemia, MDS, 
lymphoma, carcinoma.
Chemo-/immunotherapy Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, 
immunosuppressant medication, acute leukemia, MDS, MM, MPN, 
lymphoma, carcinoma.
Radiotherapy Idem as under ‘all’, plus: DM2, COPD, acute leukemia, MM, lymphoma, 
chemo-/immunotherapy, carcinoma.
Autologous stem cell 
transplant
Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, acute 
leukemia, MM, MPN, lymphoma, carcinoma.
Allogeneic stem cell 
transplant
Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, acute 
leukemia, MM, MPN, lymphoma, carcinoma, (timing of previous) 
autologous HSCT. 
(degree of ) leukopenia Idem as under ‘all’, plus: abdominal surgery, DM2, COPD, 
immunosuppressant medication, acute leukemia, MDS, MM, 
carcinoma, chemo-/immunotherapy, radiotherapy, (timing of ) HSCT.
All determinants were associated with the variables listed under ‘all’. In addition to these, several other potential 
confounders were identified per determinant. 
Atherosclerosis = systemic or coronary atherosclerosis. GFR = glomerular filtration rate (GFR) below 30 ml/min 
during at least one week of the risk period (calculated according to the Modification of Diet in Renal Diseases 
(MDRD) equation). Dialysis =  hemodialysis, peritoneal dialysis, or continuous veno-venous hemofiltration needed 
for at least one day during the risk period. DM2 = diabetes mellitus type 2. COPD = chronic asthma bronchiale or 
chronic obstructive pulmonary disease. MDS = myelodysplastic syndrome. MPN = myeloproliferative neoplasm. 
MM = multiple myeloma. Immunosuppressant medication = medication under subcategory H02 (cortico-
steroids) or L04 (other immunosuppressants) within the Anatomical Therapeutic Chemical (ATC) classification 
index. Chemo-/immunotherapy = medication under subcategory L01 within the ATC index plus antithymocyte 
globulin. HSCT = hematopoietic stem cell transplant.
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Table S5   Association between non-hematological malignancies and red cell 












Carcinoma 112 (22.3) 183 (18.2) 1.30 (0.99-1.70) 1.01 (0.75-1.37) 7
Breast 8 (1.6) 13 (1.3) 1.30 (0.53-3.18) 1.02 (0.40-2.58) 0
Colorectal 24 (4.8) 47 (4.7) 1.08 (0.64-1.81) 0.86 (0.49-1.49) 0
Lung 17 (3.4) 24 (2.4) 1.47 (0.77-2.78) 1.22 (0.63-2.37) 0
Prostate 4 (0.8) 16 (1.6) 0.53 (0.17-1.61) 0.49 (0.16-1.53) 0
Renal cell 6 (1.2) 14 (1.4) 0.91 (0.35-2.41) 0.83 (0.31-2.23) 0
Urothelial 7 (1.4) 13 (1.3) 1.11 (0.44-2.84) 1.09 (0.41-2.89) 0
Other 12 (2.4) 31 (3.1) 0.77 (0.39-1.53) 0.83 (0.41-1.68) 1
Stromal and mesenchymal 9 (1.8) 26 (2.6) 0.69 (0.31-1.50) 0.74 (0.33-1.65) 1
Values are n (%). Only subtypes of solid tumors with at least 20 patients diagnosed are presented. * Adjusted for 
the matched variables: number of transfused red cell units and hospital. † Additionally adjusted for other 
potential confounders (for details, see Table S4).
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SUMMARY AND FUTURE PERSPECTIVES
Summary and future perspectives
In this thesis, we report on various determinants which we found associated with red cell 
alloimmunization in humans, with the eventual aim to reduce red cell alloimmunization 
and its potentially detrimental consequences by risk factor based matching strategies. 
Here, we first highlight the identified risk factors against the background of former 
evidence. Finally, we discuss future research perspectives. 
Optimizing red cell antigen matching: critical antigens
Antibody formation to red cell alloantigens requires exposure to alloantigens together 
with a certain activation of the recipient’s humoral immune system. The reported allo-
immunization prevalences are surprisingly variable ranging from only 3% to as high as 
58%.1-9 These wide ranges likely reflect the differences in study designs and selected 
patients, e.g. inclusion of previously transfused and thus more exposed patients, inclusion 
of previously alloimmunized patients, and the length of serological follow-up. Our strategy 
of use of an incident new-user cohort enables estimation of the incidences of allo-
immunization as a function of exposure within a cohort of transfusion-naive patients. 
With this approach, our group previously managed to confirm the intuitive assumption 
that the risk to develop alloantibodies increases with the transfusion burden.10 
 Expansion of our cohort from two to six participating hospitals allowed us to assess 
antigen-specific alloimmunization incidences and with it the exposure corrected immuno- 
genicity of these antigens. In chapter 2, we illustrate that anti-E, anti-K, anti-Jka, and anti-c 
are the most prevalent formed alloantibodies among the 7.7% of transfused patients who 
formed alloantibodies after having received at least 40 units of red cells. With a policy of 
serological matching against their cognate antigens, the population would have benefited 
from a 74% reduction of red cell alloimmunization. 
 Considering prevention by matching for certain antigens, it is important to realize 
that antigens are not equally distributed nor are they equally immunogenic. Several 
studies reported on antigen immunogenicity estimates over the past decades.11-14 Likely 
related to the often used ‘Giblett-equation’, these studies yielded conflicting conclusions 
regarding the potency of all antigens, except for K (Figure 1). Giblett-based calculations 
deduce immunogenicity estimates from prevalence figures by comparing the observed 
numbers of antigen-specific antibodies with the calculated probability of non-self antigen 
exposure. 
 However, several factors potentially influencing the results obtained by this equation 
need to be taken in consideration: 
 First, the Giblett equation is based on average antigen frequencies in a donor and 
recipient population of Caucasian origin and assumes that the chance of alloimmunization 
140
CHAPTER 7
is linearly increasing with antigen exposure. However, it seems more likely that when one 
has not formed an alloantibody after multiply mismatched units, the likelihood to do so 
after the next mismatched unit will be even smaller because of the recipient being a so 
called ‘non-responder’ patient. Accordingly, most hemophilia patients receiving prophylactic 
clotting factor infusions form inhibitors to these products early after initiation of regular 
suppletion.15 Consequently, for an antigen with moderate frequency (e.g. Jka), the cumulative 
incidence curve rises relatively early during accumulation of red cell transfusions and then 
flattens after N red cell transfusions, because patients lacking expression of this antigen 
will reasonably be fastly exposed and immunized. Contrary, for an antigen with low 
frequency (e.g. K) the initial increase of the incidence curve will be slower because, 
although most red cell recipients  do not express the antigen themselves, this also applies 
to the donor population. Thus, the odds of encountering non-self K as compared to 
non-self Jka per transfused red cell unit are far lower. Figure 2 illustrates this exposure- 
related flattening for a fictitious antigen Y with moderate frequency and an antigen Z with 
low frequency. At time point 1, the number of patients who have formed anti-Y far exceeds 
those who have formed anti-Z, while at time point 2 these numbers approximate one 
another. Ultimately, prevalence-based immunogenicity estimates derived from the Giblett 
equation will induce an overestimation of the relative immunogenicity of low-frequent 
antigens (e.g. K), especially in a multiply transfused population.
 A second important caveat in assessing antigen immunogenicity concerns current 
RhD matching strategies. In fact, the likelihood to be exposed to the C, c, E, and e antigens 
is determined by the influence of RHD and RHCE gene-linkage. That is, as only 6% of the 
Figure 1  Summary of previously estimates of antigen immunogenicity with K as reference.
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Caucasian RhD-negative population express the E antigen,16 RhD-negative patients 
receiving only RhD negative red cell products are rarely exposed to E. Conversely, as 67% 
of RhD-positive individuals lack E,16 23% of RhD-positive patients are at risk of E alloimmu-
nization with routine RhD matching. None of the reported prevalence-based calculations 
accounted for this gene-linkage. Consequently, when matching for one antigen indirectly 
also involves matching for another (gene-linked) antigen, inaccurate estimations of 
antigen exposure, and thus of the antigens’ immune system stimulating potencies, will be 
made.
 Third, prevalence-based calculations estimate the antigen’s potency relative to another 
(e.g. relative to K), however, do not inform about absolute risks according to alloantigen 
exposure. The latter, however, will be specifically decisive when debating extended matching 
for the individual patient.
 Finally, previously reported studies did not consider higher immunization risks due to 
intrinsic antigen differences between e.g. Caucasian donors and recipients from non- 
Caucasian origin (e.g. hemoglobinopathy patients), neither considered the lower risk of 
some patients due to receiving extended matched products (e.g. auto-immunized or 
Figure 2  The estimated relative immunogenicity of antigens is dependent on exposure.
As fictitious antigen Z represents a low-frequent antigen as compared to the fictitious moderate frequent 
antigen Y, most responsive patients will have been exposed and thus have formed anti-Y at time point 1, while 
primary exposure still occurs after time point 1 for antigen Z. Consequently, the four-fold higher estimated 


































previously alloimmunized patients or women in the reproductive age). As the odds for 
antigen exposure in all these patient populations differs from that in the general, 
non-extended matched Caucasian patient population, earlier presented immunogenicity 
calculations represent a mixture of these risks.
 Considering the above, we limited our incident new-user cohort to primarily Caucasian 
red blood cell recipients, while we plotted the incidence of antigen-specific alloimmuni-
zation as a function of exposure to all units received and second to only all antigen- 
positive units received by all antigen-negative patients. The latter enabled us to deduce 
unbiased relative antigen immunogenicities from these incidences. With this approach, 
we confirm in chapter 2 that K indeed is the most immunogenic antigen, followed by E, 
Cw, e, Jka, and c. Based on these data, prophylactic extended matching for the K, E, e, Jka, 
and c antigens would prevent 74% of primary alloimmunization events. While K, E, e, and 
c matching is often attempted for in high risk patients, prevention of anti-Jka is currently 
not aimed for in developed countries.17, 18 Yet, our results underline the importance of Jka 
matching as this antigen is shown to be highly potent in eliciting an antibody response 
with the antibody known to easily induce complement mediated hemolysis. Although 
the observed high immunogenicity of Cw might come as a surprise, we do not recommend 
to implement extended matching for this antigen. The chance of subsequent exposure 
after primary immunization is only 2% per transfused unit16 and, more importantly, severe 
hemolysis by anti-Cw is rare.19-21  
 Finally, we have to realize that even with complete (molecular) typing of red cell recipients, 
it is unlikely to find a completely matched red cell unit for all patients due to limited donor 
resources.12 Furthermore, matching logistics will be even more compromised in countries 
with less organized blood collecting services as compared to the Netherlands, as well as 
in case of red cell recipients with a different ethnic background from the donor population, 
and in situations of acute need of blood and related lack of time e.g. acute trauma.
 Notwithstanding the above, the in our studies provided knowledge on the potency 
of several red cell antigens hopefully enables clinicians and blood bankers to prioritize 
which blood group antigens should be primarily matched between donor and recipient. 
Optimizing red cell antigen matching: identifying the 
critical patient population
Next to exposure to high immunogenic non-self red cell antigens, alloimmunization 
requires a recipient´s immune system to be capable of mounting a significant adaptive 
immune response upon exposure. Currently, there is a limited understanding of what 
factors dictate and which immune cells and signals are essential to this specific immune 
response in humans. In this light, the factors we found associated with alloimmunization 
risk need to be placed into the complex string of events leading to alloimmunization. 
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Inflammation as a modulator of alloimmunization
Contrasting the processing of most microbial organisms in lymph nodes, senescent and 
damaged red cells are primarily sequestered in the red pulp of the spleen. Under non- 
inflammatory circumstances, splenic macrophages play a major role in clearing these cells 
from the circulation via their SIRPα interacting with CD47 on red cells.22-25 Lower levels of 
clearance seem to take place in the liver, while essentially no clearance occurs in peripheral 
lymph nodes.23 Mice experiments showed that in the absence of inflammation these 
animals only rarely form red cell alloantibodies following red cell transfusions,26 possibly 
related to the functioning of red pulp macrophages during these circumstances. Indeed, 
red pulp macrophages have been implicated in both the induction of regulatory T cells 
and the inhibition of CD4+ T cell responses.24 As red pulp macrophages are important for 
clearing ageing autologous hematopoietic cells, they are rightly situated to have a 
regulatory function protecting against harmful autoimmune responses. 
 It is generally believed that for a more effective adaptive immune response, antigenic 
stimulation needs to be accompanied by additional, often cytokine mediated, ‘danger 
signals’ originating from e.g. pathogen-activated innate immune cells.27-29 In line with this, 
we observed an association between a patient’s inflammatory condition due to infection 
at the time of red cell transfusion and the development of red cell alloantibodies. In 
chapter 3, we demonstrate alloimmunization risk to be modulated by the type of 
infection, its intensity, and the patient’s inflammatory response. In detail, patients with 
severe (tissue-invasive) bacterial and viral infections demonstrated higher alloimmuniza-
tion incidences as compared to the general transfused patient population. In intriguing 
contrast, blood-borne infections with Gram-negative bacteria (known to express LPS on 
the outer surface of their cell membrane) coincided with an almost 2-fold reduction of 
alloimmunization risk. The available evidence supports the following hypotheses on the 
underlying immunological mechanisms:
 First, in murine red cell transfusion models, exposure to several pro-inflammatory 
pathogen-associated molecular patterns (PAMPs) such as poly(I:C) and hypomethylated 
CpG-containing bacterial DNA unequivocally promoted red cell alloimmune responses.23, 
26, 30-32 Of interest, not all inflammatory triggers unanimously enhance alloantibody 
production, as lipopolysaccharide (LPS) pretreatment was associated with substantially 
suppressed alloimmunization rates in mice.31 
 These sharp contrasting outcomes on red cell alloantibody production with mono- 
administration of poly(I:C) versus LPS in mice underline that, within a similar inflammatory 
clinical phenotype, different intracellular signalling cascades and specific gene expression 
profiles can be activated depending on the specific interaction with their receptors on 
innate immune cells (pattern recognition receptors, PRRs). 33, 34 With a cell specific 
distribution of Toll-like receptors (TLRs),33, 34 it seems reasonable to argue that a specific 
type of innate stimulus evokes a specific innate immune response. 
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Currently, dendritic cells (DCs) have been shown to be key players in the process of red cell 
alloimmunization as they are the important drivers of CD4+ T cell responses. Following 
LPS administration, impairment of in vivo CD4+ T cell proliferation via malfunctioning of 
a specific type of splenic conventional DCs (named “bridging channel CD8- 33D1+ DCs”) 
was identified to underlie diminished alloimmunization with allogeneic red cells 
transfused.27 The authors ascribed this phenomenon to a LPS-induced preactivation of 
these DCs leading to a lost capacity to present red cell alloantigens. Yet, in light of the 
above mentioned experiments, one might question whether and how these tolerance 
inducing mechanisms are trigger-specific, i.e. LPS causing a restraint of conventional DC 
maturation and skewing red blood clearance towards the macrophages, while poly(I:C) 
and CpG predominantly trigger DC activation. 
 A second interesting suggestion can be derived from etiologic mechanisms of some 
autoimmune diseases in which immune activation due to antigenic mimicry by several 
microorganism has been postulated. 35-37 Similarly, in experimental models, previous 
exposure to microbial T cell epitopes via a pathogen with small peptide homology to red 
cell antigens was demonstrated to significantly enhance primary alloantibody responses.38 
Whether potential existing similar mimicry between certain bacterial or viral epitopes 
could have played a causal role in our observations, can yet not be substantiated. However, 
the distribution of alloantibodies known to also occur ‘naturally’ (i.e. supposedly originating 
from red cell antigen-microbe mimicry) did not differ between patients with and without 
severe bacterial infections, disseminated viral infections, and Gram-negative bacteremia, 
suggesting an at most minor influence of mimicry. 
 Finally, we should consider our results to be at least partly influenced by the clinical 
conditions and treatments that necessarily follow the specific infections we studied. 
These sequel mediated associations may have been missed and as such not included in 
our multivariate regression analyses. In this respect, various antibiotics, including some 
types of cephalosporins commonly used for the treatment of Gram-negative bacterial 
infections, are known to suppress mitogenic responses of B and T lymphocytes.39-41 Similarly, 
severely septic patients in addition to antibiotics often receive corticosteroids to diminish 
the potential harmful effects of extensive cytokine release. In consistency with our findings 
reported in chapter 5, such treatments likely also attenuate the alloimmune response in 
patients with Gram-negative sepsis. 
 Unlike murine ´single-stimuluś  experiments, real-life microbial infections in humans 
thus bring along exposure to a spectrum of simultaneous modulators. In addition to 
the treatments given, one microorganism may contain various components of which 
some might suppress (e.g. bacterial lipopeptides and LPS) and others might stimulate 
(e.g. hypomethylated CpG-containing bacterial DNA) adaptive immune responses.42, 43 
As such, it might well be possible that the presence of two different species, although 
belonging to the same microorganism family (e.g. Gram-negative enterobacteriae), 
disparately affect red cell alloimmunization. Unfortunately, the size of the current study 
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limits us to properly evaluate this. So far, except for one study demonstrating non- 
significant enhancement of red cell alloimmunization in polyoma virus infected mice,38 
the immune modulating potential of individual microorganism species with regard to red 
cell alloimmunization has not been assessed. Hopefully in the future, larger data sets 
could further detail and substantiate the in chapter 3 observed associations between 
types of infections and red cell alloimmunization. 
The spleen’s critical role
As mentioned earlier, the spleen´s unique anatomy and location amidst the circulatory 
system allows an intimate contact between its resident immune cells and blood cells 
passing this organ.24, 44, 45 The spleen is a preferential site for follicular B cell maturation 
and critical for the survival of IgM memory B cells, the latter being a unique B cell 
population in the marginal zone of the spleen producing natural IgM antibodies to e.g. 
polysaccharide structures.46-49 In asplenic patients, IgM memory B cells are absent and 
these patients are at increased susceptibility to encapsulated bacterial infections. 
 Although T cell dependent B cell responses are generally preserved following 
splenectomy,46 the spleen has been shown pivotal for antibody production against both 
autologous and allogeneic hematopoietic cell antigens.50-55 Even in the presence of 
pro-inflammatory poly(I:C) stimulation, splenectomized mice showed a substantially 
attenuated antibody production against allogeneic red cells,23 which at least was due to 
an impairment of priming and proliferation of antigen-specific CD4+ T cells outside the 
splenic microenvironment.27, 52, 55 So far not evaluated, splenectomy may also result into a 
restraint of B cell priming together with red cells shunting away towards the highly 
tolerogenic hepatic compartment.55, 56 As such, removal of the spleen is used as a 
beneficial treatment for steroid-refractory autoimmune-mediated thrombocytopenia 
(ITP) and anemia (AIHA).57-59
 In chapter 4, we evaluated the role of the spleen and, more specific, a history of 
splenectomy in transfusion-induced primary red cell alloimmunization. Alloimmunization 
following splenectomy was a highly unlikely event (relative risk (RR) 0.04, CI 0.01-0.55). 
Only one patient among an estimated number of 443 splenectomized patients (0.23%) 
developed red cell alloantibodies upon subsequent red cell transfusions, which is in sharp 
contrast with the 2.1% alloimmunization prevalence mentioned in chapter 2. Intriguing, 
splenectomy did not prevent the induction of an anti-M antibody, implicating a maintained 
IgM memory B cell response in this single patient. Thus, although of substantial influence, 
splenectomy is here demonstrated not to completely abrogate red cell alloimmune 
responses. We hypothesize some remaining splenic tissue or previously immunized B cells 
transferred via a concomitant transplantation of a solid organ to account for this single 
immunization. 
 Our results seem in contradiction with the few published cross-sectional studies in 
thalassemic and sickle cell patients of which some reported splenectomy to be associated 
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with antibody induction and others did not find any association.60-62 None so far observed 
an abrogation of red cell alloantibody induction following splenectomy. However, one 
should recognize that thalassemic patients in need of splenectomy are often highly 
transfusion dependent. As most of these former studies did not correct for the cumulative 
numbers of red cells units received at the time of primary alloimmunization, potential ex-
posure-related confounding should be considered. In addition, incomplete reporting of 
data, such as the receipt of extended matched and/or leukoreduced blood by some but 
not all analyzed patients, may have further compromised the validity of these studies. 
Finally, none of these studies comment on the timing of splenectomy in relation to the 
primary alloimmunization. Possibly, some of the splenectomized patients were already 
alloimmunized before this surgical intervention. As such, we cannot exclude that the 
different results and conclusions of these earlier studies as compared to our study are to 
be explained by the presence of (indication) bias.. 
 Following our results, concerns for red cell alloantibody development in anatomic 
asplenic patients who are in need of high numbers of red cell transfusions seem 
unnecessary. As such, they do not need products matched beyond ABO/RhD. Future 
studies will need to (re-)evaluate whether this conclusion can also be extended to other 
asplenic patient populations e.g. patients with functional hyposplenism associated to 
celiac disease, autoimmune rheumatic disease, or caused by vaso-occlusive sickle cell 
disease crises. 
Treatment-related immunosuppression
Finally, in chapter 5 and 6, we illustrate the strong protective role of immunosuppressive 
therapy in general. First, patients using corticosteroids and/or other immunosuppressive 
agents demonstrated a two-fold decreased risk of red cell alloimmunization (RR 0.55, CI 
0.34-0.91). Second, patients with acute leukemia (either of myeloid or lymphoblastic 
origin), with mature (B or T cell) lymphomas, or patients post-autologous or -allogeneic 
stem cell transplantation, demonstrated a three-fold decreased incidence of clinically 
relevant antibodies against red cell alloantigens, which could similarly be ascribed to 
 immunosuppressive (chemo-/ immuno)therapy. 
 These are the first large studies to support decreased alloimmunization risk in immuno-
compromised patients. As such, although not coming to a surprise, they are of importance 
to the transfusion medicine field. 
 Contrasting our results, previous studies concluded oncologic patients to have a 
similar or even an increased alloimmunization risk as compared to the general transfused 
population.4, 7, 9, 63, 64 However, as the likelihood that one has formed alloantibodies 
increases with the number of exposures, patients who have formed alloantibodies will in 
general have been exposed to a higher number of red cell transfusions as compared to 
non-alloimmunized patients. These earlier studies thus roughly compared high-intensively 
transfused patients with less intensively transfused patients. As illustrated in chapter 2, 
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such an analysis will without doubt reveal an existing association of red cell alloimmunization 
with diseases that are in general supported with intensive red cell transfusions. Indeed, 
myelodysplastic syndrome (MDS) has so far been defined as a risk factor for alloimmuni-
zation and matching for high immunogenic antigens in this patient population reduces 
alloimmunization.65 Yet, the observed association between MDS and red cell alloimmuni-
zation seems not due to intrinsic characteristics of the disease as we here demonstrate, 
but is primarily explained by the fact that MDS patients are often transfusion dependent 
and, consequently, exposed to a much higher transfusion burden. Thus, MDS patients not 
receiving treatment have a similar red cell alloimmunization risk per transfusion event, and 
are even protected from alloimmunization during treatment with chemotherapeutic 
agents. Thus, in general, one should take into account both the expected cumulative 
exposure as well as current treatments with immunosuppressive agents with regard to 
matching strategies for the individual hemato-oncological patient. Indeed, a recent study 
did not find any benefit of additional Rh/K matching in patients with acute leukemia and 
lymphoma as hardly any patient formed antibodies,65 likely related to their immuno-
suppressive condition. 
 Our RRs do not take into account the dosing of and duration of immunosuppressive 
treatments, and whether or not agents were received as part of a combination regimen. 
It is rational, however, to regard patients receiving multiple dose-intensive immuno-
suppressive agents as more likely unresponsive to red cell alloantigen exposure. Also, 
patients at advanced stage of treatment i.e. patients still under treatment and already 
having received a large number of immunosuppressive treatments, might be considered 
more immunosuppressed as compared to patients who just initiated their treatment 
course. In line, following chemo- and/or immunotherapy for malignancies, the immune 
system remains dysfunctional for a certain period of time, depending on the intensity of 
the received treatment.66-69 
 Our findings support the notion that dose-intensive immunosuppressive therapy is 
the principal determinant of alloimmunization as non-treated patients with acute leukemia 
and mature lymphoma showed similar alloimmunization incidences to patients without 
these disease entities. However, we cannot exclude non-measured confounders associated 
with the likelihood of not receiving treatment (e.g. co-morbidities and disease stage) to 
have counteracted diminished immune responses. Intriguing, but only of speculative 
nature, the observed effects could be partly due to a direct interplay between the tumor 
and cells of the immune system. This process of host immune system subversion is a 
common hallmark of both hematological and solid tumors. Inflammatory signals from 
malignant cells initiate the recruitment of immune suppressor cells such as myeloid- 
derived suppressor cells and Foxp3 expressing regulatory T cells. Additionally, the production 
of effector cell suppressing cytokines (e.g. IL-10, TGF-β, and TNF-α), and polarization from 
a T helper 1 towards a T helper 2 response consequently result into the establishment of 
a tumor tolerant microenvironment.70-74 If this mechanism would attribute to the observed 
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diminished alloimmunization incidences in patients with hematological malignancies, 
one would expect that especially patients with advanced stage of disease independent of 
the receipt of treatment would be protected from red cell alloimmunization. Unfortunately, 
the patient numbers in this study were too small to discriminate the alloimmunization risk 
per stage of disease. 
Optimizing red cell antigen matching: future perspectives
The ultimate goal of the ongoing R-FACT study is to eventually establish an accurate allo-
immunization prediction model, thereby enabling practical and risk-based clinical 
decision on extensive matching. In this perspective, the identified determinants of red cell 
alloimmunization (whether associated to induction or protection) serve as an important 
start for such a model. Yet, continuing research is needed to advance our understanding 
of immunobiological process of red cell alloimmunization, and identify other relevant 
determinants of this process. Ultimately, our efforts should lead to a prospective study on 
the feasibility and efficiency of extended matching for high-risk patients, with risk classifi-
cations based on the here and in future to be identified determinants. 
Nature and Nurture
Future research focusing on other clinical determinants of alloimmunization should emphasize 
on  ‘nature’ and ‘nurture’ as patient-based modulators of red cell alloimmunization. 
 Regarding nurture, it has repeatedly been suggested that certain environmental 
factors skew adaptive immune responses. For example, (early) exposure to bacterial 
commensals and helminthes infections have been implicated to modulate the immune 
system towards protection against various autoimmune diseases such as type 1 diabetes 
mellitus by selectively modulating the T helper 2 response and driving the regulatory arm 
of the immune system.75-77 The latter also seems to explain the low propensity to develop 
allergic disorders observed in helminth-infected cohorts.78 Vice versa, the dramatic 
increase in atopic diseases in the developed world might be a direct consequence of 
the eradication of helminth infections.75 Thus, growing up in rural areas or keeping 
domesticated animals during early childhood (both associated with high microbial 
burden exposure), one’s dietary contents (associated to the biomass and diversity of gut 
microbiota),79 and use of antibiotics among other factors may all modulate the patient’s 
response to allogeneic red cell antigens, similarly as they do for chronic inflammatory 
disorders.80-82
 Next, taking a patient’s genetic constitution (‘nature’) into consideration when deciding on 
matching seems another interesting approach. Although the costs and logistic challenges 
of high-throughput genotyping of blood group systems are still high, these tools will 
likely become available on a more routine base. Thus, genetic risk factor screening could 
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in future be easily added to these blood group gene arrays.83 As we more extensively 
discussed in chapter 1, only a minor fraction of the genetic basis of red cell alloimmunization 
so far has been elucidated, with the majority of studies merely having focused on HLA 
gene polymorphism associations.84-90 Knowledge of this topic can be extended by 
learning from related diseases e.g. evidence on the polygenic nature of inhibitor formation 
upon factor VIII administration in hemophilia A patients. This disease and its treatment has 
several features in common with red cell transfusions e.g. administration of the product 
via the blood stream, a risk to induce alloantibody formation upon exposure, and (at least 
in a subgroup of patients) the administration of a human-derived product. Over the last 
decade, the hemophilia research field has made several steps forward by linking a large 
number of single nucleotide polymorphisms (SNPs) in immunomodulating genes to 
inhibitor formation including SNPs in the CTLA-4, tumor necrosis factor (TNF)α, and 
interleukin-10 (IL-10) genes. 91-97 Second, a genome-wide association study on RhD allo-
immunization by Sanquin Research in collaboration with Cambridge University just 
recently finished its sampling of DNA material from over 2,000 pregnant women and will 
soon start its analysis.98 Obviously, results from this study might be translatable to allo-
immunization to other red cell antigens and should help design future genetic research 
on transfusion-induced red cell alloimmunization. 
 Consistent with research on hemophilia A, studies performed in patients vaccinated 
against hepatitis B, measles, and influenza have demonstrated that variations in genes 
controlling adaptive immunity may predict vaccine efficiency.99, 100 Although targeting a 
different antigenic processing pathway (due to their non-intravenous administration and 
a common use of conjugates or other adjuvants), microbial vaccines similarly to red cell 
alloimmunization aim to affect T cell dependent adaptive immunity. As such, the genetic 
background of vaccine non-responders might overlap with patients not forming red cell 
alloantibodies despite repeated allogeneic red cell exposure. In this regard, meta-analyses 
for hepatitis B responses found evidence that variants in class II HLA and IL-4 were 
significantly associated with humoral immune responses.100-103 Other studies suggested 
associations with SNPs in cytokine genes, cytokine receptor genes, and toll-like receptor 
(TLR) genes. A comprehensive overview of these studies has been recently published by 
Newport et al.99 
 With the human genome sequence being completely elucidated and current 
techniques enabling high-throughput genome-wide analyses, it now seems feasible to 
extrapolate the above mentioned evidence into a large scale case-control study on 
genetic risk factors that modulate red cell alloimmunization. In this regard, we are currently 
planning to further expand our ongoing R-FACT study by prospectively sampling patient 
material at the time of red cell alloantibody detection from both antibody responders and 
non-responders. Subsequent analyses on immunomodulating genes should at least 
focus on polymorphisms in HLA class I and II genes (preferentially in relation to antigen- 
specific alloimmunization), and genes related to immune cell signaling e.g. chemo- and 
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cytokines and their receptors, toll-like receptors, molecules involved in costimulation, and 
nuclear transcription factors.  
 In addition to the above mentioned nurture and nature associated risk factors, 
biomarkers of the immune status of the patient may be predictive of red cell alloimmuni-
zation. In a first (retrospective) analysis on this subject which we discussed in chapter 3, 
we did not observe any association of the level of leukocytosis and CRP values as markers 
of inflammation with alloimmunization, possibly due to the multifactorial nature of these 
parameters. Other immune markers such as quantity and functionality of B, helper T, 
and regulatory T cell subsets might be better discriminative. Yet, such an analysis requires 
a complex study encompassing a substantially large cohort of patients being sampled 
at fixed time points over a considerable period of follow-up. 
 Finally, IgG immune responses to childhood vaccinations, as well as (age-adjusted) 
titers of naturally occurring IgM antibodies against antigen A and antigen B may predict 
the response to allogeneic donor red cells. Especially the latter seems intriguing as these 
IgM responses represent T cell independent immune responses.104 Interestingly, the 
spleen and its proper functioning seems essential both for induction of T cell independent 
memory B cell responses 44, 105, 106 as well as IgG responses to red cell allogens (as discussed 
in chapter 6). 
Benefits of matching
The studies presented in this thesis have tried to find an answer on questions starting 
with ‘who’ and ‘what’. Who deserves to receive extensively matched donor red cell units? 
What red cell antigens should be taken into consideration when deciding to transfuse 
extended matched donor red cells? 
 The ‘why’ question has not received much attention so far. Yet, it is the driving force 
behind our studies. 
 Extensive matching in patients with sickle cell disease and thalassemia has proven to 
be effective, although most studies did not directly compare extended with non-extended 
matched patients.61, 107 Preemptive extended matching for selected antigens (here: 
matched for the antigens c, C, E, K, Fya, Jka, and S) as compared to merely ABO/RhD 
matching reduced the primary alloimmunization rate by 5.3% (8.1% versus 2.9%) in a 
cohort of patients undergoing elective (cardiac) surgery.108 In a post hoc analysis on 
patients who received merely red cell units, this absolute risk difference increased further 
to 8.0% (9.4% versus 1.4%; confidence interval (CI) 0.4-16.0). Indeed, patients who received 
platelets next to extended matched red cell units had comparable alloimmunization rates 
as compared to those receiving ABO/RhD matched units as they developed (non-D) Rh 
and K antibodies after cognate antigen exposure through platelet transfusions. Therefore, 
the few residual antigen incompatible red cells in platelet products can counteract the 
potential effect of extended red blood cell matching with regard to red cell alloimmunization 
prevention. Future studies should explore whether less antigen exposure by single donor 
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platelet apheresis products or even Rh/K matching with platelet transfusions could further 
reduce alloimmunization. Due to the low red cell antigenic load with platelet transfusions, 
we, however, estimate that the additive risk of non-matched platelet transfusions is negligible 
both for low immunogenic antigens and for the immunocompromised patient population. 
 In most cases, transfusions can be matched to existing antibodies thereby preventing 
antibody-antigen interactions and thus hemolytic transfusion reactions. Pregnancies, 
however, may be severely complicated by earlier alloimmunization due to ongoing 
maternal antigen exposure by the fetus. This especially accounts for earlier developed 
anti-K and anti-c.109 For this reason, matching beyond ABO and RhD in women of 
childbearing age is nowadays routine practice in most European countries. In the 
Netherlands, women under 45 years of age receive K, and since 2011 additionally c and E, 
matched blood.17 Although several reports have demonstrated an increased risk of fetal 
hemolytic complications for red cell alloimmunized pregnant women,109, 110 no studies so 
far have assessed the beneficial effects of the introduction of K, c, and E matching in 
young women on alloimmunization incidences and its clinical consequences. 
 In this respect and in addition to our data reported in chapter 2, we observed 
significantly lower cumulative alloimmunization incidences among women under 45 
years of age as compared to women above 45 years of age (4.4%, (CI 0.2-20.5) and 9.5% (CI 
4.8-16.2) after 40 units received, log-rank p 0.013, Figure 3 upper panel). These differences 
seemed solely due to decreased Rh/K alloimmunizations in young women, since allo-
immunization rates to non-Rh/non-K antigens did not differ between women under and 
above 45 years of age (Table 1). Furthermore, men under and above 45 years of age 
demonstrated similar alloimmunization incidences, excluding age as an explanatory 
factor. Of importance for accurate interpretation, the majority of the young women in our 
cohort received K, but not c and E, matched blood as this latter matching practice has 
only been nationwide established since 2011. Indeed, the 10 immunizations against c and 
E which we observed in women under 45 years of age all occurred before the introduction 
of matching for these antigens. In contrast, only one single anti-K immunization event 
occurred. 
 A preliminary analysis, which needs to be consolidated by extended follow-up, 
suggests a significant effect intensification from additional c and E matching (Figure 3, 
bottom panel). Only 4 of 741 (0.54%) women under 45 years of age consecutively 
transfused from January 2011 onwards as compared to 27 of 1,810 (1.49%) receiving red 
cell units between 2005 and 2010 developed alloantibodies. Due to the short follow-up 
and the consequently small cohort of women who received both K, c and E matched 
blood, differences fail to reach statistical significance (log-rank p 0.08). Notwithstanding 
the latter caveat, these findings strongly suggest that matching for E and c in addition to 
K is substantially effective in reducing alloimmunization rates. 
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Figure 3  Additional matching for K, c, and E protects against alloimmunization.
Upper panel: cumulative incidences of red cell alloimmunization according to age and sex. Lower panel: 
cumulative incidences of red cell alloimmunization in women under 45 years matched for K (cohort 2005-2010), 
and in addition also to c, and E (cohort 2011-2013). Only data from non-censored cohorts of at least 200 subjects 
are presented.











































M ≤ 45           549        230         109           55
M > 45        2,287        819         409         236
F ≤ 45           417        161           78           38






9,014        472         207         108





Cumulative number of red cell units transfused
At risk, n
cohort 2005-2010        304       117          58           28
cohort 2011-2013        101        36          14           10
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Additional antibody formation
Although the work presented in this thesis focuses on primary alloimmunization against a 
single antigen, it is well known that previously auto- or alloimmunized patients are at increased 
risk of developing additional antibodies with subsequent transfusions.111, 112 As such, avoidance 
of exposure to antigens to which immunization has already occurred in addition to avoidance 
of exposure to high immunogenic antigens, is currently aimed for in these patients. 
 The risk to subsequently develop additional alloantibodies after primary immunization 
is patient-specific, i.e. resulting from a so-called high-responder phenotype to which 
nature and nurture associated factors contribute.113, 114 In addition, immune activation by 
existing red cell alloantibodies themselves might play a role. In this regard, an immune 
response elicited to a particular high immunogenic  antigen might enhance the response 
to weaker antigens. One potential mechanism, closely related to the earlier mentioned 
“non-exofacial polymorphic structures” (NEP) hypothesis (see chapter 1),115 involves 
epitope spreading. Here, (an epitope of) antigen X appears in the context of a HLA class II 
molecule carried by a naive B cell as a result of this cell’s phagocytic ability. When the B cell 
receptor (BCR) on this B cell is specific for antigen Y, subsequent activation of this B cell by 
a CD4+ T cell which is sensitized against antigen X will lead to production of antibodies specific 
for antigen Y. Thus, immunization against antigen X may induce immunization against 
antigen Y. 
 Alternately, existing antibodies of IgG class can also suppress rather than enhance an 
immune response to non-cognate antigens.116, 117  Here, phagocytosis of IgG opsonized 
allogeneic red cells via Fcγ receptors results into a rapid clearance of these cells from the 
circulation, thus preventing B cells from binding to other non-self red cell antigens. 
Additionally, IgG opsonized red cells may elicit inhibitory FcγRIIB signaling in B cells and as 
such prevent B cell activation. The earliest evidence for such an existing ‘antibody-mediated 
immune suppression’ (AMIS) was provided by the observation that ABO incompatibility 
between mother and child affords a degree of protection against Rh hemolytic disease 
of the fetus and newborn, because of anti-A or anti-B antibodies destroying the fetal red 
cells in the maternal circulation before immune system recognition.118 Similarly, next to 
protecting against RhD immunization, prophylactic anti-D administration to women 
bearing a RhD-positive child was recently associated to an additional significant decreased 
risk to develop anti-E (personal communication, Zwiers, Koelewijn, van der Schoot et al, 
manuscript in preparation). 
 Current evidence of observational studies so far does not substantiate either epitope 
spreading nor AMIS to dominate immune responses in case of existing non-RhD 
antibodies. In this regard, in one study the type of first formed antibodies appeared not 
to be associated with the probability and type of the subsequent alloimmunization.119 
In agreement, we observed similar cumulative alloimmunization incidences to the non- 
matched non-Rh/K antigens in women under 45 years as compared to the rest of our 
incident new-user cohort (Table 1). 
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Nevertheless, prevention of primary alloimmunization is of upmost importance both in a 
setting of epitope spreading as well as with AMIS. In case of high clinical relevance of 
epitope spreading, further prevention of alloimmunization (i.e. after a first antibody has 
already formed) would not suffice. Instead, absolute prevention of (CD4+ T cell) sensitization, 
by primary avoidance of all or at least most allogeneic antigens would avoid both primary 
and subsequent additional immunization. In case the concept of protective AMIS proves 
to also exist beyond RhD antibodies, secondary matching to prevent (further) alloimmuni-
zation seems less needed. Again, primary matching for at least all high immunogenic 
antigens should deserve our main emphasis. 
 Yet, only a subset of the patient population can practically receive extended matched 
products due to financial costs and logistic feasibility, hereby once more underlining the 
high importance of accurate identification of the high-responder patient and high-risk 
conditions for alloimmunization. Accordingly, the studies and their outcomes presented 
in this thesis will serve future tailoring of preventive matching strategies by having 
identified respectively exposure to certain high immunogenic antigens, an infectious- 
disease related inflammatory condition, a treatment induced state of immunosuppression, 
and a functioning spleen to be ultimate determinants of red cell alloimmunization. 











2 0.11 (0.00-18.19) 0.20 (0.01-1.82) 0.37 (0.00-5.47) 0.27 (0.01-2.02)
5 0.58 (0.00-9.00) 0.57 (0.08-2.39) 0.82 (0.02-6.59) 0.66 (0.09-2.75)
10 0.91 (0.01-9.76) 0.99 (0.20-3.22) 1.07 (0.02-8.89) 1.14 (0.18-4.22)
20 0.91 (0.01-9.76) 1.34 (0.23-4.66) 1.07 (0.02-8.89) 1.71 (0.26-6.21)
40 1.41 (0.01-15.87) 1.97 (0.30-7.07) 1.76 (0.01-18.31) 1.71 (0.26-6.21)
Women under 45 years of age demonstrated similar alloimmunization rates to non-Rh/K antigens as compared 
to older women.
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In Nederland doneren jaarlijks meer dan 300.000 donoren bloed. Rode bloedcel transfusies 
vormen een essentieel onderdeel van de behandeling van patiënten bij wie de aanmaak 
van bloed gecompromitteerd is of bij wie sprake is van anemie door acuut of chronisch 
bloedverlies. 
 Rode bloedcellen bevatten op de buitenmembraan van de cel diverse eiwit-, vet- en 
suikerstructuren. Deze structuren kunnen tussen individuen onderling in geringe mate 
verschillen. Voorbeelden hiervan zijn de suikerstructuren die het ABO bloedgroep systeem 
vormen en het Rhesus (Rh) D eiwit. Naast het ABO en Rh bloedgroep systeem zijn er 
inmiddels nog 34 andere bloedgroep systemen geïdentificeerd met hierin in totaal meer 
dan 340 structuren die als een bloedgroep antigen zijn benoemd. Door het polymorfisme 
van deze membraanstructuren kan het ontvangen van rode bloedcellen met daarop voor 
de ontvanger onbekende antigenen een activatie van het immuunsysteem induceren 
met als resultaat de vorming van antistoffen gericht tegen deze onbekende antigenen. 
Bij een herexpositie aan het onbekende antigeen door bijvoorbeeld transfusie of zwanger- 
schap zal het immuunsysteem door haar geheugencapaciteit in korte tijd gestimuleerd 
worden tot productie van hoge titers antistoffen met als gevolg dat de getransfundeerde 
bloedcellen intravasaal en/of extravasaal afgebroken worden. Een dergelijke acute 
hemolytische transfusiereactie kan zeer ernstig verlopen met zelfs dodelijke afloop. Het is 
daarom standaard praktijk om ABO en RhD compatibel bloed te transfunderen, gezien 
antistoffen tegen met name deze antigenen gemakkelijk zeer ernstige reacties kunnen 
induceren. Patiënten met een hoog risico op het vormen van antistoffen of voor wie de 
gevolgen van alloimmunisatie desastreus kunnen zijn ontvangen daarnaast ook bloed 
dat compatibel is voor andere Rh antigenen en voor het K antigen. Ondanks het effect van 
deze preventieve maatregelen vormen toch nog vele patiënten rode bloedcel antistoffen. 
 Dit proefschrift beschrijft studies naar de determinanten van rode bloedcel allo-
immunisatie. Identificatie van deze determinanten stelt ons in staat om voor de individuele 
patiënt voorafgaand aan de bloedtransfusie een inschatting van het risico op anti-
stofvorming te maken. Daarmee kan het huidige meer gegeneraliseerde matchingsbeleid 
omgebogen worden naar een patiëntspecifieke strategie met naar verwachting een 
reductie van antistofvorming en haar klinische en logistieke gevolgen. 
 Hoofdstuk 1 geeft een algemene inleiding van dit proefschrift. Het beschrijft de 
huidige kennis en stand van zaken met betrekking tot de pathogenese van rode bloedcel 
alloimmunisatie, haar klinische consequenties, methoden ter diagnostiek en huidige 
maatregelen ter preventie. Ten aanzien van de pathogenese spelen zowel het aangeboren 
als het adaptieve immuunsysteem een essentiële rol waarbij dendritische cellen in de milt 
een belangrijke link tussen beide systemen vormen. Andere factoren van invloed op rode 
bloedcel alloimmunisatie die achtereenvolgens toegelicht worden zijn: 1. de kans op 
blootstelling aan een onbekend rode bloedcel antigen; 2. de potentie van dit rode 
bloedcel antigen om het immuunsysteem te stimuleren tot antistof productie (‘antigen 
immunogeniciteit’); 3. de genetische constitutie van de patiënt waarbij voor onder andere 
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diverse polymorfismen in HLA klasse II een associatie met antistof vorming na rode bloedcel 
transfusies is gevonden; 4. klinische condities als hemoglobinopathieën die vaak gepaard 
gaan met een hoge mate van antigen dispariteit tussen donor en ontvanger en daarnaast 
gekenmerkt worden door een chronische inflammatie. 
 In hoofdstuk 2 illustreren wij dat bijna 8% van de veelvuldig getransfundeerde 
patiënten alloantistoffen vormen, met name gericht tegen het K, E, Jka en c antigen. 
Uitbreiding van het standaard ABO/RhD matchingsbeleid gericht op deze antigenen zou 
74% van alle alloimmunisaties voorkomen, maar brengt uiteraard ook aanzienlijke kosten 
en logistieke beperkingen met zich mee. Voorwaarden voor antistofvorming betreffen 
blootstelling aan een onbekend antigen als ook een zekere mate van immunogeniciteit 
van dit antigen. In het verleden is deze antigen immunogeniciteit in meerdere studies 
geschat met de zogenaamde ‘Giblett rekenmethode’.  Wij bespreken diverse kant- 
tekeningen van deze op prevalentiecijfers gebaseerde methode en leveren een alternatieve 
rekenmethode. Deze schat de immunogeniciteit van rode bloedcel antigenen op basis 
van incidentiecijfers uitgezet tegen geobjectiveerde blootstelling van het voor de ontvanger 
onbekende antigen. Hierbij tonen wij aan dat K het meest potente antigen is, gevolgd 
door E, Cw, e, Jka en c. Het antigen Fya blijkt in een niet-Kaukasische bevolking weinig 
immunogeen. Met name de bevindingen rondom anti-Jka vorming zijn opvallend en, 
mede ook gezien haar complementbindende vermogen, van belang voor de huidige 
praktijk waarin Jka matching tot heden nog geen hoge prioriteit verdiende. 
 In hoofdstuk 3 tot 6 bespreken wij achtereenvolgens diverse klinische condities die 
van invloed zijn gebleken op het vormen van rode bloedcel antistoffen. 
 Muizenexperimenten hebben bij herhaling laten zien dat een transfusie welke ontvangen 
wordt tijdens een door een synthetisch viraal peptide geïnduceerde inflammatoire conditie 
leidt tot een versterkte alloimmunisatie respons. In analogie hieraan tonen wij in hoofdstuk 3 
aan dat rode bloedcel alloimmunisatie gemoduleerd wordt door infectieuze condities, 
namelijk het type infectie, de intensiteit van deze infectie en de inflammatoire respons van 
de patiënt op deze infectie. Wij vonden een verhoogde incidentie van allo immunisatie in 
patiënten die ten tijde van ernstige bacteriële en virale infecties rode bloedcel transfusies 
ontvingen. Opvallend, maar ook nu in lijn met eerdere bevindingen in muizenexperi-
menten, vertoonden juist patiënten met Gram-negatieve bacteremiën een tweevoudige 
reductie van alloimmunisatie incidentie. Het lijkt dus aannemelijk te concluderen dat een 
specifieke inflammatoire stimulus leidt tot een specifieke immuno logische uitkomst. 
Wij hypothetiseren een belangrijke rol voor de diverse ‘Toll-Like Receptoren’ die elk een 
specifieke intracellulaire signaalcascade kunnen aanzetten en daarmee kunnen leiden tot 
een uniek gen expressie profiel. Daarmee is het zelfs niet ondenkbaar dat infecties met 
micro- organismen van verschillende species een verschillende uitwerking op rode bloedcel 
alloimmunisatie hebben. Toekomstige grootschalige  epidemiologische studies zullen 
hopelijk dit vraagstuk beantwoorden en daarmee een matchingstrategie uitgaande van 
een uniek klinisch inflammatoir fenotype van de patiënt doen optimaliseren. 
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Hoofdstuk 4 bespreekt de rol van de milt, een orgaan van belang voor B cel maturatie en 
ontwikkeling van IgM ‘memory B cellen’. Mede gezien de milt de verbinding vormt tussen 
de bloed- en lymfecirculatie, is deze essentieel gebleken in de vorming van antistoffen 
tegen autologe en allogene hematopoëtische celantigen. Onze studie toont aan dat rode 
bloedcel alloimmunisatie zeer onwaarschijnlijk (maar niet uitgesloten) is na het ondergaan 
van een chirurgische splenectomie. Slechts één patiënt binnen een (geschat) cohort van 
443 patiënten (0.23%) vormde alloantistoffen tegen rode bloedcel antigenen na een 
splenectomie, overeenkomend met een 20-voudig verlaagd risico. Na een splenectomie 
lijkt additioneel antigen matching dus niet van meerwaarde te zijn voor de Kaukasische 
patiënt. Alhoewel deze resultaten aansluiten bij de kennis omtrent de immunologische 
functie van de milt en eerder vergelijkbare conclusies zijn getrokken na splenectomie 
experimenten met muizen, hebben enkele retrospectieve, observationele studies in he-
moglobinopathie patiënten juist een verhoogd risico op alloimmunisatie na splenectomie 
gesuggereerd. Andere studies vonden juist geen associatie. Wij bespreken mogelijke 
verklaringen voor de discrepantie van deze studies met onze bevindingen en hypothetiseren 
zelfs dat ook de hemoglobinopathie patiënt na chirurgische splenectomie dan wel met 
een functionele asplenie een gereduceerd (relatief) risico heeft op (additionele) antistof 
vorming. Omdat juist voor deze patiëntenpopulatie alloimmunisatie een ernstige bedreiging 
vormt van een optimale (transfusie)behandeling, is het van groot belang om onze 
bevindingen en conclusies te verifiëren in deze patiëntenpopulatie. 
 Als laatste illustreren wij in hoofdstuk 5 en 6 de sterk beschermende rol van gebruik 
van immunosuppressieve middelen op rode bloedcel antistof vorming. In hoofdstuk 5 
wordt dit besproken voor de algemeen getransfundeerde patiëntenpopulatie. Zelfs zonder 
correctie voor cumulatieve dosis van therapie vonden wij een vijfvoudige reductie van 
het risico op alloimmunisatie bij gebruik van corticosteroïden in combinatie met andere 
immunosuppressieve middelen. In hoofdstuk 6 wordt het risico op alloimmunisatie 
geanalyseerd voor de oncologische en hemato-oncologische patiëntenpopulatie. Mede 
door een therapie-geïnduceerde myelosuppressie ontvangen deze patiënten tijdens hun 
behandeling vaak een veelheid aan bloedtransfusies. Afhankelijk van de specifieke 
oncologische entiteit en de intensiteit van de benodigde therapie zal een zekere mate van 
immuungecompromitteerdheid ontstaan. Wij tonen aan dat patiënten met acute 
(myeloïde dan wel lymfatische) leukemie, met een myelodysplastisch syndroom (MDS), 
met een matuur B of T cel lymfoom, en patiënten na een autologe dan wel allogene 
 hematopoëtische stamceltransplantatie allen een sterk verlaagd risico op alloimmunisatie 
hebben. Deze risicoreductie is toe te schrijven aan het sterk immuunsuppressieve karakter 
van de behandeling. Patiënten met deze ziekte entiteiten die om welke reden dan ook 
geen behandeling ondergingen, toonden een risico dat vergelijkbaar is met de algemene 
getransfundeerde bevolking. Daarmee dienen wij kritisch te kijken naar het huidige 
matchingsbeleid van MDS patiënten. Op basis van onze resultaten adviseren wij dat zowel 
de (geschatte) transfusie behoefte als ook het krijgen van een immuunsuppressieve 
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behandeling meegenomen wordt in de afweging om een MDS patiënt meer volledig 
gematcht bloed te verstrekken. In zijn algemeenheid zou gesteld kunnen worden dat 
voor de incidenteel getransfundeerde MDS patiënt geen specifieke vereisten gelden, 
maar dat de intensief getransfundeerde MDS patiënt op basis van een verhoogd cumulatief 
 alloimmunisatie risico volledig Rh, K compatibel bloed ontvangt tenzij hij op dat moment 
behandeld wordt met sterk immunosuppressieve middelen. 
Bovenstaande R-FACT studies zijn geïnitieerd met als doel om een accuraat alloimmunisatie 
predictiemodel op te stellen waarmee voor elke patiënt met een uniek klinisch fenotype 
een welafgewogen beslissing omtrent rode bloedcel antigen matching genomen kan 
worden. Voor deze geïndividualiseerde aanpak is het van groot belang dat het proces van 
alloimmunisatie begrepen wordt. In dit proefschrift hebben wij enkele klinische 
determinanten van rode bloedcel alloimmunisatie geïdentificeerd die als basis kunnen 
dienen voor een dergelijk predictiemodel. Toekomstige studies zullen gericht moeten zijn 
op het blootleggen van andere factoren van invloed. Na kritische evaluatie van financiële 
kosten en praktische uitvoerbaarheid zowel aan de donorzijde van de keten als bij het 
lokale transfusielaboratorium, zullen factoren op het gebied van genetische constitutie, 
opvoeding en omgeving, donor gerelateerde zaken, en klinische condities hopelijk 
uiteindelijk geïntegreerd kunnen worden in één goed functionerend risicomodel. 
Hiermee zal naar verwachting alloimmunisatie en haar soms desastreuze klinische 
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AIHA autoimmune hemolytic anemia
ALL acute lymphoblastic leukemia
AMIS antibody-mediated immune suppression’
AML acute myeloid leukemia
APC antigen presenting cell
ATC index Anatomical Therapeutic Chemical index
ATG anti-thymocyte globulin
BCR  B cell receptor
CI confidence interval
CLL chronic lymphatic leukemia
CNS coagulase-negative staphylococcus
COPD chronic obstructive pulmonary disease
DAMP damage-associated molecular pattern
DAT direct antiglobin test
DC dendritic cell
DHTR delayed hemolytic transfusion reactions
DM diabetes mellitus
Fy Duffy
GFR glomerular filtration rate
HDFN hemolytic disease of the fetus or newborn
HLA human leucocyte antigen
HSCT hematopoietic stem cell transplantation











NEP non-exofacial polymorphic structure
PAMP pathogen-associated molecular pattern  
Poly(I:C) Polyinosinic:polycytidylic acid
PRP pattern recognition receptor
Rh Rhesus
RR relative risk
SNP single nucleotide polymorphism
TCR T cell receptor
TFH T follicular lymphocytes
TLR toll-like receptor
TNF tumor necrosis factor
TRIX Transfusie Register Irregulaire antistoffen en X(kruis)-proeven

